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Abstract 
 
The large FK506-binding proteins FKBP51 and FKBP52 are Hsp90 associated cochaperones that 
modulate steroid hormone receptor signaling. It has been shown that FKBP51 is a negative regulator 
whereas FKBP52 is a positive regulator of the glucocorticoid receptor. A majority of patients suffering 
from depression show an altered response to glucocorticoids. Furthermore, polymorphisms in the 
FKBP51 encoding gene were associated with human stress response and several psychiatric 
disorders. Recently, FKBP51 knockout or knockdown was shown to have a protective effect on stress-
coping behavior in animal models of anxiety and depression.  
In a neuroblastoma cell line FKBP51 suppresses the elongation of neurites whereas FKBP52 enhanced 
it. All FKBP ligands reported so far, including rapamycin and FK506, show only negligible selectivity 
between FKBP51 and FKBP52, since the residues within the active site are completely conserved both 
on the sequence and the structural level. Due to the antagonistic effect of FKBP51 and FKBP52, the 
opposing activity of these proteins cannot be examined with the present FKBP inhibitors. Therefore, 
we envisioned a chemical genomics tool to address these selectivity problems. Using structure-based 
design and protein mutagenesis we engineered an enlarged cavity into the active sites of FKBP51 and 
FKBP52. In turn, we synthesized a series of complementary ligands with protruding side chains that 
were designed to fit into this new cavity and to prevent binding to the wild-type proteins. The best 
ligands of this series showed low nanomolar affinities while maintaining 500 to 1000-fold selectivity 
for mutated FKBP51/52 over wildtype proteins.  
Using these artificially selective ligands in a cell model of neuronal differentiation (N2a cells), we 
showed that specific inhibition of overexpressed FKBP51 restores neurite outgrowth whereas specific 
inhibition of overexpressed FKBP52 has the opposite effect. This is the first proof of pharmacological 
activity of FKBP51 ligands in a relevant cellular model. Furthermore we unambiguously show that 
selectivity is crucial for the effect. This could at least in part explain the inconsistencies and 
conflicting results that have plagued the field of neuroimmunophilin FKBP ligands in the past.  
During our synthesis campaign we made the discovery that certain ligands can induce a 
conformational change in the binding pocket of FKBP51 and that these substances consistently show 
substantial selectivity versus FKBP52. Based on several co-crystal structures we rationally designed a 
series of these induced fit ligands which finally led to inhibitors (iFit-1, IFit-2) with low nanomolar 
affinities (4-6 nM) for wildtype FKBP51 and up to 10000 fold selectivity versus FKBP52. These ligands 
are the most potent and selective ligands reported for FKBP51 so far. In a neurite outgrowth assay 
they enhanced neurite outgrowth whereas FK506 was less active. These ligands provide the basis for 
the development of drug-like FKBP51 inhibitors to pharmacologically probe the role of FKBP51 in a 
whole animal context. 
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A. Introduction 
 
1. The biology of Immunophilins 
 
1.1 FK506-binding proteins and Cyclophilins 
 
 
Fig. 1: The prototypic FKBP ligands FK506 and rapamycin and the cyclophilin ligand CsA. Blue (FK506, rapamycin): FKBP 
binding domain, blue (CsA) cyclophilin binding domain. Green (CsA, FK506) calcineurin binding domain, green (rapamycin) 
mTOR binding domain. 
 
FK506-binding proteins (FKBP) and cyclophilins (Cyp) belong to the class of immunophilins which are 
defined by their ability to bind immunosuppressive ligands like FK506, rapamycin (Rap), and 
Cyclosporin A (CsA, Fig. 1). FKBPs and Cyps minimally contain a peptidyl-prolyl-isomerase (PPIase) 
domain that catalyzes the interconversion of cis-trans isomers of X-Pro peptides and that binds to 
immunosuppressive drugs. For all aminoacids except proline the equilibrium of cis/trans 
isomerization lies on the trans side. In proteins these 19 aminoacids adopt almost exclusively the 
trans configuration. X-Proline dipeptides can occur either in the cis or the trans configuration in 
folded proteins, whereas in the unfolded state there is an ratio of cis/trans 2:8. Therefore in many 
protein folding processes the cis/trans isomerization of X-Pro displays the rate determining step. 
PPIases help proteins to fold in a correct way by catalyzing the isomerization of proline residues.1  
The immunosuppression is not mediated by inhibition of the PPIase activity but by enabling FKBPs to 
form a ternary complex with calcineurin (for FK506) or mTOR (for Rap). In complex with FKBP-FK506 
calcineurin is not able to dephosphorylate nuclear factor of activated T-cells (NF-AT) which is needed 
for IL-2 expression and T-cell activation. The main mediators are FKBP12, and partially FKBP12.6 and 
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FKBP51.2 mTOR assembles two complexes mTORC1 and mTORC2. The kinase activity of mTORC1 can 
be specifically inhibited by FKBP-Rap complexes which in turn leads to less phosphorylation of 
p70S6Kinase and 4E-BP1, both key regulators in protein translation and thereby causing the 
immunosuppressive effect.2, 3,4  
 
 
Fig 2: Proline cis/trans isomerization 
 
The human genome encodes 17 different FKBPs, which are named according to their size in 
kilodaltons (e.g., FKBP12, FKBP38, FKBP51 and FKBP52). Table 1 shows the different known FKBPs 
and their biochemical roles in mammalian cells known so far5.  
 
Name Associated Binding 
Partners 
Functions Cellular 
Compartment 
hFKBP12a6, 7 
hFKBP12.68, 9 
hFKBP12c5 
FK506/Calcineurin 
Rap/mTOR 
Type I TGFβ receptor 
Muscle ryanodine receptor 
Inositol receptor 
cardiac ryanodine receptor 
regulator of cell cycle Cytosol 
hFKBP15p5  Protein coding cofactor ER 
hFKBP22p5    
hFKBP25p5    
hFKBP24p5    
hFKBP63p5    
hFKBP65p10  elastin chaperone  
hFKBP3611, 12 clathrin and Hsp72 glyceraldehyde-3-phosphate 
dehydrogenase inhibitor 
Nuclear 
hFKBP3713 Aryl receptor Transcription of genes Cytosol 
hFKBP37i14  Amarosis syndrome Cytosol 
hFKBP3815 Bcl, FK506 Development of cancer cells Cytosol 
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Hedgehog signalling 
hFKBP5116 SHR, HSP90, Akt Negative Modulator of SHR Cytosol 
hFKBP5217 SHR, HSP90 Positive Modulator of SHR Cytosol 
hFKBP25n18 YY1, HMG-II Transcription of genes Nuclear/Cytosolic 
hFKBP1355 F-Actin Colocalized with F-Actin in 
growth cones of dorsal root 
ganglion neurons 
Cytosol 
Table 1: Biochemical roles and distribution of human FKBPs 
 
The second class of immunophilins are the cyclophilins. The human genome encodes at least 16 
unique cyclophilins, all containing a highly conserved Cyp18-homology domain, which shows PPIase 
activity. Many of them bind tightly to the unselective cyclophilin ligands CsA and sanglifehrin A. 19, 20 
The Cyp-CsA complex forms a ternary complex with the phosphatase calcineurin (CN) similar to 
FKBP12-FK506. In this heterocomplex calcineurin is also unable to dephosphorylate its substrate 
NF-AT which is required for T-cell activation which again leads to the immunosuppressive effect3. 
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1.2 The biology of FKBP51 and FKBP52 
 
1.2.1 Structure and function of FKBP51 and FKBP52 
                         
 
Fig 3: Crystal structures of FKBP51 and FKBP52  
 
The large FKBP homologs FKBP51 and FKBP52 have first been identified in complex with steroid 
hormone receptors (SHR).21, 22 The binding to SHRs is mediated by the heatshock protein 90 (Hsp90), 
where they act as co-chaperones.23 Since then these proteins received great attention because of 
their steroid hormone signaling-regulating roles. Many endocrine related diseases are known for 
which FKBP51 and FKBP52 are potential therapeutic targets, such as for example stress related 
diseases, prostate cancer, breast cancer, male and female contraception and metabolic diseases. To 
better understand the role of these FKBPs in these diseases new non-immunosuppressive ligands are 
needed.  
FKBP51 and FKBP52 are close homologs and share 70% sequence similarity.23 They possess a similar 
domain architecture (Fig. 3), consisting of the FKBP12 like N-terminal PPIase domain (FK1), followed 
by another FKBP12 like domain (FK2) which although structurally similar to FK1 possesses no PPIase 
activity. At the C-terminus a tetratricopeptide (TPR) domain facilitates the binding to the EEVD motif 
at the C-terminus of Hsp90.24, 25 The overall architecture of the domains of FKBP51 and FKBP52 is 
very similar. The orientation of FK1 and FK2 differ only slightly but the TPR domain orientation of 
FKBP52 is tilted compared to that of FKBP51. It has to be considered that FKBP52 was not crystalized 
TPR domain 
FK2 
 
FK1 
FK2 
 
FK1 
FKBP51 FKBP52 
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as a whole, but in two parts due to its instability in solution. The crystal structure in Fig. 3 shows the 
reconstruction based on the two parts. The loop linking the FK2 and the TPR domain could be flexible 
and the orientations of the TPR domains could be due to different crystal packing.  
The FK1 and FK2 domain are connected by a linker of seven to nine amino acids. FKBP52 has a casein 
kinase 2 phosphorylation (CK2) sequence (TEEED) in this linker which is not present in FKBP51 (the 
correspondent sequence is FED). It is thought that the phosphorylation of FKBP52 by CK2 at T143 
decreases binding to Hsp90 and thereby abrogates the activating effect. This effect could be due to a 
reorientation of the FK1 domain upon phosphorylation.26 
 
 
1.2.2 The role of FKBP51 and FKBP52 in steroid receptor signaling 
 
FKBP51 and FKBP52 are regulators of steroid hormone receptor (SHR) binding activity. In most 
reports FKBP51 acts as a negative modulator on SHRs27, whereas FKBP52 is a positive regulator of 
androgen receptor (AR)28, glucocorticoid receptor (GR)29 and progesterone receptor (PR)30. Fig. 4 
shows a model of the maturation and regulation of SHRs. Either FKBP51 or FKBP52 enters the mature 
Hsp90-dimer-SHR complex, which is stabilized by p23. The FKBP binds to the C-terminus of Hsp90 via 
the TPR domain. The present model proposes the FK1 domain and especially the proline rich loop of 
FKBP51 and FKBP52 interacts directly with the ligand binding domain of the SHR. If FKBP51 is present 
the binding affinity for the respective hormone decreases, whereas if FKBP52 is in the complex the 
binding affinity is increased.31  
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Fig. 4: Model of FKBP51 and 52 on steroid hormone maturation and ligand binding. 
 
The PPIase enzymatic activity is not required for the modulation of the SHRs, but the FK1 domain and 
especially the proline rich loop which sits on top of the binding pocket, is crucial.32 Differences in this 
loop seem to be the cause for the different functions of the FKBPs, shown by the mutations, A116V 
and L119P in FKBP51 that switched the activity to full FKBP52-like characteristics towards AR 
activation.32  
FKBP51 and FKBP52 also play a role in steroid hormone receptor localization. In the ligand free state 
the SHRs primarily stay in the cytoplasm, whereas ligand bound SHRs are mainly nuclear or 
translocate to the nucleus.33, 34 It has been suggested that the accumulation of ligand bound SHR in 
the nucleus is enhanced by active retrograde transport driven by the dynein-dynactin complex which 
co-immunoprecipitate with the Hsp90-FKBP52 and with the GR and MR.35, 36  
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1.2.3 Effects of FKBP51 and FKBP52 on the endocrine system 
 
1.2.3.1 FKBP52 knockout mouse 
 
FKBP52 knockout mice (52KO) are viable but females are completely infertile. Male 52KO mice 
display a phenotype consistent with androgen insensitivity syndrome, hypospadias, penis length and 
weight of the penis was reduced, smaller seminal vesicles, smaller prostate glands, slightly lower 
sperm motility, collectively showing that mainly secondary sex organs are affected whereas primary 
sex organs like testes seemed to be unaffected.28, 37 Female 52KO mice show no big change in 
phenotype but are sterile. This is due to progesterone insensitivity causing failures in decidualization 
and embryonic implantation.38 Thus, FKBP52 is crucial for correct development of reproductive 
organs in male and female mice which is mainly caused by AR and PR insensitivity.  
 
1.2.3.2 FKBP51 knockout mouse 
 
Under basal conditions FKBP51 knockout mice (51KO) show no robust phenotype. 51KO male and 
female mice are fertile and males show normal reproductive organs. Thus AR signaling is unaffected 
and also no changes in GR activity could be observed.37 A possible explanation for the unanticipated 
absence of an effect on GR is the nature of the cortisol secretion under stress, and indeed recently 
Touma and coworkers could show, that 51KO in mice leads to a more active coping behavior after 
exposure to different types of stress. Additionally the hypothalamus-pituitary-adrenal (HPA) axis 
response on stress was altered. 51KO mice showed a stronger suppression of corticosterone 
secretion after treatment with a low dose of dexamethasone.39 These findings were supported by the 
results of Hartmann et al. who showed in a chronic model of social defeat stress, that 51KO mice 
responded less to a novel acute stimulus and showed an enhanced recovery, as well as more active 
stress-coping behavior.40 Additionally O’Leary and coworkers demonstrated that FKBP51 deficiency in 
aged mice led to more active stress-coping in the forced swim test and the tail suspension test. Both 
are well established paradigms to assess antidepressive effects.41 All these findings strongly support 
the hypothesis that FKBP51 plays an important role in endocrine regulation of the HPA axis by 
reducing GR responsiveness. This makes FKBP51 a promising target in stress related diseases.  
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1.2.4 FKBP51 in stress related diseases 
 
In stress related diseases such as major depression, bipolar disorder, post-traumatic stress disorder 
(PTSD) and anxiety disorder patients often display an imbalance in the stress hormone system called 
the hypothalamus-pituitary-adrenal (HPA) axis (Fig. 5). In healthy individuals this hormone system 
triggers the physiological and behavioral response to stressors. This can be measured by an increase 
in blood cortisol levels that peaks after 15-30 min and then slowly declines after termination of the 
stressor. Cortisol is a catabolic steroid hormone that activates energy metabolism in various tissues 
and acts as a negative regulator on the HPA axis.42  
 
 
Fig. 5: Hypothalamus-pituitary-adrenal axis with hormone regulation cascades 
 
Upon stress the hypothalamus secretes corticotropin releasing hormone (CRH) which induces the 
production of adrenocorticotropic hormone (ACTH) in the pituitary gland. ACTH in turn increases the 
release of cortisol in the adrenal gland into the blood. Cortisol is binding to the GR and MR which in 
turn inhibit the further release of CRH and ACTH thereby maintaining homeostasis of the HPA axis. 
Additionally, an ultrashort feedback loop is thought to be present at the cellular level. Activated GR 
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increases the FKBP51 expression which in turn decreases the affinity of the GR for cortisol. 
Malfunctions in these negative feedback loops are thought to be a cause for an inappropriate 
reaction of the HPA axis to stress which is often observed in depressive patients. 
FKBP51 is a known negative modulator of GR activity. Its physiological relevance was supported by 
findings in squirrel monkeys which show an increased blood cortisol level associated to decreased GR 
activity and an overexpression of the more potent squirrel monkey FKBP51.43, 44 These findings 
initiated human genetic studies on FKBP51 in major depression. In these studies identified single 
nucleotide polymorphisms in the FKBP51 encoding gene were associated with the response to 
antidepressants and with more lifetime depressive episodes.45 Similar studies followed that 
confirmed these findings46, 47 and found gender-specific effects.47, 48 FKBP51 genetic variants could 
also be linked to bipolar disorders48 and significant associations where also found to suicidal 
events.49-52 Polymorphisms in the FKBP51 encoding gene also influence the recovery from 
psychosocial stress in healthy individuals53. Another link could be observed from FKBP51 gene 
variants to peritraumatic dissociation54 which is an important risk factor for development of a PTSD.55 
The connection to PTSD was also found in other studies.56 All these findings clearly show that FKBP51 
contributes to the etiology of stress-related psychiatric disorders. 
 
1.2.5 Cancer and cell proliferation 
 
FKBP51 is up-regulated by androgens (natural: dehydrotestosterone, synthetic: R1881) which made it 
an interesting target for androgen dependent cancer types. Indeed, FKBP51 has consistently been 
reported to be up-regulated in human prostate cancer cells.57 FKBP51 was also found to be up-
regulated in prostatic hyperblasia.58 Further FKBP51 was shown to promote the assembly of the 
Hsp90 chaperone complex and thereby regulates androgen receptor signaling in prostate cancer 
cells.59, 60 However, the unanticipated potentiation of AR by FKBP51 is a very special case because in 
all other reported studies FKBP51 is a negative regulator of SHR. Although, this effect was not seen in 
all reported studies and seems to be cell-type dependent.61 The FKBP unselective ligand FK506 was 
shown to inhibit cell growth after androgen stimulation in a new prostate cancer type where FKBP51 
and FKBP52 are overexpressed.  
It was demonstrated that FKBP51 suppresses the proliferation of colorectal adenocarcinoma, 
possibly due to its deactivating effect on glucocorticoid receptors62. Following dexamethasone 
treatment myeloma cells show prior cell death up-regulation of FKBP51. This could be exploited to 
enhance the myeloma killing effect of dexamethasone in future63. By an siRNA approach a link of 
FKBP51 to drug-induced NF-κB activation in human acute lymphoblastic leukemia could be shown. 
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This was supported by inhibition using rapamycin64. In a recent study the role of FKBP51 in 
melanocyte malignancy was outlined65. In a different cell line Pei and coworkers were able to 
identify FKBP51 as a negative regulator of the Akt pathway by serving as a scaffolding protein for 
PHLPP. A reduced expression of FKBP51 in certain cancer types could be correlated with increased 
AKT phosphorylation which resulted in a reduced cell sensitivity to chemotherapeutics66. 
Much less is known about the implications of FKBP52 in cancer but recently it could be shown that 
prevention of hormone-induced dissociation of the Hsp90-FKBP52-AR complex results in inhibition of 
androgen-stimulated prostate cancer cell proliferation67.  
Due to their modulating actions on steroid hormone receptors and their implications in the according 
diseases, FKBP51 and FKBP52 represent promising drug targets for anti-cancer therapy.  
 
1.2.6 Immune function 
 
FKBPs also play a role in immune function and inflammation. The best known effect of FKBPs is their 
ability to form ternary complexes with the immunosuppressive drugs FK506 and rapamycin (see 
Chapter 1.1). Besides these prominent immunosuppressive effects various other implications were 
published during the last years. Recent studies showed FKBP51 to be up-regulated in CD34+ bone 
marrow cells in patients with rheumatoid arthritis.68, 69 Park and co-workers demonstrated that 
FKBP51 can modulate NF-κB-dependent gene expression in Newcastle disease virus-infected 
chickens.70 Further it was shown that FKBP51 modulates the stability of IκB and the phosphorylation 
of NF-κB and enhances its DNA binding.71 A very recent study connects FKBP51 expression with 
asthma after administration on inhaled corticosteroids.72 Additionally, in patients suffering from 
chronic obstructive pulmonary disease an up-regulation of FKBP51 could be observed.73 FKBP51 plays 
also a role in endogenous MHC class II-restricted antigen presentation. FK506 was able to inhibit the 
presentation of endogenous MHC class II-restricted minor histocompatibility antigens in primary 
dendritic cells (DC) in vitro. This effect could be rescued by RNAi mediated reduction of FKBP51.74  
 
1.2.7 Effect on neurodegenerative diseases 
 
Besides their role in immunosuppression, FKBPs have repeatedly been linked to neurodegeneration 
in several animal models like transient focal cerebral ischemia in rats or in MPTP mouse models of 
Parkinson's disease.75, 76 Gold et al. showed in a rat sciatic nerve crush model that the 
immunosuppressive drug FK506 accelerated nerve (re-)generation.77 This effect could also be 
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transferred to human patients receiving hand transplants.78 FK506 binds unselectively to FKBP 
proteins and the mediator of the the neuroprotective effect could not be elucidated so far. Early 
research was focused on the most abundant FKBP12 as the main mediator of the neuroprotective 
effect of FK506. It could be shown that adding FK506 to primary neurons during or after glucose 
deprivation limited the induced damage. This effect could be reverted by a FKBP12 antibody or the 
competitive inhibitor rapamycin.79 Importantly, the use of non-immunosuppressive derivatives of 
FK506 which are not able to form a ternary complex ruled out a calcineurin-dependent mechanism 
for the observed neuroprotective activity.80, 81 In primary hippocampal cell cultures from FKBP12 
knockout mice FK506 retained neurotrophic activity, thus devalidating the prototypic FKBP12 as the 
relevant target in this model. The mitochondrial FKBP38 and the Hsp90 co-chaperone FKBP52 have 
been suggested as alternative targets82, 83 (for detailed reviews see84,85). Present FKBP ligands that 
show neuroprotective effects bind unselectively the whole group of FKBPs, with most research 
focused on FKBP12, FKBP38 and FKBP52. Quinta and co-workers could show that neurite outgrowth 
in mouse N2a cells is favored by FKBP52 over-expression or FKBP51 knock-down, and is impaired by 
FKBP52 knock-down or FKBP51 over-expression, nicely showing the antagonistic activities of FKBP51 
and 52 on neuronal differentiation.86 FKBP51 and FKBP52 were also found to play a role in tau 
turnover which is a key phenomenon in Alzheimer’s disease.87, 88  
All these findings suggest that immunophilins and especially the larger homologs FKBP51 and FKBP52 
are important for neuronal processes involved in neurprotection, neuroregeneration and neuronal 
differentiation. Additionally, because of the antagonistic effects of FKBP51 and FKBP52 in different 
systems it is particularly important to develop FKBP subtype selective Ligands to dissect the opposing 
roles of these proteins. 
 
1.3 Chemical biology of FKBP ligands 
 
1.3.1 Immunosuppressive FKBP ligands 
 
Since the discovery of FK506 and rapamycin (Fig. 1) in the 1990s and the characterization of their 
immunosuppressive effect a lot of research has been devoted to the improvement of these ligands in 
terms of side effects, solubility and efficacy. Fig. 6 shows FK506 and rapamycin analogs that are used 
in the clinic. The efforts in this field increased even more after the discoveries that rapamycin has 
beneficial effect on longevity in mice89, improves behavioral and cognitive deficits in models of 
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neurodegeneration like Alzheimer’s90, Parkinson’s91 and Huntington’s disease92 and in cancers due to 
misregulated mTOR pathway.93  
 
 
Fig. 6: Clinically used FK506 and rapamycin analogs
84
 
 
1.3.2 Non-immunosuppressive FKBP ligands 
 
Up to now almost no drugs are available to treat chronic neurodegenerative diseases. Gold and co-
workers found in the early 1990s that besides its immunosuppressive effects FK506 has also 
neurotrphic activity. These effects were shown in a rat sciatic nerve model.77, 94 These findings 
stimulated a whole field to search for non-immunosuppressive immunophilin ligands that still display 
this neuroprotective effect. These ligands were termed neuroimmunophilin ligands. 
Almost 20 years of medicinal chemistry and biochemistry efforts produced a variety of non-
immunosuppressive ligands based on the known natural products (Fig. 7) where the effector domain 
is changed. This abolished the binding to calcineurin/ mTOR (e.g., FK1706, meridamycin, 
normeridamycin, ILS920, Way-124466, Wye-592, L685-818). These ligands demonstrated their effect 
in animal models of cerebral ischemia83, 95, traumatic brain injury96, diabetic neuropathy97, 
Parkinson’s disease75, 98, 99, and various types of physical neuronal injury.81, 100-102 
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Fig. 7: Neuroimmunophilin ligands based on biosynthetic or semi-synthetic analogs of 
FK506 or rapamycin
84
 
 
In addition a vast number of synthetic FKBP ligands have been reported which are based on the 
pipecolyl/prolyl diketoamide core derived from FK506 and rapamycin. All these compounds lack the 
effector domain of FK506 and are thus not immunosuppressive. Fig. 8 shows a collection of reported 
synthetic neuroimmunophilin ligands that showed neurotrophic activity. VX-10,367 and VX-7109 
where patented for stimulating neurite growth in nerve cells and are the most potent FKBP12 ligands 
known to date.103 GPI1046 received a lot of attention due to its effect on neurite outgrowth from 
sensory neuronal cultures with reports of picomolar potency In vivo. Additionally GPI-1046 
stimulated the regeneration of lesioned sciatic nerve axons.80, 104 Analogs of GPI1046 were also 
published to be neurotrophic (GPI1485, JNJ460).105 However these results were challenged by other 
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groups.104, 106 Moreover, GPI1046 was also reported to be inactive in PPIase assay by us and others.85 
Our own unpublished data shows that GP1046 is also inactive for the higher homologs FKBP51 and 
FKBP52.  
Most of the studies in the literature are focused on FKBP12 but Gold and coworkers showed that also 
other proteins can mediate the effect.82 This was corroborated by using various FK506 analogs that 
are claimed not to bind FKBP12 (VX-853, V-13,661 and V-13,670, Fig. 8).75, 102 Furthermore the 
selective FKBP38 inhibitor DM-CHX was shown to be active in an animal model of focal cerebral 
ischemia.83 
All these results show that FKBP ligands can have neuroprotective or neurotrophic activities and may 
be potentially useful in certain neurodegenerative diseases or after neuronal loss. Although a lot of 
inconsistencies still exist possibly by differences in cellular and animal models or ligands used. Also 
the relevant targets are still controversially discussed.85 
 
 
Fig.8: Synthetic neuroimmunophilin ligands. The core of FK506 or rapamycin or equivalent groups 
are shown in yellow
84
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1.4 Targeting the PPIase binding pocket of FKBP51 and FKBP52 
 
 
      
Fig. 9: (A) Natural product FKBP ligand FK506, FKBP binding domain (blue), effector domain (green). (B) Synthetic FKBP 
ligand SLF FKBP binding domain (blue). (C) Co-crystal structure of FK506 and FKBP51. (D) Co-crystal structure of SLFand 
FKBP51.  
 
As outlined in the previous chapter most of the synthetic immunophilin ligands were designed to 
bind FKBP12. These ligands were derived from the diketoamide pipecolinic core of FK506 and 
rapamycin lacking the effector domain and are exemplified by SLF107 (Fig. 9).The pyranose ring was 
exchanged by a tert-pentyl group which proved to be a good isoster. SLF showed binding affinity for 
FKBP12 in the range of FK506 (low nanomolar) but for the larger homologs FKBP51 and FKBP52 it 
was substantially less affine (low micromolar).108 Therefore, the Hausch group solved the co-crystal 
structure of SLF and FKBP51109 and compared it to the co-crystal structure of FK506 and FKBP51110 as 
a starting point for rational ligand design. The amino acids of the binding pocket are almost 
superimposeable and SLF also shows the important hydrogen bonds from I87 to the pipecolate 
carbonyl group and from Y113 to the amide carbonyl group. W90 forms the bottom of the binding 
pocket and the pipecolyl ring sits on top of the indole ring. SLF was the only ligand in the literature 
W90 
I87 
Y113 W90 
I87 
Y113 
 (A)          (B) 
 
 
 
 
 
 
 (C)          (D) 
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that was described for FKBP51108 at the start of this thesis while for FKBP52 three ligands were 
known.95, 105  
Gopalakrishnan and co-workers performed the first structure activity relationship (SAR) analysis to 
determine the contributions of individual substructures of SLF (Fig. 10).109 The affinities were 
measured using the fluorescence polarization assay described by Kozany et al.108 SLF bound to 
FKBP51 with ~8µM and to FKBP52 with ~10µM. 
 
 
Fig. 10: Synthetic analogs of SLF for SAR analysis 
 
Replacement of the pipecolyl core by proline or 4,5-dehydropipecolinic acid resulted in a 4-6 fold 
reduction in potency. The change to thiomorpholine-3-carboxylic acid abolished binding to FKBP51 
and FKBP52.  
Furthermore they employed different top-groups. The smaller groups (Fig. 10, A-D) showed no 
binding to FKBP51 and FKBP52. To eliminate the free charge at the free acid moiety of F and G they 
changed it to morpholine H which increased the binding affinity by 2-4 fold compared to SLF and a 
slight preference for FKBP52 could be observed. This trend could also be seen in a sulfonamide series 
of compounds also published by the Hausch group111. They replaced the ester at C1 G by an amide 
which abolished binding to FKBP51 and FKBP52. Finally, they replaced the oxyacetyl group of the SLF 
top-group by an amine I which resulted in the best binding compound 1 (Fig. 11) of this series. It 
showed binding to FKBP51 of ~4 µM and to FKBP52 of ~1µM.  
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Fig. 11: Exchange of tert-pentyl by 3,4,5-trimethoxyphenyl  
 
They continued by replacing the tert-pentyl group with 3,4,5-trimethoxyphenyl (Fig. 11) which 
resulted in a 2 fold decrease in binding for the larger FKBPs. Additionally two clinically used non-
immunosuppressive FK506 analogs were tested on their binding to FKBP51 and FKBP52 (Fig. 8). 
Biricodar showed affinity in the range of SLF ~8 µM whereas Timcodar showed no affinity for any 
FKBP tested.  
 
 
Fig. 12: Overlay of the important amino acids of the binding pocket of FKBP12, FKBP51 and FKBP52. The not conserved 
amino acids are marked in red. 
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The binding pocket of all FKBPs is highly conserved .The most prominent changes are found in the 
70s loop (amino acids 71-76 of FKBP51/52) and the proline rich loop (amino acids 118-122 of 
FKBP51/52) (Fig. 12). The most important change in the amino acid sequence between FKBP51 and 
FKBP52 can be found in position 119 in the proline rich loop. A L119P mutation in FKBP51, which 
introduces the proline found in FKBP52, conferred significant potentiation activity towards steroid 
hormone receptors, whereas the converse P119L mutation in FKBP52 decreased potentiation.32  
Thus, they planned to target the proline rich loop with with a new series of compounds comprising a 
substituted cyclohexyl ring (Fig. 13) instead of the tert-pentyl. This would be more close to the 
pyranose ring of FK506.  
 
 
Fig. 13: Cyclohexyl substituted ligand series targeting the proline rich loop 
 
The SAR of these compounds and the crystal structures that they published showed that FKBP51 and 
FKBP52 are tolerant to different stereochemistries at the cyclohexyl substituent. The best binding 
compounds of this series C1 and C2 (Fig. 14) show binding affinities of 1 µM to 4 µM. 
 
 
Fig. 14: Best binding examples of the substituted cyclohexyl ligand series. 
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For FKBP12 it was shown that the diketo amide moiety can be bioisosterically exchanged to 
sulfonamide112, 113. To determine the binding of sulfonamide ligands to FKBP51 and FKBP52 
Gopalakrishnan et al. developed a solid phase strategy for the synthesis of a focused sulfonamide 
library111.  
Out of 36 compounds with aromatic sulfonamides they identified 5 hits for the binding to FKBP51 
and FKBP52 which displayed a slight preference for FKBP52. The hits showed moderate binding 
affinities with ~10 µM.  
For the best hits the morpholine top-group (Fig. 15) was employed and increased the binding affinity 
to nanomolar levels for S1 and to low micromolar for S2. Therefore ligand S1 displays the best known 
ligand for the large FKBPs to date. With this strategy they could show that a bioisosteric replacement 
of the diketo amide to sulfonamide with conservation of the hydrogen bonds leads to potent FKBP51 
and FKBP52 inhibitors.  
All of the described ligands in this chapter unfortunately show no selectivity between FKBP51 and 
FKBP52 and at least 10 to 100-fold higher affinity for FKBP12.  
 
 
Fig. 15: Top-group substitutions of the best hits 
1.5 Artificially selective ligands 
 
 
Fig. 16: Chemical inducer of dimerization AP1510 based on an SLF dimer 
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In the early 1990s Spencer et al.114 developed chemical inducers of dimerization (CID) to control 
intracellular signal pathways that are normally controlled by protein-protein interactions. Therefore, 
they conjugated two FK506 molecules together via a linker and termed it FK1012. This was improved 
by the development of the bivalent synthetic analog AP1510115 (Fig. 16). These CIDs can bind and 
dimerize proteins of interest which are fused to a FKBP12 “tag” and thereby specifically activate 
signaling. The major disadvantage is the high affinity to endogenous FKBPs which are highly 
expressed. This leads to unwanted heterodimers that interfere with the signaling pathways which are 
to be observed.  
 
 
Fig. 17: Priciple of artificial selective ligands. Bulky 
modification at the ligand abolishes binding to the wildtype 
but allows binding to the mutant 
 
To address this selectivity problem the group of Holt116 used a chemical genomics approach to 
redesign the FKBP12-ligand interface by engineering a new pocket into the active site. At the same 
time they synthesized ligands that exploit the newly formed cavity in the binding pocket (Fig. 17 and 
Fig. 18). These ligands showed a substantial decrease in binding affinity to the wildtype but high 
affinity to the mutant protein. This technique is also called the bump and hole concept.  
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Fig. 18: (A) Model of ligand 10 in the crystal structure of FKBP12
WT
. Steric clash of the Cα substituent with Phe36 (red). (B) 
Co-crystal structure of 10 with the mutated FKBP12
F36V
. Cα substituent fits into the new formed cavity. 
 
To achieve that goal they investigated the co-crystal structure of FK506 and FKBP12 and concluded 
that an exchange of the Cα carbonyl to larger substituents would sterically clash with either Tyr26 or 
Phe36 and should abolish or decrease binding. In turn a compensating mutation at one of these 
amino acids would restore binding (Fig. 17 and Fig. 18). The best ligand (1, Fig. 20) showed an affinity 
of 1.8 nM to the F36V mutant of FKBP12 and to the wildtype FKBP12 of 2930 nM. This ligand can 
differentiate 1,000-fold between WT and was further dimerized via a short linker to form AP20187 
(Fig. 19) which was then used to activate Fas signaling in a mouse model of conditional cell 
ablation116.  
 
 
Fig. 19 Mutant selective FKBP12 CID AP20187.  
 
CIDs have been used in a broad range of applications for dimerization of for example membrane 
receptors: Erythropitin receptor117, PDGF-ß-R / Insulin receptor118, epithelial growth factor receptors 
/ hepatocyte growth factor / thrombopoietin receptor119 or for the induced activation of apoptosis by 
dimerization of the FAS receptor or the dimerization of caspases115, 120-122.  
Banaszynski et al. from the Wandless group further expanded that field by designing a method to 
reversibly regulate protein stability in living cells using a synthetic analog termed Shield-1123  
Phe36 Val36 
Cα Cα 
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Another very prominent example of the bump and hole strategy is the selective inhibition of mutant 
kinases shown by Bishop from the lab of Kevan Shokat.124 With this technique they designed a 
selective cdc28 inhibitor and showed for the first time the effect of the inhibition of this specific 
kinase. This technique was also applied to other kinases.125  
 
2. Aim of the study 
 
 
Fig. 20: Starting point of the synthetic campaign 
 
FKBP51 is a known negative modulator of glucocorticoid receptor (GR) activity whereas its closest 
homolog FKBP52 activates the GR.  
The natural product FK506, rapamycin and all other reported FKBP ligands show if at all a selectivity 
for FKBP12 because of their high structural and sequence similarity84. Due to the opposing effects of 
FKBP51 and FKBP52 these ligands are not suited to study the role of these proteins in GR signalling.  
The goal of the study was to design and synthesize ligands that solve that selectivity issue of the 
known FKBP ligands.  
We envisioned a chemical genomics tool to artificially design selective ligand mutant pairs for FKBP51 
and FKBP52. Therefore structure-based design should be used to synthesize ligands with protruding 
Cα substituents and site directed mutagenesis to introduce an enlarged cavity into the active sites of 
FKBP51 and FKBP52 to compensate for the Cα substituent. Starting point for the synthesis was the 
FKBP12F36V mutant selective ligand 1116 (Fig. 20). This chemical genomics tool was intended to be 
applied to more complex in vitro GR binding assays and cellular assays like GR reportergene assays to 
probe the pharmacological tractability of FKBP51 and its potential as a druggable target.  
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B. Results and Discussion 
 
1. Chemical genomics to selectively address FKBP-sub-types 
 
1.1 Design of FKBP mutant specific engineered (FMSE) ligands 
 
 
Fig. 21: FKBP mutant-specific engineered ligand 1 
 
All FKBP ligands reported so far, including rapamycin and FK506, show only negligible selectivity for 
individual FKBP homologs since the residues within the active site are completely conserved both on 
the sequence and the structural level except for FKBP38.110 FKBP51 and 52 have been shown to have 
opposing effects on steroid hormone receptors as well as on neurite outgrowth. FKBP51 in most 
cases reduces receptor sensitivity, whereas FKBP52 is a positive regulator of SHRs.31 Likewise in a 
neuroblastoma cell line FKBP51 suppressed the elongation of neurites whereas FKBP52 enhanced 
it.86 Due to these antagonistic effects, these proteins cannot be examined with present FKBP 
inhibitors. Chemical genomics provides for this case the perfect tool to artificially overcome this 
selectivity issue by engineered mutant-ligand pairs. A large hydrophobic amino acid in the active site 
is mutated to a smaller amino acid, which generates a new hole in the binding pocket. In turn, a 
complementary ligand is engineered with a protruding sidechain that fits into this new cavity. This 
sidechain performs two tasks; first it should increase the affinity to the mutated protein and second 
decrease the affinity to the wildtype. In previous work in the Hausch lab phenylalanine 67 was 
mutated to valine to open a new cavity in the binding pocket. Complementarily, compound 1 
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(Fig. 21) with a Cα ethyl in (S)-configuration was synthesized, which is a tight and selective binder of 
FKBP12 carrying a homologous F36V mutation.116 Compound 1 showed moderate binding affinity to 
FKBP51F67V (51mut) of IC50~2µM and to FKBP52
F67V (52mut) of IC50~22µM. The affinities to the 
wildtype proteins were >100 µM. While this compound showed good selectivity vs the wildtype 
proteins of greater than 50 fold, the affinity had to be improved substantially to allow for cellular 
experiments. We thus used 1 as a starting point to synthesize a series of analogs to optimize the 
interaction with the mutated FKBP51/52 binding site (Fig. 22).  
 
 
Fig. 22: General structure of FKBP mutant specific engineered 
ligands 
 
1.2 Synthesis of the FMSE ligands 
 
The top group of the ligands 5a was synthesized by an improved procedure based on the synthetic 
route published by Keenan et al.107 The first step was an aldol condensation of commercially available 
3-hydroxyacetophenone and 3,4-dimethoxy-benzaldehyde using potassium hydroxide (Fig. 23). The 
chemoselective reduction of the double bond of 2 was performed in a high pressure autoclave using 
Lindlar catalyst. The free aromatic alcohol of 3 was subsequently alkylated with tertbutyl 2-
bromoacetate. 4a was then subjected to (R)-stereoselective reduction in the autoclave using a Noyori 
catalyst. 5a was obtained with excellent enantiomeric excess of >95%. 
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Fig 23: (a) KOH, EtOH/H2O, 80-99%, RT. (b) Pd/C/BaSO4, H2 30-40 bar, MeOH, 88-95%. (c) K2CO3, BrCH2COOtBu, aceton, 
60-75%. (d) Noyori cat, H2, i-propanol, 80%, >95% ee. 
 
The pipecolinic acid analogs 7a and b were synthesized from commercially available (S)-Pipecolinic 
respective (S)-thiopipecolinic acid using standard Fmoc protection (Fig. 24). 7a and 7b and the Fmoc-
(S)-Proline analog 7c were further esterified with the alcohols 5a and b. 
 
 
Fig. 24: (a) TEA, Fmoc-Cl, DCM, RT, 90-95%. (b) 5a or 5b EDC, DCM, RT, 50-70%. (c) 4-Methyl-piperidine, 
DCM, RT, 70-90% 
 
Based on the FKBP12F36V co-crystal structure with compound 1 it is clear that the Cα substituent has 
to be in the (S)-configuration to fit best into the new hole (Fig 21)107. First attempts to synthesize 
different Cα substituted ligands were performed by non-stereoselective alkylation of commercially 
available 2-(3,4,5 trimethoxyphenyl)acetic acid using various alkylbromides, and eventually 
separation of the diastereomers of the final product. Unfortunately, the coupling of 17-19 (Fig. 25) to 
8 resulted in almost exclusive formation of the unwanted Cα (R)-configuration which was determined 
by comparison with the HPLC shift of the active isomer of compound 1 and is in line with the low 
binding affinity of the products 24dia (data not shown). This was subsequently corroborated with the 
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HPLC shifts of the active compound which were later synthesized in a stereoselective manner 
(compounds 24-28). 
We envisioned a stereoselective synthesis using the Evans auxiliary (Fig. 26) to obtain Cα 
substitutions in (S)-configuration.126 We chose allyl because of its larger size compared to ethyl and 
because the literature shows broad application of allyl halides in stereoselective Evans alkylation.127, 
128 Therefore 2-(3,4,5-trimethoxyphenyl)acetic acid 11 was converted to the stable active 
pentafluorophenol ester to give 20 which was then coupled with (S)-isopropyloxazolidinone to give 
the imide 21. 
 
 
Fig. 25: (a) LiHMDS 2.2 eq, R-Br, THF, RT, 60-80% (b) HATU, 
DIEPA, DCM, 50-60%.  
 
The key step in this synthesis, the stereoselective alkylation was performed after formation of the 
sodium enolate, which reacted with allyl bromide to give 22 with 60% yield and dr >95:5 (determined 
by HPLC and NMR). The imide was cleaved to give the free acid 23.  
 
 
Fig. 26: (a) EDC, C6H5OH, DCM, RT 90-95%. (b) BuLi, (S)-isopropyloxazolidinone, THF, -78°C-0°C, 60-80%. (c) NaHMDS, THF, 
allyl bromide, -78°C, 50-60%. (d) LiOH, H2O2, THF/H2O 8:5, 0°C-RT, 60-90%  
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The allyl substituted ligand series was synthesized by amide bond formation of 8a-c/9a-c with 23 to 
give the final compounds 24-28 with a dr of >90:10 (determined by HPLC and NMR). Compounds 18 
and 19 were obtained after tert-butyl deprotection with 10% TFA in DCM with 50% yield. The 
3,4-dehydropipecolinic ester core 33 was synthesized from (S)-allylglycine 29 according to the 
published procedure of Varray et al.129 33 was coupled to 23 and the ester was cleaved to give 34, 
which was esterified with the morpholine top group 5b providing the ligand 35 with dr of >95:5.  
 
 
Fig. 27: (a) HATU, DIPEA, DCM, RT, 40-50%. (b) TFA, DCM, 0°-RT, 50-60%. (c) o-nitrobenzenesulfonyl 
chloride, TEA, DCM, RT, 60%. (d) TMSCl, MeOH, 0°C-RT, 99%. (e) Allylbromide, K2CO3, DMF, RT, 83%. 
(f) RT,Grubbs Cat. II, DCM, reflux, 90%. (g) Thiophenol, Cs2CO2, CH3CN, RT, 81%. (h) HATU, DIPEA, 23, 
DCM, RT, 68%. (i) LiOH, THF/H2O, RT, 80%. (j) EDC-HCl, DMAP, 5b, DCM, 0°C-RT, 62%.   
 
1.3 Biochemical characterization of the FMSE-ligand-mutant pairs 
 
To determine the IC50 values of the engineered ligands to the proteins, we performed in vitro 
fluorescence polarization binding assays with the FK1-domains of FKBP51, FKBP52 and the 
corresponding mutated FK1-domains according to Kozany et al.108 Table 1 shows the binding 
B. Results and Discussion _____________________________________________________________ 
28 
 
affinities of the synthesized ligands. We generated a series of Cα allyl compounds bearing different 
core and top groups. The final compounds were synthesized either with a hydrophilic top group, 
containing a free acid moiety for better solubility, or a morpholine group for better cell permeability. 
Compound 24 was the first synthesized and showed already an improvement compared to the ethyl 
compound 1. The affinity for FKBP51F67V increased upon exchange of ethyl to allyl to 0.7 µM showing 
that the artificial cavity in the mutated proteins can accommodate bigger substituents than ethyl. We 
next exchanged the pipecolinic core to proline to probe the effect of a smaller ring on binding. The 
IC50 of the proline derivative 25 increased by 2-fold for the mutated proteins but also 4-fold for the 
wildtypes. Thus, the selectivity vs the wild type proteins decreased slightly. By exchanging the 
hydrophilic acid moiety by morpholine a strong increase in binding affinity occurred. Substitution of 
the free acid of 24 by morpholine yielded 26 and increased the affinity by 12-fold for the wildtype 
proteins and by almost 100-fold for the mutated proteins. The selectivity of mutated vs wildtype 
proteins increased to 1000-fold. Encouraged by this effect we synthesized the proline derivative 27, 
unfortunately the binding affinity decreased by 3-fold for the wildtype, and 10-fold for the mutant. 
This is in contrast to proline compound 25 with the free acid top group where this proline 
modification resulted in an increase of affinity compared to pipecolate. The selectivity of 27 also 
decreased slightly. We further substituted the core by thiomorpholine 28, which caused a drop of 10-
fold in affinity whereas exchange to the 3,4-dehydropipecolinic core 35 showed affinity in the range 
of 26. Tab. 1 shows the SAR of the allyl series.  
 
 
 
Tab. 1: SAR of the allyl series for FKBP51F67V 
 
 
Fig. 28 shows the binding curves of the two best compounds 26 and 35. Compound 26 was kindly 
synthesized by the LDC based on our results as a control for further experiments.  
In summary, we improved the binding affinity to the mutated proteins by 1000-fold compared to 
compound 1 while maintaining 500 to 1000-fold selectivity for mutated FKBP51/52 over wildtype 
proteins. These selective ligand-mutant pairs can be used in a model system created by chemical 
genomics to examine the selective inhibition of FKBP51 and 52. This system can be used in different 
cellular assays (e.g. reporter gene, neurite outgrowth assay) where FKBP mutant proteins can be 
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overexpressed. The best ligands bind with IC50 in the low nanomolar range, which enables for specific 
inhibition of mutated protein over endogenous proteins.  
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Fig.28: Biochemical characterization of artificially selective FKBP mutant-ligand 
pairs with 26 and 35. Purified FK1-domains of 51wt (2 nM), 52wt (2 nM), 
51mut (2 nM) and 52mut (10 nM) were measured in a fluorescence 
polarization binding assay by titrating 26 or 35 using 3nM of compound F2 
(Chapter 4.1) as a tracer
108
. 
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Tab.2: General structure of the ligands, and binding affinities (IC50) in µM. Purified FK1-domains of 51wt (2 nM), 52wt (2 
nM), 51mut (2 nM) and 52mut (10 nM) were measured in a fluorescence polarization binding assay by titrating the 
compounds using 3nM of compound F2 (Chapter 4.1) as a tracer
108
. (a) Solubility limit. (b) Compounds were provided by a 
collaboration with the Lead Discovery Center GmbH (LDC) 
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1.4 Effect of selective inhibition of mutated FKBP51 and 52 on neurite 
outgrowth in N2a neuroblastoma cells 
 
FK506 analogs have repeatedly shown neurotrophic or neuroregenerative effects in cellular and 
animal models. However, due to overlapping functions of FK506-binding proteins and the lack of 
selectivity of the ligands it proved difficult so far to exactly pinpoint the relevant FKBP. Some FKBPs 
show negative and others positive effects on neuronal function.  
To pharmacologically probe the role of FKBP51 and FKBP52 on neuronal function we used N2a cells 
as a cellular model for the differentiation of neuronal progenitor cells. Quinta et al. had previously 
shown that FKBP51 and FKBP52 have opposing effects in this model.86 Similar effects were observed 
in our system. Overexpressing FKBP51 inhibited neurite outgrowth (Fig. 29B, lanes 3 in Figs. 29C/D) 
compared to control transfection. In contrast, overexpression of FKBP52 enhanced the outgrowth of 
neurites compared to control (Fig. 30, lane 3). Fortunately, the neurite outgrowth-suppressing or 
stimulating effects of FKBP51 or FKBP52 were not affected by the point mutation F67V in the active 
site. 
As we were especially interested in whether FKBP51 can be pharmacologically targeted, we tested 
the effect of the selective inhibitors on FKBP-modulated neurite outgrowth. Transfection with empty 
vector pRk5 displays the basal neurite length after starvation (Fig. 29A, Fig. 29D/E, lane 1). The 
addition of 26 and 35 only marginally affected neurite outgrowth under these conditions. Likewise 
they did not revert the neurite outgrowth suppression by overexpressed wildtype FKBP51 (Fig 29D/E, 
lane 4), to which they bind with 1000-fold less affinity than to the mutant FKBP. However, the neurite 
outgrowth suppressed by the mutated FKBP51 was almost completely rescued by the mutant-
selective inhibitors 35 (Fig. 29C, Fig. 29D, lane 6). Almost identical results were obtained with the 
ligand 26 (Fig. 29E, lane 6). 
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Fig. 29: Rescue of neurite outgrowth assay in N2a-cells overexpressing FKBP51 by artificially selective ligand 26 and 35. (A) 
Transfection control vector prK5 and application of DMSO (B) Overexpression of FKBP51F67V and application of DMSO (C) 
Overexpression of FKBP51F67V and application of 20 µM Compound 35. (D) and (E) Each bar represents the mean of the 
neurite length (in mm) of 20-30 cells after the indicated treatment. 
 
Next we tested the consequence of selective inhibition of FKBP52 on neurite outgrowth. Again, 35 
did not inhibit the basal neurite outgrowth or the enhancement induced by the wildtype FKBP52 
(Fig. 30, lane 2 and 4). In contrast, inhibition of the mutated FKBP52 abolished the neurite 
stimulation completely even below basal level (Fig. 30, lane 6). 
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Fig. 30: Suppression of FKBP52 enhanced neurite outgrowth in N2a-
cells overexpressing FKBP52 by artificially selective ligand 35. 
 
 
The previous results strongly suggested inhibition of FKBP51 and FKBP52 to have opposite effects. To 
unambiguously proof this we co-overexpressed FKBP51 (wildtype and mutant) and FKBP52 (wildtype 
and mutant) in all four possible combinations and monitored the effects of the mutant-selective 
ligand 35 on neurite outgrowth behavior (Fig. 31). Simultaneous overexpression of FKBP51 and 52 
wildtype and mutants in all combinations (Fig. 31, lane 3, 5, 7 and 9) resulted in neurite length 
comparable with basal conditions (overexpression of control vector) which can be attributed to the 
opposing effects of FKBP51 and FKBP52. As expected, 35 had no effect on basal conditions, and only 
a small effect on cells overexpressing wildtype FKBP51 and wildtype FKBP52 (Fig. 31, lane 2, 4). 
Likewise, inhibition of mutated FKBP52 coexpressed with wildtype FKBP51 by 35 caused a shortening 
of the neurites due to selective, blocking the positive effect of FKBP52 while sparing the suppressing 
effect of FKBP51 (Fig. 31, lane 7 and 8). Selective inhibition of mutated FKBP51 co-expressed with 
wildtype FKBP52 by 35 lead to neurite outgrowth in line with leaving the positive effect of FKBP52 
(Fig. 31, lane 5 and 6). Importantly inhibiting the two mutated proteins at the same time resulted in 
neurites with the same length as the corresponding DMSO control (Fig 31 lane 10) consistent with a 
mutually canceling effect of simultaneously inhibiting both FKBPs. Taken together, in these model 
experiments with artificially selective ligand mutant pairs, we unambiguously showed that FKBP 
inhibiting ligands can have neurite outgrowth-stimulating or suppressing effects, depending whether 
FKBP51 or FKBP52 is more relevant in the system.  
In summary, we for the first time demonstrated activity of FKBP51 ligands in a relevant cellular 
model thereby providing the first experimental proof of concept for the feasibility to 
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pharmacologically target FKBP51. We showed in a cell model of neuronal differentiation, that specific 
inhibition of overexpressed FKBP51 restores neurite outgrowth whereas specific inhibition of 
overexpressed FKBP52 has the opposite effect. We therefore propose FKBP51-selective ligands as 
neuroprotective agents and that selectivity vs. FKBP52 will be crucial for a therapeutic benefit. This 
could be helpful for neurodegenerative diseases like Alzheimer’s and Parkinson’s disease but also 
during stress or in depression, which are characterized by neural loss or atrophy. 
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Fig. 31: Co-expression of FKBP51 and 52 and engineered sensitive 
mutants thereof. Either addition of DMSO or inhibition by 35. 
* indicates mutated proteins 
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2. Solving the selectivity issue by an induced fit mechanism 
 
 
2.1 Induced fit as a basis for selectivity  
 
 
 
Fig 32: (A) Co-crystalstructure of SLF and FKBP51FK1. (B) Structure of IF63. (C) Co-crystalstructure of 24 and FKBP51FK1. For 
better visibility of the binding pocket K121 was removed from the crystal strucures) highlighted are in blue the important 
hydrogen bonds from I87 to the C1 carbonyl group and from Y113 to the pipecolinic amide carbonyl C8. Further W90 is 
shown which displays the bottom of the binding pocket. F67 that is displaced to accommodate 24 is indicated in red. 
 
Our model system (chapter 1.3) showed that selectivity between FKBP51 and FKBP52 is necessary. 
However, the design of wildtype selective ligands for the wildtype proteins is extremely challenging 
due to the structural similarity of the binding pocket of the different FKBP subtypes. All ligands tested 
before showed almost the same binding affinity for FKBP51 and 52.  
In the assay results of our model system we noticed a slight preference of some of the Cα-substituted 
compounds for FKBP51 (1, 24, 25, 26, Tab. 2). This was unexpected as the Cα-allyl group would clash 
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with F67 in a binding mode typical for FKBP ligands (Fig. 32A, 34A). Intrigued by this finding we 
solved the co-crystal structures of 24 at a resolution of 1.4 Å and compared it with the co-crystal 
structure of the unselective FKBP ligand SLF with FKBP51 (Fig. 32A). This revealed that compound 24 
induces a conformational change in the binding pocket of FKBP51 that allows the protruding Cα allyl 
group to fit into a newly formed hole. More precisely, the Cα allyl substituent of 24 displaces F67 
(Fig. 32C) which flips out of the binding pocket to form a new hole in the binding pocket. Fig. 33 
shows the superposition of the co-crystal structures of FKBP51FK1/24 and FKBP51FK1/SLF. The major 
changes are found in the 60s and 70s loop which together with the proline rich loop contains the 
most important structural differences between the FK1 domains of FKBP51 and FKBP52. The 40s and 
the proline rich loop are known to be the most flexible part of the protein.109, 110 
 
Fig. 33: Superposition of the backbone traces of the co-crystal structure of FKBP51FK1/24 (pink) and the 
co-crystal structure of FKBP51FK1/SLF (green).  
 
The most interesting and prominent structural changes are observed in the amino acid sequence 
from G64 to N74 (GKKFDSSHERN, 60s to 70s loop Fig. 33, Fig. 34). The flip of F67 causes most of the 
surrounding amino acids to change their conformation. The side chains of K65 and K66 are not 
defined in the crystal structure, probably due to their flexibility, as they are solvent accessible. No 
ordered electron density for these amino acids could be observed. Interestingly, D68 almost retains 
the conformation compared to the co-crystal structure of FKBP51FK1/SLF although it is directly 
proline rich 
loop 
70s loop 
F67 
51FK1/24 
51FK1/SLF 
 
60s loop 
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neighboring F67 and it lost its saltbridge to R73, which possibly is replaced by S70. The conformation 
of S69 stays the same whereas S70 is flipped upwards together with a large conformational change 
of H71. The orientation of D72 only slightly changes whereas the orientation of R73 and N74 are 
completely changed.  
 
 
 
Fig. 34: Structural changes of G64 to N74 (60s and 70s) induced by 24. (A) 24 modeled into the co-crystal structure of 
FKBP51FK1/SLF. (B) co-crystal structure of FKBP51FK1/24 
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These extraordinary results provided a structural explanation for the unexpected binding of 24 to 
FKBP51. We therefore started the synthesis of a series of variously Cα substituted ligands to further 
elaborate the scope of this induced fit mechanism. 
 
2.2 Synthesis of iFit FKBP51 ligands 
 
The iFit (inducing fit) ligands were synthesized by a similar synthetic route as the FKBP subtype 
specific engineered ligands.  
We synthesized ligands consisting of three main parts the “Core”, the “Cα-Sub” and the “Top group” 
(Fig. 35). Core structures are either (S)-proline or (S)-pipecolinic acid. The “Top group” is a complex 
alcohol or amine, containing one or two substituted phenyl/pyridine rings with an ionizable moiety 
(acid, morpholine or pyridine) to increase solubility or cell permeability. The “Cα-Sub” is an alkyl 
substituent in Cα-position of the Core with (S)-conformation that protrudes into the hydrophobic 
binding pocket of FKBP proteins and induces the conformational rearrangement. We synthesized Cα 
substituents of different sizes ranging from allyl to benzyl to identify the best group for the induced 
sub-pocket. 
 
 
 
Fig. 35: General structure of synthesized iFit ligands 
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2.2.1 Cyclopropylmethyl and benzyl series 
 
2.2.1.1 Design and synthesis of Cα cyclopropylmethyl and benzyl ligands 
 
  
Fig. 36: (a) EDC, DCM, RT, 50-70%. (b) 4-Methyl-piperidine, DCM, RT, 70-90% 
 
Fmoc-(S)-pipecolate 6a and Fmoc-(S)-Proline 6c were esterified with alcohols 5a-d and after Fmoc 
cleavage the Products 36b and 37a-e could be obtained with good yields.  
We aimed to enlarge the Cα bump from allyl to cyclopropylmethyl because the co-crystal structure of 
24 clearly indicated that a cyclopropyl ring would fit better into the induced sub-pocket than the 
smaller allyl group. The synthesis of the cyclopropylmethyl substituent under the conditions used for 
allyl proved to be challenging. The stereoselective alkylation of the Evans imide with 
cyclopropylmethyl bromide only gave trace amount of the desired product (Fig. 37). 
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Fig. 37: (a) NaHMDS, THF, R-Br, -78°C, <5%. (b) LiOH, H2O2, THF/H2O 8:5, 0°C-RT, (c) EDC, (S),(S)-pseudoephedrine, DCM, RT, 
80-90%. (d) LiHMDS, LiCl, cyclopropylmethyl iodide or benzyl bromide, THF, -78°C-0°C, 40-50%. (e) 4 M H2SO4, dioxane, 0°C-
reflux, 50-60%. 
 
We concluded that the Evans imide was too deactivated to be properly reacted with non-allylic 
primary or secondary alkylbromides. We therefore decided to use a more active amide auxiliary for 
this type of substrate, the Myers pseudoephedrine (Fig. 37). This auxiliary shows a higher scope of 
possible alkylations in the literature.130 Using the Myers auxiliary the primary cyclopropylmethyl 
halide could be successfully reacted with moderate yield. Towards this end 2-(3,4,5 
trimethoxyphenyl) acetic  acid 11 was first coupled with (S),(S)-pseudoephedrine to give 40. The 
amide enolate was formed using LiHMDS and was further alkylated with either cyclopropylmethyl 
bromide or benzyl bromide, to give 41a and b. For the reactions to occur, it proved to be crucial to 
dry the LiCl at 150°C over night in high vacuum and additionally flame dry it under high vacuum prior 
use. The acids 39a and b were liberated, using 4 M H2SO4 in dioxane under reflux.  
39a and b were coupled to 36b, 37a and to 37b by the same conditions using HATU to provide the 
ligands 42-45 (Fig. 38). 
 
 
Fig. 38: (a) HATU, DIPEA, DCM, RT, 40-50%. (b) TFA, DCM, 0°-RT, 50-60%. 
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2.2.1.2 Biochemical activity of cyclopropylmethyl and benzyl ligands 
 
We tested this series of compounds in our in vitro FP competition assay (Tab. 3). From our FKBP 
subtype-specific engineered ligand screen we knew that changing from a pipecolinic core to proline 
core and exchange of the free acid moiety to morpholine can increase the binding affinity to the 
wildtype FKBPs in the allyl series (see Tab. 2) but at a cost of reduced selectivity. Fortunately, the 
larger Cα substituent cyclopropyl-methyl, restored selectivity and further increased the affinity 
(Tab. 3). Compound 42 binds to FKBP51 with 9.9 µM and shows no binding to FKBP52 up to the 
solubility limits of compound 42. To explore the limits of the induced cavity, we enlarged the Cα 
substituent from cyclopropylmethyl to benzyl. Compound 45 lost completely its ability to bind to 
either wildtype FKBP51 or FKBP52, indicating that the protruding phenyl ring is too big to be 
accommodated by the protein. Another interesting effect is that 42 shows affinity for FKBP12 in the 
range of FKBP52 which is not the case for all other compound series tested so far. Up to now all 
ligands show much higher affinity for FKBP12, typically 10-1000 fold. 
With increasing from allyl to cyclopropylmethyl we were able to increase the affinity to FKBP51 
around 2-fold, increase the selectivity vs FKBP52 at least >10-fold and further discovered the first iFit 
ligands that show binding to FKBP12 in the same range as to FKBP51 (e.g. compound 42).  
To explore whether the induced fit binding mode observed with 24 also extended to this new series 
we solved the co-crystal structures of FKBP51FK1 and 27 at a resolution of 1.2 Å and that of 42 with a 
2.1 Å resolution (Fig. 39A, 39C). The ligands adopt a very similar conformation as 24, and retain the 
two important hydrogen bonds to I87 and Y113. The overall architecture of the proteins is mostly 
superimposable (Fig. 40A). The main differences are in the 40s and the proline rich loop. The 40s 
loop of the 27 and 42 co-crystal structure is superimposable and adopts from S69 to N74 almost the 
same conformation as the co-crystal structure with SLF, interestingly, a flip of these amino acids as 
observed in the co-crystal structure of 24 does not occur(Fig. 34A,B). G64 to D68 is superimposable 
in the three induced fit crystal structures. The proline rich loop of all co-crystal structures diverge 
likely due to the flexibility of this region that has been observed earlier.109, 110 
The proline cores of 24 and 42 adopt two different envelope conformations (Fig. 40C) which has an 
impact on the orientation of the C1 carbonyl to Cα segment. Especially the orientation at the C1 and 
the C8 carbonyl which form the important hydrogen bonds to I87 and Y113 is important. Although 
the proline core cannot be perfectly overlapped to the pipecolate core, the C1 carbonyl to Cα 
segment of 27 resembles much better the conformation of 24 than the conformations of the closer 
homolog 42 (Fig. 40C). 
 
 
B. Results and Discussion _____________________________________________________________ 
42 
 
 
 
 
Tab. 3: General structure of the ligands, and binding affinities (IC50) in µM. Purified FK1-domains of FKBP51
WT
 
(2 nM), FKBP52
WT
 (2 nM), FKBP51
F67V
 (2 nM) and FKBP52
F67V
 (10 nM) were measured in a fluorescence 
polarization binding assay by titrating the compounds using 3nM of compound F2 (Chapter 4.2) as a tracer.
108
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Fig 39: (A) Co-crystal structure of 27 and FKBP51FK1. (B) Structure of 27. (C) Co-crystal structure of 42 and FKBP51FK1. (D) 
Structure of 42. For better visibility of the binding site K121 was removed from the crystal strucures 
 
From these crystal structures it is not obvious why 26 or 27 lost selectivity compared to 24 and 42. It 
seemed that increasing the size of the Cα substituent accounts for increasing selectivity, which is 
displayed by the binding affinities (Table 3). The co-crystal structures of the iFit ligands revealed that 
the pro-(S)-proton at Cβ of the iFit ligands pointed into the open space of the binding pocket. We 
therefore decided to introduce a substituent at the Cβ (Fig. 39C) position, that additionally could be 
cyclized with the allyl substituent. We thus continued with the synthesis of the cyclohexenyl/ 
cyclohexyl series of compounds. 
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Fig. 40. (A) Superposition of the backbone traces of the co-crystal structure of FKBP51FK1/24 
(grey) and the co-crystal structure of FKBP51FK1/27 (green). (B) Overlay of 27 (green) and 42 
(blue). (C) Overlay of 27 (green) and 24 (grey). 
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2.2.2 Cyclohexenyl/Cyclohexyl series 
 
2.2.2.1 Design and synthesis of cyclohexenyl/cyclohexyl ligands  
 
 
Fig. 41 (a) NaHMDS, THF, cyclohexenyl-bromide, -78°C, 50-60%. (b) LiOH, H2O2, THF/H2O 8:5, 0°C-RT, 60-90%. (c) Pd/C, 30 
bar H2, MeOH, RT, 90-99%.  
 
The Evans auxiliary modified trimethoxyphenylacetic acid building block 21 could be successfully 
reacted with cyclohexenyl bromide under the same conditions as established for allyl bromide to give 
46 as a mixture of four diastereomers with an overall yield of 63% (Fig. 41, Annex Fig. A). After flash 
chromatography, the mixture could be separated to obtain fractions of 46a/b with 55% and fractions 
of 46c/d with 8% yield (Annex Fig. B and C). 46a/b and 46c/d were each obtained with a 
diastereomeric rate at Cα of 99%. The reaction also showed a preference for one diastereomer at the 
Cβ position. 46a/b was obtained as a 85:15 mixture of diastereomers. This annotation is supported by 
analytical HPLC and finally analyzed by 13C NMR analysis (analytical HPLC, Annex Fig. C, NMR, Annex 
Fig. D). 46a/b could not be separated and was subsequently used as mixture of diastereomers. The 
absolute configuration of the preferred diastereomer was finally determined in the co-crystal 
structure of the cyclohexenyl-containing ligand 51 and will be discussed later. The imide 46a/b was 
cleaved to give the free acid 47a/b as a 85:15 mixture of diastereomers which could be partially 
resolved by analytical HPLC (Annex Fig. E). In parallel, the double bond of 46a/b was reduced to give 
48 with a diastereomeric excess of 99% at Cα. No tailing in the analytical HPLC (Annex Fig. F) and no 
additional peaks in the NMR (Annex Fig. G) can be observed for 48. The acid 49 was liberated as 
described for 47. 
B. Results and Discussion _____________________________________________________________ 
46 
 
 
Fig. 42: (a) HATU, DIPEA, DCM, RT, 40-70%. (b) 10% TFA, DCM, RT, 50-70% (for 50, 55 and 56). * 85:15 
mixture of diastereomers 
 
Coupling of 47a/b to 37a-d readily provided the cyclohexenyl derivatives 50-53 (Fig. 42) as mixtures 
of diastereomers at Cβ of 85:15 which could not be further separated. The di-amide ligand 55 was 
synthesized like its ester homologs 50-53 and was also obtained as a 85:15 mixture of diastereomers. 
To further explore different Cα substituents and to remove the Cβ stereocenter we synthesized 
cyclohexyl analogs 56 and 57 from 37a and 37b coupled with 49. Table 4 shows the inhibition 
constants (Ki) of the cyclohexenyl/cyclohexyl series calculated from the binding data obtained with 
the fluorophores F2 and F4. Due to the high binding affinity of the cyclohexyl/cyclohexenyl-
containing ligands tracer F2 was not sufficient anymore. We therefore had to design a new tracer F4 
for our fluorescence polarization assay (for a detailed description see Chapter 4.3).  
We were pleased to see our rationale confirmed. The cyclization at the Cβ position increased the 
affinity substantially to low nanomolar levels. The best iFit ligands to date, compounds 56 and 57, 
show a Ki of 4 ± 0.3 nM and 6 ± 2 nM for FKBP51FK1. This is comparable to the natural product 
rapamycin (Ki 6 ± 1 nM) and almost one order of magnitude better than the natural product FK506 
(Ki 93 ± 19 nM). Most important, the compounds showed no binding or very weak binding to FKBP52. 
Another interesting fact of the compounds is the preference over FKBP12. All 
cyclohexenyl/cyclohexyl compounds show at least 4-5 fold selectivity for FKBP51 over FKBP12 which 
makes them the first of this kind. For the cyclohexyl iFit ligands the selectivity of FKBP51 vs FKBP12 
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increased to >15-20 fold. All known FKBP ligands show a strong preference for FKBP12 over FKBP51 
and FKBP52 of 100 to 1000 fold. Further optimization of this feature could lead to even more FKBP51 
selective ligands.  
 
2.2.2.2 Biochemical activity of cyclohexenyl/cyclohexyl ligands 
 
 
Fig. 43: (A) Co-crystal structure of 43 and FKBP51. (B) Structure of 51. For better visibility of the binding pocket K121 was 
removed from the crystal strucures  
 
We solved a co-crystal structure of 51 and FKBP51 of a resolution of 1.25 Å (Fig. 43A). The pipecolinic 
core of 51 adopts a chair conformation. The whole ligand is except the core and the Cα substituent 
almost superimposable to 27 (Fig. 44A). With the help of the co-crystal structure we were able to 
define the preferred configuration at the Cβ carbon. As indicated in Fig. 43B the best binding 
configuration at Cβ is (S). Probably 47a is also the major diastereomer of the alkylation (Fig. 41). 
However, we cannot exclude the possibility, that 47a is the minor diastereomer formed in the 
alkylation but has a much higher binding affinity.  
The cyclohexenyl ring sits tightly in the induced subpocket with the alkene moiety pointing into the 
binding pocket (Fig. 43A). 
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Tab.4: General structure of the ligands, R2 is represented by the grey boxes. Inhibition 
constants (Ki) in nM. Purified FK1-domains of FKBP51
WT
 (4,5 nM) with F4 (3 nM), 
FKBP52
WT
 (400 nM) with F1 (20 nM), and FKBP12
WT
 (10 nM) with F1 (3 nM) were 
measured in a fluorescence polarization binding assay by titrating the compounds. 
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Fig. 44: (A) Overlay of ligand 27 and 51 in complex with FKBP51FK1. (B) Ribbon. (B) Superposition of the backbone traces of 
the co-crystal structure of FKBP51FK1/27 (green) and the co-crystal structure of FKBP51FK1/51 (cyan)  
 
 
The overall architecture of the co-crystal structures 27, 42 and 51 are superimposable except the 60s 
and the proline rich loop. Fig. 44B shows the ribbon overlay of the 51FK1/27 and 51FK1/51 co-crystal 
structure. The major differences can be found in the amino acids L61 to F66 (60s loop). The amino 
acids have to further reorientate to accommodate to the larger cyclohexenyl substituent (Fig. 45). 
The proline rich loop shows its slight flexibility which was also visible in the other co-crystal 
structures (Fig. 44B).  
To further elaborate the binding properties of cyclohexenyl substituted ligands we synthesized four 
more compounds with different top groups 50-53 and one with a proline core 54. For ligand 52 (Ki 50 
± 62 nM) we chose the symmetric dipyridine top group known from the structurally related drug 
candidate Biricodar (Vertex Pharmaceuticals). The pyridine rings replace the substituted phenyl rings; 
pyridine constitutes a good compromise between hydrophobicity and solubility due to the 
protonizeable amine. The advantage is lower molecular weight and a decrease in complexity by 
losing one stereocenter. The exchange resulted in a slight loss in affinity compared to 51 (Ki = 26 ± 
4 nM), but retained selectivity for FKBP51. Replacement of the morpholine by a free acid 50 (Ki = 23 ± 
4 nM) showed no substantial difference in binding affinities but strongly increases the water 
solubility. The top group of 53 was identified in a different ligand series in our group, as a smaller 
replacement for the bisubstituted top groups of the described ligands. Even more than the bipyridine 
top group it decreases molecular weight and removes one stereocenter. The binding affinity of the 
resulting compound 53 dropped substantially but selective binding for FKBP51 was sill clearly 
proline rich 
loop 
60s loop 
F67 
core 
Cα 
51FK1/27 
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27 
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detectable at low micromolar levels. The exchange of the pipecolate core to proline 54 (Ki = 40 ± 6 
nM) resulted in a slight decrease of binding affinity compared to 51. The exchange of the top-group 
ester by an amide 55 (Ki 328 ± 40 nM) decreased the affinity by more than 10 fold compared to 52 
(Ki = 23 ± 4 nM). This could be due to the additional H-donor of the amide which is predicted to 
intramolecularly point to the trimethoxyphenyl group in a typical FKBP bound conformation. This 
interaction is likely less favorable than the van-der-Waals contacts of the corresponding pipecolate 
ester. It is noteworthy that 55 is the first pipecolate amide ligand with clearly detectable affinity for 
FKBP51. This is important as the pipecolate ester represents an undesired metabolic liability. The 
best compounds of this series and the best binding iFit ligands to date are 56 (Ki = 4 ± 0.3 nM) and 57 
(Ki = 6 ± 2 nM). The reduction of the double bond of the cyclohexenyl ring resulted in a 4-fold 
increase in binding affinity.  
These compounds are the first reported FKBP51 ligands which bind with low nanomolar affinity and 
additionally show selectivity of more than 10000-fold over FKBP52. Another important point is the 
selectivity vs FKBP12. 56 and 57 are the first FKBP ligands that have selectivity > 10 for FKBP51 vs 
FKBP12. 
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Fig. 45: (A) Structural change of the 60s loop induced by 51. (A) 51 modeled into the co-crystal 
structure of FKBP51FK1/27(green). (B) co-crystal structure of FKBP51FK1/51 (cyan).  
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2.2.2.3 Effect of iFit ligands on neurite outgrowth  
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Fig. 46: Selective inhibition of FKBP51 wildtype by FK506, 50 and 57 
at 1 µM 
 
Fig. 46 shows our first results using iFit ligands in a neurite outgrowth assay performed under basal 
conditions without overexpression of FKBP51 or FKBP52 proteins. The first lane (blue) displays the 
DMSO control, which reflects the basal length of neurite outgrowth in this assay. By adding the 
unselective FK506 we observe no increase in neurite length but rather a slight decrease. This result is 
different to the results reported by Quinta et al86 but it is consistent with our previous results which 
showed that inhibition of both FKBPs at the same time show no effect (Fig. 46). In contrast selective 
ligands 50 and 57 significantly increased the neurite lengths. These results support our previous 
hypothesis that selectivity for FKBP51 could be beneficial for the development of ligands with 
neuroregenerative properties. 
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2.2.3 Cα-hydroxy series 
 
    
Fig 47: (A) Co-crystal structure of 51 and FKBP51. (B) Modeling of the 64a into the co-crystalstructure of 51 
 
Molecular modeling revealed that a potential hydrogen bond could be formed between D68 and an 
hydrogen donor group at Cα (Fig. 47). To test if an additional hydroxy group at Cα is tolerated, we first 
synthesized compound 60 (Fig. 48). We started from commercially available 2-(3,4,5 
trimethoxyphenyl)acetic acid and oxidized it with seleniumdioxide131 to obtain 58 the α-keto acid was 
alkylated with allylmagnesium bromide to give racemic 59. The racemate was coupled to 37a to give 
60 as a 1:1 mixture of diastereomers with modest 25% yield. Upon treatment of 60 with 10% TFA to 
deprotect the t-Bu-group, however the Cα hydroxy group readily eliminated to give the undesired 62 
as the major product and only trace amounts of 61. As expected 62 showed no affinity for FKBP51 or 
52 (data not shown).  
 
 
(A)         (B) 
 
 
 
 
 
 
 
       
D68 
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Fig. 48: (a) SeO2, pyridine, reflux, 92%. (b) Allylmagnesium bromide, THF, -78°C-RT, 60%. (c) 37a, HATU, DIPEA, DCM, RT, 
25%. (d) 10% TFA/DCM, 0°C-RT 
 
To solve this problem we designed a different synthetic route where the alkylation was performed in 
the last step (Fig. 49). First, we synthesized Biricodar/63.132 Then the Cα-carbonyl was alkylated using 
cyclohexylmagnesium bromide which readily yielded a racemic mixture of 64a/b. The diastereomers 
64a and 64b could be separated using reversed phase HPLC. Under these conditions no elimination 
of the Cα hydroxy group was observed. 
 
 
Fig. 49: (a) HATU, DIPEA, DCM, RT, 40-70%. (b) Cyclohexylmagnesium bromide, THF, -78°C 
 
Of these only one diastereomer 64a (Ki = 77 ± 11 nM, Tab. 4) bound with good binding affinity in the 
nanomolar range, whereas the other diastereomer did not show any binding within the limits of the 
assay. Thus, addition of a hydroxy group at Cα seems to be tolerated (in the correct stereochemical 
configuration) but overall it does not seem to add additional binding energy. However, it highly 
simplifies the synthesis of the ligands and allows simple access to a broad range of potential Cα 
substituents (described in the outlook). 
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We plan to expand these series of compounds to the morpholine top group to improve the binding 
affinity. Main advantage of this methodology is that a broad scope of Grignard reagents can be used. 
Furthermore, it is not dependent on tedious stereoselective alkylations using auxiliaries although it 
requires separation of the diastereomers by preparative HPLC.  
 
2.2.4 Cα symmetric ligand series 
 
 
Fig. 50: (a) HATU, DIPEA, DCM, RT, 74-78%. (b) 10% TFA/DCM, RT, 64-82% 
 
To estimate the contribution on binding of the three methoxy groups of the lower part of the ligands, 
we synthesized compound 68 from commercially available α-keto-2-phenylacetic acid. In addition we 
synthesized the symmetric Cα ligand 69 from 2,2-diphenylacetic acid. Due to the high binding affinity 
of the cyclohexyl ligand series we also synthesized the symmetric dicyclohexyl ligand 70. Both 
symmetric ligands lost their affinity to the larger FKBPs completely and only Cα keto analogue showed 
moderate affinity for FKBP12 (Table 6).  
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Tab. 7: General structure of the ligands, and binding affinities (IC50) 
in µM. Purified FK1-domains of FKBP51
WT
 (280 nM), FKBP52
WT
 
(400 nM), FKBP12
WT
 (10 nM) were measured in a fluorescence 
polarization binding assay by titrating the compounds using 20 nM F2 
as a tracer for FKBP51
WT
/52
WT
 and 3 nM for FKBP12
WT
. 
 
2.2.5 Synthesis of Cα substituted rapamycin 
 
 
 
Fig. 51: (a) TBSOTf, 2,6-Lutidine, RT, 80%. (b) NaCNBH3, MeOH, 0°C-50°C, 20%.  
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The immunosuppressive effect of rapamycin results from inducing ternary protein complexes with 
the FKBPs and the kinase mTOR, an important regulator of cell growth and proliferation. The most 
prominent partner of rapamycin is believed to be FKBP12. Research in Hausch lab showed that 
rapamycin complexes of larger FKBP protein family members can tightly bind to mTOR and potently 
inhibit its kinase activity (März et al. Manuscript in preparation).  
To investigate the role of the different FKBPs involved in the ternary FKBP-rapamycin-mTOR 
complexes a FKBP subtype-selective rapamycin analog is needed. We intended to synthesize a Cα 
modified rapamycin derivative as depicted in Fig. 51 by introducing an ether at the C9 carbonyl 
group. We started with protection of the hydroxyl groups 10, 28 and 40 by TBS. For this reaction 
TBS-Cl was not reactive enough, so TBDMS-OTf had to be used. Under these conditions hydroxy 
group 28 and 40 were protected smoothly to give 71 with 80% yield. It was also possible to isolate 
the hemiacetal hydroxyl group 10 protected product 72 with 3% yield. With the double protected 
derivative 71 we next targeted the selective reduction of the Cα carbonyl assuming that the 
α-keto-amide would be the most electrophile position. The reduction proved to be very difficult. 
Using numerous different reaction conditions (Superhydride, LiAl(OtBu)3H, DIBAL, LiAlH4, NaBH4, 
NaB(OAc)3H) only trace amounts of product could be obtained. Finally we discovered reaction 
conditions (NaCNBH3 0°C-50°C) that reduced the C9 carbonyl with moderate 20% yield.  
We decided to further modify the obtained compound with a methyl group at the C9 hydroxy group. 
We explored different bases (Lutidine, K2CO3, LiHMDS, NaH) and MeI or MeOTf but until now no 
product could be isolated.  
To overcome the problems of the aforementioned synthetic route we engaged in the synthesis of a 
Cα-hydroxy, Cα-allyl derivatized rapamycin analog. This was inspired by the results with the synthetic 
ligand 64a. Mechanistic studies on rapamycin and ascomycin showed that the C9 carbonyl group is 
the most reactive in the molecule133, 134, so we planned a simplified synthetic route without 
protecting groups. We decided to start with allylmagnesium bromide but this reaction produced 
mono- to polyallylated compounds due to the high reactivity of the reagent also at -78°C. Fig. 52 
indicates the most reactive functional groups of rapamycin for an attack of allylmagnesium bromide. 
The most electrophilic positions of rapamycin are the C1 ester, the C9 carbonyl group, the C10 
hemiacetal, and the two other carbonyl groups at C26 and C32. To improve the chemo selectivity we 
decided to use less reactive reagents and activate the C9 carbonyl by a lewis acid. We chose 
allytrimethylsilane and tetraallyltin as allyl donors, while the carbonyl group was activated by 
In(OTf)3. Allytrimethylsilane failed to produce any product but with tetraallyltin defined peaks of 
mono-, di-, tri and tetrasubstituted products were observed. By RP-HPLC it was possible to separate 
mono-allylated 24% 75-978, di-allylated 7% 75-1021, and tri-allylated 3% 75-1063 derivatives.  
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Fig. 52: (a) THF, -78°C. (b) InOTf3, THF, RT, 24,2%. 
 
All of the alkylated rapamycin derivatives of 75 showed a dramatically decreased affinity for the 
wildtype and the F67V mutated FKBP proteins, and showed a selectivity for FKBP12 of greater than 
100-fold. Unfortunately with the applied alkylation conditions no good binder could be isolated from 
the reaction mixture. Mono-allylated 75-978 binds to FKBP12 with an IC50 of around 5 µM whereas 
rapamycin binds in this assay to FKBP12 with an IC50 of around 30 nM which accounts to a 100-fold 
loss in binding affinity. Di- and tri allylated 75-1021 and 75-1063 lost affinity to FKBP12 in the same 
order of magnitude and showed only micromolar affinity. Binding affinity to FKBP51FK1/FKBP52FK1 
wildtype and F67V mutant decreased to undetectable levels greater than 100 µM. From the Cα 
hydroxy ligand series (Chapter 2.2.3) it is clear that the stereochemistry at Cα is essential for binding. 
The stereochemistry of the reduction could not be determined of the isolated derivatives because 
not enough material for NMR interpretation was obtained.  
 
2.3 Structural basis for the selectivity 
2.3.1 Structure-activity relationship of the iFit ligands 
 
We synthesized a series of Cα-substituted ligands to identify new compounds that induce the 
conformational change and thereby increase the selectivity. The exchange of the free acid 
substructure to the morpholine substructure increased the binding affinity in the allyl and 
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cyclopropylmethyl series substantially whereas in the cyclohexenyl/cyclohexyl series this exchange 
showed no additional increase in binding affinity. The Biricodar pyridine top-group lowered the 
affinity 2 fold compared to the free acid or morpholine analogs but decreases molecular weight and 
has one less stereocenter. We employed the even smaller monovalent top-group of 53 which 
resulted in a substantial loss in activity to micromolar levels.  
The exchange from pipecolate to proline core is context-dependent and accounts only for minor 
changes in binding affinity whereas the piperidine-2-carboxamide core showed a 10-fold decrease in 
binding affinity.  
We increased the Cα substituent to cyclopropylmethyl which slightly increased the affinity. Upon 
increasing the size to cyclohexenyl/cyclohexyl the affinity could be increased to low nanomolar 
levels. These compounds are the first reported FKBP51 ligands that bind with sub-micromolar to low 
nanomolar affinity, and additionally show up to 10000-fold selectivity over FKBP52 and up to 10-fold 
selectivity over FKBP12. To determine if the alkene of the cyclohexenyl ring has an important effect 
on binding, we reduced the double bond. This further increased the binding affinity by almost 10-
fold.  
We synthesized the hydroxy compounds 64 and isolated the correct diastereomer which binds with 
similar affinity as the related compound 52. Although we only synthesized one example yet it 
indicates that the Cα-cyclohexyl/Cα-hydroxy substitution is almost equivalent to Cα-cyclohexenyl. We 
wanted to explore the limits of the induced binding pocket, so we enlarged the 
allyl/cyclopropylmethyl series to benzyl. This substituent is too large to be accommodated by the 
FKBP proteins. No binding affinity in the range of the assay could be measured.  
 
 
Tab. 8: SAR of iFit ligands (~ equal but context dependent)  
 
The final SAR for binding of the iFit ligands to wildtype FKBP51 is shown in Tab. 8. The free acid 
showed in combination with cyclohexyl slightly better binding affinity than the morpholine top 
group, followed by the bipyridine substituent. The smallest monovalent top group showed the worst 
binding affinity. In combination with cyclohexenyl or cyclohexyl the pipecolinic core gave the best 
binding affinity, and for the Cα substituents cyclohexyl was a little bit better than cyclohexenyl but 
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both of them were around 10 to 100-fold better than cyclopropylmethyl and allyl. The worst Cα 
substituents were ethyl and benzyl.  
 
2.3.2 Quantification of the induced conformational change 
 
We quantified the conformational change in FKBP51 by measuring the distances from F67 to I87, 
W90 and F130, and the dihedral angle that defines the orientation of the phenyl ring of F67 (Fig. 53). 
We compared these values to the co-crystal structure of unselective ligands FK506 and SLF, and to 
the apo structure. The distance from F67 Cζ↔I87 Cδ increased from 7.1-7.3 Å to 14.9-15.2 Å. In the 
same way, the distance between F67 Cζ↔W90 Cθ increased from 7.0-7.3 Å to 12.5-12.8 Å. The 
distance between F67 Cζ↔F130 Cζ extended from 3.7-3.8 Å to 10.8-10.9 Å. The dihedral angle of 
F67 changed from 58.9°-63.8° to -152.2°-(-177.0°). All Cα substituents synthesized by us varying from 
allyl to cyclohexyl are able to induce this conformational change in FKBP51. This induced 
conformation seems to be substantially less favorable for FKBP52, resulting in selectivities between 
100 to 1000-fold. In addition cyclohexenyl and cyclohexyl strongly contribute to binding affinity. 
 
 
 
Fig. 53: Conformational reorganization of F67: (A) apo crystal structure of FKBP51FK1; (B) co-crystal structure FKBP51FK1 
and 51. The dihedral angle N-Cα-Cβ-Cγ defining the conformational flip is indicated. (C) Distance of F67 Cζ to I87 Cδ, F67 Cζ 
W90 Cθ and F130 Cζ in Å. Distance of F67 Cζ of co-crystal structures to F67 Cζ of the apo structure without ligand in Å. 
Dihedral angle of F67 N-Cα-Cβ-Cγ. 
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2.3.3 Evaluation of the co-crystal structures 
 
2.3.3.1 The Cα-Substituent 
 
To examine the structural basis for the unexpected selectivity of the iFit ligands for FKBP51 we solved 
four co-crystal structures with the FK1 domain of FKBP51 and compounds 24, 27, 42 and 51. Fig. 54 
shows the induced subpocket in the protein and a spacefilling model of the ligands. Fig. 54A and 54B 
show the allyl compounds 24 and 27. As described in Chapter 2.2.1 we enlarged the Cα substituent to 
cyclopropylmethyl, because we hypothesized that a bigger substituent would fill the cavity better 
than allyl. By comparing the space filling models of the co-crystal structures of allyl ligands 24 and 27 
(Fig. 54A and B) and the cyclopropyl of 42 our assumption proved to be true. It is easy to recognize 
that cyclopropyl fits much better into the hole than the allyl substituent of 27 (Fig. 54C), and thereby 
not only increases the binding affinity but also the selectivity for FKBP51. We observed that a 
substitution at Cβ would be tolerated, leading to the cyclized substituent cyclohexenyl (Fig. 54D). This 
substitution dramatically increased the affinity and selectivity further. Fig. 16D shows how nicely the 
cyclohexenyl fits into the cavity that it induces. The alkene moiety points into the pocket and the 
aliphatic part outwards. The alkene moiety per se however, does not seem to be essential since the 
reduced cyclohexyl ligands interacts even better with FKBP51. So we conclude that if the 
stereochemistry of the alkene could be better defined it would be suitable for further modifications. 
 
    
Fig 54: (A) Co-crystal structure of 24 and FKBP51FK1. (B) Co-crystal structure of 27 and FKBP51. For better visibility of the 
induced sub-pocket K121 was removed from the crystal strucures. 
allyl 
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27 
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24 
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Fig 54: (C) Co-crystal structure of 42 and FKBP51. (D) Co-crystal structure of 51 and FKBP51. For better visibility of the 
induced sub-pocket K121 was removed from the crystal strucures. 
 
2.3.3.2 The Trimethoxyphenyl Moiety  
 
Fig. 55 shows the orientation of the trimethoxyphenyl moiety in the four co-crystal structures. The 
(S)-configuration at Cα directs the trimethoxyphenyl ring out of the binding pocket. The movement is 
further limited by the top-group which does not allow it to turn. In all structures the ring adopts the 
same orientation. Only the para methoxy group seems to be free to change orientation, indicating 
that this methoxy might be less important. In our SAR we showed that by removing the methoxy 
groups the affinity drops dramatically. The crystal structures show van der Waals interaction 
between the methoxy groups and the side chains. Aromatic hydrogen bonds can be observed from 
the ortho positions of the trimethoxyphenyl ring to D68 on one side and to Y113 on the other side 
which are both in 3.4 Å distance. The side chains of the amino acids Y57, D68, Y113, S188 and I122 
are in van der Waals distance to the trimethoxyphenyl ring. More different substructures have to be 
synthesized to perform a SAR study to better understand the structural implications of this part of 
the ligand.  
 
 
(C)         (D) 
 
42 51 Cyclohexyl Cyclopropylmethyl 
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Fig 55: Comparison of the trimethoxyphenyl moiety (A) Co-crystalstructure of 24 and FKBP51FK1. Aromatic hydrogen 
bonds formed between D68/Y113 and the ortho positions of the trimethoxy phenyl ring (B) Co-crystalstructure of 27 
and FKBP51FK1. (C) Co-crystalstructure of 42 and FKBP51FK1. (D) Co-crystalstructure of 51 and FKBP51FK1. For better 
visibility of the sub-pocket K121 was removed from the crystal strucures 
 
2.3.3.3 The Top Group 
 
We tested four different top groups in our SAR study. Of these, two of them were crystalized, the 
morpholine substructure and the free acid substructure. In general, the morpholine and the free acid 
top groups show the best binding affinities in a similar range. Interestingly for smaller Cα substituents 
like allyl and cyclopropylmethyl, the morpholine substructure performed around one order of 
magnitude better than the free acid top group. In contrast, the bigger cyclohexenyl/cyclohexyl 
substituents show only marginal differences between the two top groups. The free acid performed 
here around two times better than the morpholine. In the co-crystal structures the A and B phenyl 
rings all show almost the same conformation. Only in one of the SLF structures the A ring is rotated 
180° compared to 24, indicating the free acid is flexible and does not contribute substantially to the 
binding (Fig. 56B-C). Both rings sit nicely in shallow groves on the surface of the protein, mainly 
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contributing to binding by non-directed hydrophobic interactions. In addition, in all co-crystal 
structures aromatic hydrogen bonds of both rings to the amino acid backbone are present.  
 
   
  
  
Fig. 56: (A) General structure of the ligands. (B) Co-crystal structure of FKBP51FK1 and IF63. (C) Co-crystal 
structure of FKBP51FK1 and 21. (D) Co-crystal structure of FKBP51FK1 and 27. (E) Co-crystal structure of FKBP51 
and 42. (F) Co-crystal structure of FKBP51FK1 and 51. 
 
Ring A forms a hydrogen bond from its ortho position to the amide carbonyl of Q85 and ring B from 
the meta position to the amide carbonyl of G84. In addition the morpholine co-crystal structures of 
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27 and 51 show in addition a bridging water molecule which connects the morpholine amine with the 
amide carbonyl of Q85. These findings probably explain the strong gain in affinity for the ligands with 
small Cα substituents but cannot explain why in the large cyclohexeny/cyclohexyl series this increase 
is not present or even reversed. More research on the top group has to be performed to evaluate the 
SAR. 
 
3. Summary and Outlook on Selective FKBP Ligands 
 
Taken together, by using functionally active FKBP51 and FKBP52 mutants that were sensitive to 
engineered inhibitors (FMSE inhibitors) we unambiguously demonstrate that FKBP ligands can have 
both neurite outgrowth-stimulating and neurite outgrowth-suppressing effects. Furthermore, the 
shown results provide a rationale for the design of selective ligands for FKBP51 by exploiting a 
conformational change which induces an extended binding pocket. We synthesized and evaluated 
the first selective FKBP51 ligands that bind with low nanomolar affinity and a selectivity of >1000-fold 
over FKBP52. We further applied these ligands in a cellular assay using mouse neuroblastoma cells 
(N2a) where selective inhibition of FKBP51 increased the neurite growth. These results replicated our 
results from the FSSE ligands under basal conditions. We showed that selective inhibition of 
endogenous FKBP51 has outgrowth-stimulating effects. The net effect of unselective FKBP inhibitors 
will thus depend on the relative importance of FKBP51 or FKBP52 in each cell type of interest. 
Neurite outgrowth-promoting substances have repeatedly been shown to enhance neuronal 
regeneration after neuronal insult, injury or degeneration. In the context of depression or related 
affective disorders the reduction of neuronal plasticity by the stress-induced FKBP51 is thought to 
contribute to the behavioral and cognitive deficits observed in these patients. Our results suggest 
that selective FKBP51 inhibitors could be superior to non-selective FKBP inhibitors at ameliorating 
these deficiencies.  
We postulate that our findings on iFit ligands represent a general phenomenon and that all 
compounds that induce the conformational change described by us will display a bias for FKBP51. 
Moreover, we believe that the induced additional pocket in FKBP51 discovered by us can be used to 
rationally design additional FKBP51-selective inhibitors. 
Addition of cyclohexylmagnesium bromide to Biricodar in THF at -78°C readily produced 61 as a 1:1 
mixture of diastereomers which could be successful separated by preparative HPLC (Fig. 57). This 
allows for a broad spectrum of reaction types to be employed. The first step is analogous 
modification with different alkylmagnesium bromides and change to the morpholine top group, that 
has proven to give an increase in affinity (Scheme 57). Up to now cyclohexyl is the biggest Cα 
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substituent that is tolerated. Using the Grignard method it is easily possible to increase the ring to 
cycloheptane or cyclooctane or decrease it to cyclopentane. Further by using cycloalkenylmagnesium 
bromides it is possible to further modify the rings by Simmons-Smith cyclopropanation, oxidation, 
halogenation and so forth.  
The method could be further optimized by using less reactive organometallic reagents like alkylboron 
or alkylzinc reagents which can be applied to stereoselective synthesis135-137. 
With the same methodology but starting from cyclohexyl-α-keto-acetic acid, it is possible to 
investigate on the trimethoxy moiety. The starting point is 2-cyclohexylacetic acid138 80 which is 
coupled to form 81. Then a screen with different commercially available aromatic or aliphatic 
Grignard reagents can be performed (Scheme 57) to probe different R3 parts of the ligand.  
 
 
 
Scheme 57: (a) HATU, DIPEA, CH3CN, RT. (b) RMgBr, THF, -78°C. (c) RMgBr, THF, -78°C. 
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4. Fluorescent Immunophilin Tracers 
4.1 Synthesis of fluorescent rapamycin derivatives 
 
 
 
Fig. 58:Fluorescent FKBP ligand F1 and Fluorescent rapamycin derivative F2 
 
The best of our small molecule ligands reached the limits of the fluorescence polarization assay using 
the fluorescent tracer F1, due to its binding affinity to FKBP51FK1 of around 400 nM and to 
FKBP52FK1 of around 900 nM. Therefore using this tracer no compounds can be measured that bind 
better than around 200 nM for FKBP51. In our group the fluorescent rapamycin derivative F2 was 
prepared (Fig. 58)108. This tracer showed affinity for FKBP51 below 1 nM, and for FKBP52 around 1 
nM. With the fluorescence polarization mode of our Tecan plate reader it is possible to measure 
concentrations of fluorescein-labeled ligands as low as 1 nM. To measure Ki inhibition constants of 
ligands in a competition experiment it is necessary to use protein concentration equal to the Ki of the 
tracer, and tracer concentrations ideally below half the Ki value of the tracer. In this case F2 would 
have to be used in picomolar concentrations, which is not measurable in polarization mode with our 
reader. We considered two possible solutions for that problem. First, using a tracer that can be 
diluted to even lower concentrations, meaning a brighter fluorophore has to be used. Alternatively, a 
tracer with binding affinity between F1 and F2 has to be synthesized. It is difficult to predict how a 
complex fluorophores like fluorescein would influence the affinity of the ligand, so we started to 
synthesize a series of fluorescent rapamycin derivatives. We synthesized the C40-glycine modified 
rapamycin analog 71 according to Kozany et al (Fig. 59).108 Then we couple different fluorophores 
bearing an active ester to it.  
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Fig. 59: (a) NaN3, H2O, 0°C-RT, 99%. (b) 2,4,6-trichlorobenzoyl chloride, TEA, DMAP, rapamycin, THF, 0°C, 33%. (c) PPh3, 3:1 
THF/H2O, RT, 60%. (d) MFP590 (F3-oSu), DIPEA, DMF, RT, 20%. 
 
The MFP590 fluorophore was the first to be employed. Compared to fluorescein it shows a red 
shifted emission spectrum with an absorption maximum of 597 nm and an emission maximum of 624 
nm (Fig 60). Red shifted fluorophors offer better signal to noise ratios then green shifted fluorophors 
like fluorescein.  
 
 
Fig. 60 (A) Absorption (blue)/Emission (red) spectra of MFP590 εMax = 1.2x10
5
 L mol
-1
 cm
-1
. (B) Absorption spectra of 
F3, maximum 599 nm. 
MoBiTec® 
 
 
F3: absorption spectra 
599nm / 0,43 PEAK 
 
(A)        (B) 
B. Results and Discussion _____________________________________________________________ 
69 
 
We recorded an absorption spectra of ligand F3, which resembled the reported absorption maxima 
of the MFP590 (Fig. 60B).  
We titrated increasing concentrations of protein against F3 with three concentrations (20 nM, 5 nM, 
2 nM) unfortunately this fluorescent rapamycin derivative lost binding affinity for FKBP51FK1 
completely. This result is consistent with the findings of Kozany et al who showed that binding 
affinity for FKBP51 is strongly dependent on the linker length between the ligand and the 
fluorophor.108 More fluorophores with different linker length have to be coupled and tested. 
 
4.2 Synthesis of a fluorescent iFit ligand 
 
 
Fig. 61: (a) HATU, DIEPA, DMF, 23% 
 
Due to the problems we encountered with the fluorescent rapamycin derivatives we decided to 
synthesize a fluorescent iFit ligand according to the synthesis of fluorescent derivative F2 of SLF 
(Fig. 61).108 The free acid of 50 was activated and reacted with aminomethyl-fluorescein to give F4.  
We recorded an absorption spectra of F4 which is in line with the spectra of fluorescein showing an 
absorption maximum at 498nm with an εMax of 46900 L / (mol/cm) (Fig. 62A). We performed a FP 
binding assay and the ligand was able to bind to the FK1 domain of FKBP51 with an EC50 of 5.8 ± 0.3 
nM in addition we calculated the dissociation constant Kd = 4.4 ± 1.2 nM (Fig. 62B). To demonstrate 
the applicability of the tracer F4 for the characterization of unlabeled ligands, we tested its 
performance in FP-competition assays (Fig. 62C). The unlabeled iFit ligand 50 was able to efficiently 
compete the tracer from FKBP51FK1. We determined an IC50 value of 69.4 ± 6.3 nM and calculated 
the inhibition constant Ki = 23.5 ± 4.0 nM. We measured the binding of the fluorescent iFit ligand to 
FKBP52FK1 and as anticipated the affinity was 500 fold less than for FKBP51FK1. We assessed an EC50 
of 2611 ± 340 nM and calculated a KD of 2945 ± 1920 nM (Fig. 62D).  
In summary, fluorescent iFit ligand F4 binds 10 fold more potent to FKBP51FK1 than the unlabeled 
precursor compound 50, likely due to additional contacts of the conjugated fluorescein. The tracer 
can be competed by non-labeled ligands which enables its use in FP competition assays. Most 
important its binding affinity for FKBP51 lies between that of F1 and F2 which enables for measuring 
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binding affinities below 200 nM which was necessary to evaluate our most advanced iFit ligands. 
Finally, F4 further demonstrates nicely in a direct binding experiment to FKBP52FK1 the selectivity of 
the iFit ligands for FKBP51.  
 
F4: absorption spectra
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Fig. 62: (A) Absorption spectra of F4 (5.4 µM), maximum 498 nm. εMax = 46900 L / mol
-1
 cm
-1
. (B) Binding of 3 nM F4 to 
FKBP51FK1 measured by fluorescence polarization. (C) Competition of F4 (3 nM) with 50 for the binding to FKBP51FK1 
(4.5 nM). (D) Binding of 3 nM F4 to FKBP52FK1 measured by fluorescence polarization.  
 
4.3 Facile synthesis of a fluorescent CsA analogue to study Cyclophilin 40 
and Cyclophilin 18 ligands 
 
Cyp40 is a modulator of steroid hormone receptors and a further potential Hsp90 and SHR-
associated drug target. To be able to screen for novel inhibitors for this immunophilin a fluorescein- 
labeled CsA analogue was synthesized.  
This tracer was produced by a facile four step synthesis (Scheme 23). We show the binding of this 
tracer to Cyp40 and Cyp18 by measuring the fluorescent polarization change and demonstrate its 
(A)       (B) 
 
 
 
 
 
(C)       (D) 
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competition with Cyclosporin A. The binding data was confirmed using an enzymatic PPIase assay. 
The described tracer allows for a robust assay in a high throughput format to support the 
development of novel Cyp40 ligands. The results were published in Journal of medicinal chemistry 
letters (Gaali et al).139 
 
 
Fig. 63: (a) Boc2O, TEA, MeOH, RT, quant. (b) Grubbs Cat. II. Gen, DCM, reflux, 52% (c) 10% TFA, DCM, 0°C, 81%. (d) NHS-
fluorescein, TEA, DCM/THF 2:1, RT, 23%. 
 
4.3.1 Synthesis of the tracer 
 
The unselective cyclic undecapeptide cyclosporin A (CsA, Scheme 23) binds unspecifically to the class 
of cyclophilins in the nanomolar range. It is clinically used as an immunosuppressive drug140. We used 
CsA as a starting point for our tracer synthesis. By analyzing the co-crystal structure of Cyp18/CsA we 
noticed, that the terminal trans-alkene moiety of the unnatural aminoacid butenyl-methyl-L-
threonine (position 1 of CsA in Scheme 23) points out of the binding pocket, and is solvent 
accessible.141 This alkene is very suitable for a Grubbs metathesis reaction and thus can be used to 
introduce the fluorescent label.  
We decided to attach an amine containing linker to CsA that could be easily coupled to carboxy-
containing fluorophores. We first tried to couple Boc-allylamine or allylammoniumchloride to CsA 
which resulted in poor yields probably because metathesis catalysts are known to be sensitive to 
primary amines that are in close distance to the double bond. We thought to overcome this problem 
by using a longer linker. Therefore we first protected commercially availalable paravinylamino-
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benzene 88 with Boc2O to obtain 89 with quantitative yields. This was then coupled to CsA using 
second generation Grubbs catalyst to give 90 in good yields. The primary amine was liberated using 
10% TFA to produce 91 which was reacted with 5/6-carboxyfluorescein N-hydroxysuccinimide (NHS-
Fluorescein) to give the final compound CsA-Fl. 
 
4.3.2 Development of a fluorescence polarization assay for cyclophilin 40 and 
Cyp18 
 
The proteins Cyp40 and Cyp18 were cloned and expressed according to Gaali et al.139 The 
functionality of the purified proteins was verified by a coupled enzymatic assay measuring their 
PPIase activity. We determined Kd values of 106 ± 13 nM for Cyp40 and 12 ± 2 nM for Cyp18 (Fig. 
64A, Tab. 8). The absolute change in anisotropy was substantially larger for Cyp40 compared to 
Cyp18, likely reflecting the bigger size of the former. To verify the binding affinity of tracer CsA-Fl to 
Cyp40 and Cyp18, a coupled enzymatic PPIase assay was performed (Fig. 65).142 The measured values 
of 101 ± 24 nM for Cyp40 and 12 ± 4 nM for Cyp18 match very well with the FP-assay results shown 
above. 
 
 
 
 
 
 
 
 
Fig. 64: (a) Binding of CsA-Fl (10 nM) to Cyp18 and Cyp40 measured by fluorescence polarisation. (b) Competition of CsA 
with CsA-Fl (10 nM) for the binding to Cyp18 (10 nM) and Cyp40 (100 nM) measured by fluorescence polarisation.  
 
To demonstrate the use of the tracer CsA-Fl for the characterization of unlabeled ligands, we tested 
its performance in FP-competition assays (Fig. 64B). The prototypic ligand CsA could efficiently 
compete with CsA-Fl for the binding to Cyp40 and Cyp18. The measured Kd values were again 
(A)        (B) 
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corroborated with a PPIase assay (Fig. 65, Tab. 8). For Cyp40 there was an excellent match between 
FP and PPIase results while for Cyp18 a slightly lower Ki was observed in the PPIase assay. 
In general, CsA-Fl binds slightly more potent to both Cyp18 and Cyp40 than CsA likely due to 
additional contacts of the conjugated fluorescein. The affinities measured in this work are consistent 
with the literature values for Cyp40 as well as with the majority of reports for Cyp 18. For Cyp18 
substantial discrepancies in CsA affinities have been reported. The consensus values, however, match 
very well with the results reported in this work.29  
 
 
 
 
 
 
 
 
 
 
 
Figure 65                              : (A) Inhibition of the PPIase activity of Cyp40 (100 nM) by CsA (dashed, ) and CsA-Fl 
(continuous, ). (A) Inhibition of the PPIase activity of Cyp18 (10 nM) by CsA  (dashed, ) and CsA-Fl (continuous, ). 
 
 
 Cyclophilin FP-assay (Ki or KD) PPIase assay (Ki) 
CsA Cyp40 227 ± 22 231 ± 55 
Cyp18 34 ± 6 7 ± 1 
CsA-Fl Cyp40 106 ± 13 101 ± 24 
Cyp18 12 ± 1 12 ± 4 
Table 8: Binding and inhibition constants (nM) measured by fluorescence 
polarization or by an enzymatic PPIase assay 
 
 
In summary, we developed a facile synthesis of a fluorescein-labelled tracer CsA-Fl, which shows high 
affinity binding to Cyp40 and Cyp18. The tracer can be competed by CsA. Therefore CsA-Fl enables a 
fluorescence polarisation assay in high throughput format, which can be used for screening and 
subsequent profiling of inhibitors of Cyp40 to identify structures for the development of potential 
new drugs against breast and prostate cancer. 
(A)        (B) 
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C. Experimental Section 
 
1. Analytical Methods 
1.1 Nuclear magnetic resonance  
 
1D 1H, 13C-NMR and 2D HSQC, HMBC and COSY were recorded at the department of chemistry and 
pharmacy of the LMU on a Bruker AC 300, a Bruker XL 400, or a Bruker AMX 600 at room 
temperature. Chemical shifts for 1H or 13C are given in ppm (δ) relative to tetramethylsilane (TMS) as 
internal standard. CDCl3 and d6-DMSO were used as solvents. 
1H and 13C spectra were calibrated on 
the specific solvent. The coupling constants (J) are given in Hertz (Hz). The multiplicities are 
abbreviated as singlet (s), dublet (d), triplet (t), quartet (q) and multiplet (m).  
 
1.2 Mass spectroscopy 
 
Mass spectra (m/z) were recorded on a Thermo Finnigan LCQ DECA XP Plus mass spectrometer at the 
Max Planck Institute of Psychiatry, while the high resolution mass spectrometry was carried out at 
MPI for Biochemistry (Microchemistry Core facility) on Varian Mat711 mass spectrometer.  
 
1.3 HPLC 
 
The purity of the compounds was verified by reversed phase HPLC. All gradients were started after 
1 min of equilibration with starting percentage of solvent mixture. 
 
Analytical: 
Pump: Beckman System Gold 125S Solvent Module  
Detector: Beckman System Gold Diode Array Detector Module 168 
Column: Phenomenex Jupiter 4µ Proteo 90Å, 250 x 4.6 mm 4 micron 
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Solvent A: 95% H2O  
 5% CH3CN 
 0.1% TFA 
Solvent B: 95% CH3CN 
 5% H2O 
 0.1% TFA 
Standard Gradient: 0-100% B in 20min, 1 ml/min 
Detection  
wavelength: 220nm/280nm 
 
Chiral:  
Pump: Waters 515 HPLC Pump 
Detector: LDC Analytical Spectromonitor 5000 Photodiode Array Detector 
Column: DAICEL Chemical Industries LTD. Chiralcel OD-H 
 
Solvent A: Hexane 
Solvent B: i-propanol 
Standard Gradient: 1:1 60 min, 0.5 ml/min 
Detection  
wavelength: 220nm 
 
Preparative:  
Pump: Beckman System Gold Programmable Solvent Module 126 NMP 
Detector: Beckman Programmable Detector Module 166 
Column: Phenomenex Jupiter 10µ Proteo 90 Å, 250 x 21.2 mm 10 micron 
 
Methods: Described at the specific compound 
 
Semi- 
preparative:  
Pump: Beckman System Gold 125S Solvent Module  
Detector: Beckman System Gold Diode Array Detector Module 168 
Column: Phenomenex Jupiter 10µ Proteo 90 Å, 250 x 10 mm 10 micron 
 
Methods: Described at the specific compound 
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LC-MS: 
Pump: Beckman System Gold 125S Solvent Module  
Detector: System Gold Diode Array Detector Module 168 
Column: YMC Pack Pro C8, 100 x 4.6 mm, 3μm 
 
Solvent A: 95% H2O  
   5% CH3CN 
 0.1% Formic acid 
Solvent B: 95% CH3CN 
   5% H2O 
 0.1% Formic acid 
Standard Gradient: 0-100% B in 11 min, 1 ml/min 
Detection  
wavelength: 220nm, 280nm 
 
1.4 Silica chromatography 
 
For manual column chromatography, Silicagel 60 (Roth) with a particle size of 0.04-0.063 mm was 
used. Automated flash chromatography was performed, using an Interchim Puriflash 430 with an UV 
detector at 254 nm. Preparative thin layer chromatography (TLC) was performed on glas plates 
coated with 2 mm SiO2 (Merck SIL-G-200, F-254,). 
For TLC aluminum plates coated with SiO2 (Merck 60, F-254) were used. The spots were visualized by 
UV light and/or by staining of the TLC plate with one of the solutions below followed, if necessary, by 
heating with a heat gun.  
 
Hanessians:  5 g Ce(SO4)2, 25 g NH4Mo7O24 4 H2O, 450 mL H2O, 50 mL H2SO4 
 
Ninhydrin:  0.5 g Ninhydrin, 100 mL EtOH, 5mL AcOH  
 
Kaliumpermanganat: 1.5 g KMnO4, 10 g K2CO3, 1.25 mL 10% NaOH in 200 mL H2O 
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1.5 Data analysis of neurite outgrowth 
 
The handling and treatment of N2a cells was performed by Alexander Kirschner. Pictures of cells 
were provided as image files. Data analysis was performed using the open source program ImageJ 
(http://rsbweb.nih.gov/ij/) and the plugin NeuronJ to measure the neurite length. Per lane of the 
diagrams neurites of 20-30 cells were measured and the average with standard error was plotted 
using Sigmaplot11. 
 
2. Reagents and solvents 
 
2.1 Reagents 
 
Reagents were obtained from ABCR, Aldrich, Alfa Aeser, Fluka, Merck, Novabiochem, Roth, Sigma 
Aldrich and Synchem in common qualities puriss., p.a. or purum and used without further 
purification.  
 
Compound name CAS No. Company Product code Purity 
Allylmagnesium bromide 1M in 
THF 
1730-25-2 Aldrich 225754 - 
4’-(Aminomethyl)fluorescein 
hydrochloride 
91539-64-9 Invitrogen 1032248 ≥95 
3-Bromocyclohexene 1521-51-3 ABCR AB114158 95% 
Benzoylformic acid 611-73-4 Merck 8.41629 95% 
Cyclohexanone 108-94-1 Aldrich 398241 99% 
Cyclohexene 110-83-8 Fluka 29230 ≥99.5% 
Cyclohexylmagnesium bromide 
(1 M, in THF) 
931-50-0 ABCR AB140471 - 
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Dicyclohexylacetic acid 52034-92-1 Aldrich 333840 99% 
DCC 538-75-0 Aldrich D,800-2 99% 
Diphenylacetic acid 117-34-0 Aldrich D204307 99% 
3,4-Dimethoxybenzaldehyde 120-14-9 Aldrich 143758 99% 
DIPEA 7087-68-5 Fluka 03440 99% 
DMAP 1122-58-3 Aldrich 522805 99% 
EDC 25952-53-8 Fluka 03449 ≥99.0% 
Formic acid 64-18-6 Roth 4724.3 ≥98% 
Grubbs Catalyst 2nd Gen. 246047-72-3 Aldrich 569747 ≥99 
Fmoc-Pro-OH 71989-31-6 Novabiochem 852017 ≥98% 
HATU 148893-10-1 Novabiochem 8.51013 ≥99% 
HOAt 39968-33-7 ABCR AB281963 - 
HCl 7647-01-0 Roth 9277.1 37% 
3’-Hydroxyacetophenone 121-71-1 Aldrich 328103 ≥99% 
1-Hydroxy-7-azabenzotriazole 39968-33-7 ABCR AB281963 ≥99 
In(OTf)3 128008-30-0 Aldrich 442151 ≥99% 
Iodomethylcyclopropane 33574-02-6 Synchem CIC048 95% 
KMnO4 7722-64-7 Merck 1.05082 ≥99% 
K2CO3 584-08-7 Roth X894.2 ≥99.9% 
KI 7681-11-0 Roth 8491.1 ≥99 % 
KOH 1310-58-3 Roth 6751.1 ≥95% 
LiCl 7447-41-8 Aldrich L9650 ≥99 % 
LiHMDS 1M in THF 4039-32-1 Aldrich 22,577-0 - 
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L-Pipecolinic acid 3105-95-1 Alfa Aesar L15373 99% 
LiOH 1310-65-2 Sigma 545856 ≥99 % 
4-Methyl piperidine 626-58-4 Aldrich M73206 96% 
MgSO4 7487-88-9 Roth 0261.3 99% 
NaCl 7647-14-5 VWR 27810.295 99.8 % 
n-BuLi 2M in cyclohexane 109-72-8 Aldrich 302120 - 
NaH 60% dispersion 7646-69-7 Aldrich 45,291-2 60% 
NaHCO3 144-55-8 Roth 8551.1 ≥ 99 % 
NaHMDS 1M in THF 1070-89-9 Aldrich 24558-5 - 
NaNO2 7632-00-0 Roth 8604.1 ≥98.7% 
NH4Cl 12125-02-9 Merck 1.01145 99.8 % 
2-Nitrobenzenesulfonyl chloride 1694-92-4 Aldrich N1,150-7 97% 
Noyori catalyst 212143-24-3 ABCR AB131601 90% 
4-Phenoxystyrene 4973-29-9 ABCR AB173746 90% 
Pd/C 7440-05-3 Aldrich 75992 5% 
Pentafluorophenol 771-61-9 Aldrich 103799 99% 
(S)-4-iso-Propyloxazolidin-2-one 17016-83-0 Aldrich 298883 99% 
(S)-Pyrrolidine-2-carboxylic acid 147-85-3 Fluka 81710 ≥99% 
(1S,2S)-(+)-Pseudoephedrine 90-82-4 Aldrich 287636 98% 
Rapamycin 
53123-88-9 Cfm Oskar 
Tropitzsch 
53123-88-9 ≥95% 
tert-Butyl bromoacetate 5292-43-3 Fluka 17035 ≥97% 
Tetraallyltin 7393-43-3 VWR C04W023 96% 
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Triethylamine 121-44-8 Merck 8.08352 99% 
3,4,5-Trimethoxyphenyl acetic 
acid 
951-82-6 ABCR AB125360 99% 
TFA 76-05-1 Roth P088.2 ≥99.9% 
 
2.2 Non-commercial reagents 
 
5b, 5c, 5e, 25 and 26 were provided by the Lead Discovery Center in Dortmund. 5d was kindly 
provided by Yansong Wang (RG Hausch, MPI Psychiatry). The fluorescent tracers F1 and F2 were 
prepared as described in Kozany et al.108 by Christoph Kress (RG Hausch, MPI Psychiatry).  
 
2.3 Solvents 
 
Solvents were purchased from Roth or Sigma Aldrich with qualities, ROTOSOLV, ROTIPURAN; 
ROTIDRY or HPLC quality with ≥99% purity. Anhydrous solvents were used from Sigma Aldrich with 
sure seals. 
 
 
Compound name CAS No. Company Product code Purity 
n-Hexane 110-54-3 Roth 7339.1 ≥98% 
Cyclohexane 110-82-7 Roth 6570.4 ≥99.5% 
Ethylacetate 141-78-6 Roth CP42.6 ≥ 99.5% 
Chloroform 67-66-3 Roth Y015.3 ≥ 99% 
CDCl3 865-49-6 Roth Ae54.1 ≥ 99.38 % 
Dichloromethane 75-09-2 Roth 6053.5 ≥ 99.5% 
Dichloromethane sure seal, 75-09-2 Aldrich 270997 ≥ 99.8% 
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≥99.8 anhydrous) 
Tetrahydrofuran (sure seal, 
≥99.9 anhydrous) 
109-99-9 Aldrich Ae07.1 
≥ 99.9% 
2-propanol 67-63-0 Roth 7343.1 ≥ 99.9% 
Acetone 67-64-1 Roth 5025.4 ≥ 99.5 % 
Methanol 67-56-1 Roth 8388.4 ≥ 99 % 
Methanol HPLC 67-56-1 Roth 7342.1 ≥ 99.9 % 
Acetonitrile HPLC 75-05-8 Roth 8825.2 ≥ 99.9% 
Toluene 108-88-3 Roth Ae06.1 ≥ 99.5 % 
Diethylether 60-29-7 Roth T900.1 ≥ 99.8 % 
DMF 68-12-2 Roth A5291.1 99% 
DMF (sure seal, ≥99.8 
anhydrous) 
68-12-2 Aldrich 227056 
≥99.8 
 
3. General procedures 
 
All reactions were carried out with magnetic stirring and, when air or moisture sensitive, in flame-
dried glassware under argon (Westfalen, 99.999 Vol% Klasse 5.0). Syringes were used to transfer 
reagents. Reagents used in very moisture-sensitive reactions were dried overnight under high 
vacuum (< 1x10-2 mbar).  
 
4. Synthesis of used compounds  
 
4.1 General synthesis procedure A for the coupling of morpholine 
containing top-groups 
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The alkylated acid (20 mg, 75 µmol) was dissolved in 300 µL DCM or DMF, then DIPEA (41 µL, 
0.24 mmol) and HATU (46 mg, 0.12 mmol) were added and stirred for 15 min. Subsequently, the 
different top groups with a free secondary amine (32 mg, 60 µmol) in 300 µL DCM were added and 
stirred for 14 h. The reaction mixture was concentrated and flash chromatographed or purified by 
preparative HPLC. 
 
 
4.2 General synthesis procedure B for the coupling of free acid top-
groups 
 
The alkylated acid (57 mg, 0.21 mmol) and DIPEA (0.13 mL, 0.78 mmol) were dissolved in dry DCM 
(2 mL) at RT and stirred for 15min. Then, HATU (110 mg, 0.29 mmol) was added and stirred for 
another 15min. Subsequently, the different top groups with a free secondary amine (32 mg, 0.06 
mmol) in 300µL DCM was added and stirred for 14 h. The raw product was purified with flash 
chromatography and then the acid was liberated using 10% TFA in DCM at RT for 5h. The reaction 
mixture was concentrated and flash chromatographed or purified by preparative HPLC.  
 
4.3 Synthetic procedures 
 
(E)-3-(3,4-Dimethoxyphenyl)-1-(3-hydroxyphenyl)prop-2-en-1-one (2) 
 
 
 
3,4-Dimethoxybenzaldehyd (30.6 g, 184 mmol) and 3-hydroxyacetophenone (25 g, 184 mmol) were 
dissolved in 250 mL EtOH and cooled to 0°C in an ice bath. KOH (41.2 g, 734 mmol) was dissolved in 
200 mL H2O, cooled to ~10°C and added to the aforementioned ketone/aldehyde solution. The 
reaction mixture was allowed to warm to RT and stirred for 16 h. The solution was poured into an 
erlenmayer flask filled with ice. The ice-cooled solution was acidified with conc. HCl to pH<2. An 
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orange solid precipitated, which was filtered and afterwards dissolved in EtOAc. The product 2 was 
used without further purification (51.57g, 181 mmol, 99%). 
 
TLC [EtOAc/n-hexane 1:1.5]: Rf = 0.31. 
 
HPLC [0-100% Solvent B, 30 min]: Rt = 20.8 min, purity (220 nm) = 95% 
 
1H-NMR (300 MHz, CDCl3): δ = 7.71 (d, J = 6.6 Hz, 2H), 7.61 (d, J = 7.7 Hz, 1H), 7.53 (d, J = 1.7 Hz, 1H), 
7.47 (d, J = 1.7 Hz, 1H), 7.39-7.34 (m, 2H), 7.07-7.00 (m, 2H), 3.87 (s3, 3H), 3.82 (s, 3H). 
 
13C-NMR (150 MHz, CDCl3): δ = 189.3, 158.4, 151.6, 149.2, 144.5, 139.5, 129.9, 127.5, 123.9, 120.1, 
119.8, 119.5, 114.7, 112.0, 111.1, 56.1, 55.8. 
 
Mass (ESI+): calculated [C17H16O4+ H]
+ 285.11, found 285.00 [M + H]+.  
 
3-(3,4-Dimethoxyphenyl)-1-(3-hydroxyphenyl)propan-1-one (3) 
 
 
 
100 mg Lindlar catalyst was placed into an autoclave (Modell II, Roth) and the autoclave was flushed 
with argon. (E)-3-(3,4-Dimethoxyphenyl)-1-(3-hydroxy-phenyl)prop-2-en-1-one 1 (25,6 g, 90 mmol) 1 
was dissolved in 150 mL MeOH and poured into the autoclave, which was then closed and again 
flushed with argon. Then, 30 bar hydrogen gas (Westfalen, 99,999 Vol% Klasse 5.0) was introduced 
into the autoclave and the solution was stirred for 72 h at RT. The raw product was filtered through 
cellite and MeOH was evaporated in vacuo. Purification was performed by manual column 
chromatography with EtOAc/n-hexane 1:2 to afford 3 (22.65g, 79 mmol, 88%) as a white solid.  
 
TLC [EtOAc/n-Hex 1:2]: Rf = 0.27. 
 
HPLC [0-100% Solvent B, 30 min]: Rt = 20.9 min, purity (220 nm) = 96% 
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1H-NMR (300 MHz, CDCl3): δ = 7.55 - 7.45 (m, 2H), 7.31 – 7.24 (m, 1H), 7.05 (d, J = 1.8 Hz, 1H), 6.8 – 
6.75 (m, 3H), 3.87 (s, 3H), 3.82 (s, 3H), 3.25 (t, J = 7.4 Hz, 2H), 2.98 (t, J = 7.5 Hz, 2H). 
 
13C-NMR (150 MHz, CDCl3): δ = 200.1, 156.2, 149.5, 147.0, 139.1, 132.1, 130.0, 122.0, 120.3, 114.9, 
112.3, 112.8, 56.1, 43.9, 30.9. 
 
HRMS (EI+): calculated [C17H18O4 + H]
+ 287.1205, found 287.1278 [M + H]+. 
 
tert-Butyl-2-[3-{3-(3,4-dimethoxyphenyl)propanoyl}phenoxy] acetate (4a) 
 
 
 
To a solution of 3-(3,4-Dimethoxyphenyl)-1-(3-hydroxyphenyl)propan-1-one 3 (2 g, 7.0 mmol) and 
K2CO3 (1.9 g, 14.0 mmol) in 20 mL acetone was added tert-butyl-bromoacetate (1.1 mL, 7.7 mmol) 
and stirred for 20 h at RT. K2CO3 was filtered out and washed with aceton. The solvent was removed 
in vacuo. The raw product was dissolved in EtOAc and washed 3 times with brine. The aqueous phase 
was extracted with EtOAc. The combined organic layers were dried over MgSO4. The crude product 
was concentrated and purified by column chromatography (EtOAc/n-Hexane, 1:2) 4a (2.06g, 
5.14 mmol, 74%). 
 
TLC [EtOAc/n-Hexane 1:2]: Rf = 0.32 
 
HPLC [0-100% Solvent B, 30 min]: Rt = 26.2 min, purity (220 nm) = 98% 
 
1H-NMR (300 MHz, CDCl3): δ = 7.59 (dq, J = 5.4 Hz, J = 0.9 Hz, 1H), 7.48 (dd, J = 1.2 Hz, J = 1.5 Hz, 1H), 
7.38 (t, J = 8.1 Hz, 1H), 7.16 – 7.12 (m, 1H), 6.84 – 6.78 (m, 3H), 4.58 (s, 2H), 3.89 (s, 3H), 3.87 (s, 3H), 
3.27 (t, J = 8.1 Hz, 2H), 3.02 (t, J = 6.9 Hz, 2H), 1.51 (s, 9H). 
 
13C-NMR (150 MHz, CDCl3): δ = 198.9, 167.6, 158.2, 149.0, 147.5, 138.3, 133.8, 129.7, 121.5, 120.2, 
120.1, 113.13, 111.9, 111.4, 82.62, 65.7, 56.0, 40.8, 29.8. 
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Mass (ESI+): calculated without t-butyl [C23H28O6+ H]
+ 345.13, found 345.20 [M + H]+. 
 
(R)-tert-Butyl-2-[3-{3-(3,4-dimethoxyphenyl)-1-hydroxypropyl}phenoxy] 
acetate (5a) 
 
 
 
tert-Butyl-2-[3-{3-(3,4-dimethoxyphenyl)propanoyl}phenoxy]acetate 4a (2.06 g, 5.14 mmol) was 
dissolved in isopropanol and filled into an autoclave (Roth, Modell II). Then K2CO3 (0.71 g, 5.14 mmol) 
was added and flushed with argon. Noyori catalyst (46 mg, 41 µmol, Scheme. 24) was added and 
after closing the autoclave, it was flushed again with argon. Now 35-40 bar hydrogen gas (Westfalen, 
99,999 Vol% Klasse 5.0) was filled into the autoclave and the solution was stirred for 72h. The raw 
product was filtered through cellite and the solvent was removed under reduced pressure.  
The product was purified by column chromatography (EtOAc/n-Hex, 1:2). 5a (1.73g, 4.28 mmol, 83%) 
was obtained as a white solid. The enantiomeric excess (ee = 98%) was determined using chiral 
analytical HPLC.  
 
 
 
Noyori catalyst (ABCR, AB131601) 
 
TLC [EtOAc/n-Hex 1:2]: Rf = 0.25. 
 
HPLC (Chiral): [i-Propanol/n-hexane, isochratic, 1:1 60 min]: Rt = 37 min, purity (220 nm) = 97% 
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1H-NMR (300 MHz, CDCl3): δ = 7.29 – 7.21 (m, 1H), 6.98 – 6.90 (m, 2H), 6.80 – 6.70 (m, 4H), 4.69 – 
4.66 (m, 1H), 4.52 (s, 2H), 3.86 (s, 3H), 3.85 (s, 3H), 2.70 – 2.60 (m, 2H), 2.11 – 1.95 (m, 2H), 1.49 (s, 
9H). 
 
13C-NMR (150 MHz, CDCl3): δ = 168.4, 160.7, 149.9, 147.1, 145.5, 134.4, 129.8, 122.5, 120.4, 112.2, 
111.6, 108.8, 82.1, 74.2, 65.9, 56.1, 39.1, 29.4, 28.7. 
 
HRMS (EI+): calculated für [C23H30O6 + Na]
+ 425,1935, found 425,1946 [M + Na]+. 
 
(S)-1-(((9H-Fluoren-9-yl)methoxy)carbonyl)piperidine-2-carboxylic acid (6a) 
 
 
 
L-pipecolinic acid 1 (3.6 g, 10 mmol) was dissolved in 40 mL 10 % aqueous Na2CO3 solution and 
combined with a solution of Fmoc succinimide (3.4 g, 10 mmol) in 45 mL dioxane. The formed 
suspension was stirred for 22 h at RT. Then the reaction was quenched by addition of another 50 mL 
of H2O, followed by extraction with EtOAc. The aqueous phase was acidified to pH = 2, and again 
extracted with EtOAc. The organic phase was washed with 1 M HCl and brine, and dried over MgSO4) 
7a was concentrated (4.3 g, 8.3 mmol, 83%) and obtained as a white solid without further 
purification. 
 
TLC [EtOAc/cyclohexane 1:1, 0.1% TFA] Rf = 0.46. 
 
HPLC [0-100% Solvent B, 30 min]: Rt = 24.5 min, purity (220 nm) = 97% 
 
1H-NMR (300 MHz, CDCl3): δ (ppm) = 7.55-7.62 (m, 2H), 7.28-7.41 (m, 4H), .76-5.05(m, 1H), 4.37-
4.49 (m, 2H), 4.05-4.33 (m, 2H), 3.15 (t, J= 13.2Hz, 1H), 2.19-2.37 (m, 1H), 1.77 (s, 2H), 1.69-1.82 
(m, 3H), 1.28-1.53 (m, 2H). 
 
13C-NMR (150 MHz, CDCl3): δ (ppm) = 177.69, 156.96, 156.18, 144.19, 141.63, 128.02, 127.39, 
125.41, 120.30, 68.18, 67.91, 54.58, 54.48, 47.53, 42.27, 42.00, 27.07, 26.87, 25.02, 24.79, 21.07, 
20.94. 
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Mass: (ESI+): calculated [C21H21NO4 + H]
+ 514.41, found 514.43 [M + H]+. 
 
(S)-1-[9H-Fluoren-9-yl]methyl-ester-2-[(R)-1-{3-(2-tert-butoxy-2-oxo-
ethoxy)phenyl}-3-(3,4-dimethoxyphenyl)propyl]piperidin-2-carboxylate  
 
 
 
 
5a (100 mg, 0.248 mmol), 7a (96 mg, 0.27 mmol) were dissolved in 2 mL DCM at RT. Then EDC-HCl 
(52 mg, 0.27 mmol) was added and the micture was stirred for 14 h at RT. After concentration in 
vacuo the raw product was subjected to column chromatography (EtOAc/n-Hexane, 1:2) to yield 
Fmoc protected 8a as a slight yellow oil (139 mg, 0.19 mmol, 76%).  
 
TLC [EtOAc/n-Hexane 1:2]: Rf = 0.36. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 17.9 min, purity (220 nm) = 96% 
 
1H-NMR (300 MHz, CDCl3): δ = 7.73 (m, 2H), 7.59 (t, J = 6.6 Hz, 1H), 7.16-7.49 (m, 6H), 6.94 (d, J = 7.6 
Hz, 1H), 6.89 (s, 1H), 6.72-6.82 (m, 2H), 6.62 (m, 2H), 5.76 (br s, 1H), 5.02 (d, J = 3.7 Hz, 1H), 4.25-4.49 
(m, 5H), 4.07-4.14 (m, 1H), 3.83 (s, 6H), 3.14 (t, J = 11.1 Hz, 1H), 2.46-2.54 (m, 2H), 2.16-2.33 (m, 2H), 
2.00-2.07 (m, 1H), 1.68-1.78 (m, 4H), 1.46 (s, 9H), 1.39-1.56 (m, 1H).  
 
13C-NMR (150 MHz, CDCl3): δ = 174.50, 171.33, 168.28, 158.48, 147.73, 144.30, 142.12, 133.90, 
130.07, 128.07, 127.45, 125.48, 120.50, 120.35, 114.34, 113.66, 112.12, 111.74, 82.74, 76.82, 76.59, 
68.20, 66.16, 56.32, 56.20, 47.63, 38.44, 31.98, 31.54, 28.42, 27.23, 25.18, 21.20. 
 
Mass (ESI+): calculated [C44H49NO8 + H]
+ 736.35 found 736.36 [M + H]+. 
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(S)-[(R)-1-{3-(2-tert-Butoxy-2-oxoethoxy)phenyl}-3-(3,4-dimeth-oxyphenyl) 
propyl] piperidin-2-carboxylate (8a/37a) 
 
 
 
Fmoc-protected 8a/37a (100 mg, 0.136 mmol) was dissolved in 1.8 mL dry DCM, then 0.2 mL 4-
Methyl-Piperidine was added and stirred for 14h. The solvent was removed in vacuo and the raw 
product was purified with column chromatography (Gradient 50%-100% EtOAc in n-hexane) to afford 
8a as a colorless oil (345 mg, 0.66 mmol, 76%) 
 
TLC [EtOAc/n-hexane 1:2]: Rf = 0.36. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.5 min, purity (220 nm) = 95% 
 
1H-NMR (300 MHz, CDCl3): δ = 7.28 (t, J = 7.9 Hz, 1H), 6.98 (d, J = 7.7 Hz, 1H), 6.93 (s, 1H), 6.84 (m, 
2H), 6.71 (d, J = 8.3 Hz, 1H), 6.69 (s, 1H), 5.77 (dd, J = 6.3, 6.8 Hz, 1H), 4.55 (s, 2H), 3.91 (s, 6H), 3.42 
(m, 1H), 3.33 (s, 1H), 3.01 (m, 1H), 2.39-2.63 (m, 3H), 2.11-2.27 (m, 1H), 2.05-2.09 (m, 1H), 1.92 (m, 
1H), 1.54 (s, 9H), 1.54-1.74 (m, 4H). 
 
13C-NMR (150 MHz, CDCl3): δ = 173.42, 168.29, 158.34, 149.20, 147.64, 142.54, 134.06, 129.92, 
120.49, 120.19, 114.11, 113.54, 111.99, 111.60, 82.74, 75.21, 66.05, 61.45, 56.30, 56.21, 48.57, 
38.55, 31.63, 29.41, 28.44, 25.70, 22.56. 
 
Mass (ESI+): calculated [C29H39NO7 +H]
+ 514.43, found 514.45 [M + H]+. 
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Oxycarbonyl-2-((R)-3-(3,4-dimethoxyphenyl)-1-(3-(2-morpholinoethoxy) 
phenyl)propyl) (S)-1-(9H-Fluoren-9-yl)methylpiperidine-2-carboxylate 
 
 
 
A solution of alcohol 5b (171 mg, 0.43 mmol), carboxylic acid 6a (150 mg, 0.43 mmol), and DMAP 
(6 mg, 47 µmol) in 10 mL DCM at room temperature was treated with DCC (113 mg, 0.51 mmol). The 
mixture was stirred for 14 h after which the organic solvent was removed in vacuo. The solid was 
dissolved in diethyl ether (50mL) and filtered through a plug of celite. The filtrate was concentrated 
and then flash chromatographed (DCM/MeOH 9.7:0.3) to afford Fmoc protected 8b as brownish oil 
(280 mg, 0.38 mmol, 89%). 
 
TLC [100% EtOAc]: Rf = 0.56.  
 
HPLC [0-100% Solvent B, 15 min]: Rt = 8.8 min, purity (220 nm) = 98% 
 
1H NMR (300 MHz, CDCl3) δ 7.76 (dd, J = 14.6, 7.5 Hz, 2H), 7.60 (t, J = 6.6 Hz, 1H), 7.54 – 7.14 (m, 6H), 
6.93 (d, J = 7.7 Hz, 3H), 6.89 – 6.80 (m, 1H), 6.76 (d, J = 8.3 Hz, 1H), 6.71 – 6.56 (m, 2H), 5.78 (s, 1H), 
5.04 (s, 1H), 4.91 (s, 1H), 4.53 – 4.23 (m, 3H), 4.22 – 3.96 (m, 4H), 3.88 – 3.80 (m, 6H), 3.77 – 3.69 (m, 
3H), 3.17 (t, J = 11.8 Hz, 1H), 2.99 (d, J = 12.0 Hz, 1H), 2.85 – 2.67 (m, 2H), 2.65 – 2.49 (m, 4H), 2.40 – 
2.13 (m, 1H), 2.13 – 1.90 (m, 1H), 1.83 – 1.66 (m, 3H), 1.56 – 1.48 (m, 2H). 
 
13C NMR (75 MHz, CDCl3) δ 170.83, 158.70, 156.42, 155.77, 149.03, 147.28, 143.90, 143.88, 141.68, 
141.23, 133.50, 129.63, 127.67, 127.06, 125.03, 120.06, 119.95, 119.05, 118.88, 113.94, 113.06, 
111.66, 111.33, 67.76, 66.85, 65.59, 57.59, 54.89, 54.56, 54.06, 47.23, 38.10, 33.97, 31.17, 29.70, 
27.01, 26.82, 25.61, 24.92, 24.57, 20.57. 
 
Mass: (ESI+) calculated 735.40 [C44H50N2O8 + H]
+, found 735.57 [M + H]+. 
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(S)-((R)-3-(3,4-Dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propyl) 
piperidine-2-carboxylate (9a/37b) 
 
 
 
Fmoc protected 8b (250 mg, 0.34 mmol) was treated with 20% 4-methylpiperidine in DCM at room 
temperature. The mixture was stirred for 14 h. 4-Methylpiperidine and DCM were evaporated under 
reduced pressure. The raw product was purified by column chromatography (EtOAc/cyclohexane 2:8, 
0,2% TEA) to afford 9a/37b as a slight yellow oil (160 mg, 0.31mmol, 84%). 
 
TLC [EtOAc/cyclohexane 2:8, 0.2% TEA]: Rf = 0.3. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 11.6 min, purity (220 nm) = 92% 
 
1H NMR (300 MHz, CDCl3) δ= 7.19 (t, J= 8.1 Hz, 1H), 6.95 (s, 1H), 6.86 (d, , J= 7.8Hz, 1H), 6.72-6.80 (m, 
3H), 6.66-6.62 (m, 2H), 5.70 (t, J= 7.2 Hz, 1H), 4.35-4.18 (m, 2H), 3.85-3.77 (m, 6H), 3.42-3.27 (m, 1H), 
3.08 (s, 3H), 3.06 (s, 3H), 2.85 (s, 2H), 2.62-2.44 (m, 3H), 2.31-2.17 (m, 3H), 2.10-1.89- (m, 3H), 1.89-
1.67 (m, 3H), 1.60-1.48 (m, 2H).  
 
13C NMR (75 MHz, CDCl3) δ= 21.59, 22.00, 26.01, 31.15, 37.82, 44.12, 45.89, 55.91, 55.95, 56.67, 
57.17, 64.55, 65.60, 77.65, 111.35, 111.83, 112.36, 111.72, 119.27, 120.18, 129.57, 133 .31, 140.98, 
147.29, 148.84, 158.45, 167.88. 
 
Mass: (ESI+), calculated 513.32 [C29H40N2O6 + H]
+, found 513.29 [M + H]+. 
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(R)-(R)-3-(3,4-Dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propyl-
thiomorpholine-3-carboxylate (9b) 
 
 
 
A solution of alcohol 5b (0.10 g, 0.25 mmol), Fmoc-thiopipecolate (92 mg, 0.37 mmol), and catalytic 
amount of DMAP (3 mg, 25 µmol) in 10 mL DCM was treated with EDC (53 mg, 0.28 mmol). The 
mixture was stirred for 14 h at RT. The crude product was concentrated, flash chromatographed 
(DCM/MeOH 97:3) and consequently dissolved in 1.8 mL DCM. Then 0.2 mL 4-methylpiperidine was 
added and the mixture was stirred for 14 h at RT. 4-Methylpiperidine and DCM were evaporated 
under reduced pressure. The raw product was purified by flash chromatogrpahy (DCM/MeOH 92:8). 
9b was obtained as a slight yellow oil (32 mg, 0.13 mmol, 48%). 
 
TLC [MeOH/DCM 8:92]: Rf = 0.18. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 11.7 min, purity (220 nm) = 92% 
 
1H NMR (300 MHz, d6-DMSO) δ 7.24 – 7.16 (m, 1H), 6.91 – 6.73 (m, 5H), 6.66 (td, J = 8.2, 7.8, 2.0 Hz, 
1H), 5.63 (dd, J = 8.4, 4.7 Hz, 1H), 4.09 – 4.00 (m, 2H), 3.97 (t, J = 3.6 Hz, 1H), 3.72 – 3.67 (m, 6H), 3.58 
– 3.51 (m, 4H), 3.06 – 2.85 (m, 3H), 2.69 – 2.60 (m, 2H), 2.60 – 2.50 (m, 2H), 2.47 – 2.39 (m, 5H), 2.17 
– 2.04 (m, 2H), 1.98 (d, J = 14.7 Hz, 2H). 
 
13C NMR (75 MHz, d6-DMSO) δ 170.62, 158.91, 148.86, 147.47, 142.32, 133.89, 129.68, 120.20, 
118.75, 114.35, 112.88, 111.96, 74.91, 66.47, 65.39, 59.53, 57.34, 55.87, 54.09, 46.21, 38.16, 31.03, 
28.82, 27.36. 
 
Mass: (ESI+), calculated 531.25 [C28H38N2O6S+H]
+, found 531.21 [M+H]+. 
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(S)-1-((9H-Fluoren-9-yl)methyl)ester-2-((R)-3-(3,4-dimethoxyphenyl)-1-(3-(2-
morpholinoethoxy) phenyl)propyl) pyrrolidine-2-carboxylate  
 
 
 
5b (200 mg, 0.50 mmol), Fmoc-proline (185 mg, 0.55 mmol) and DMAP (12 mg, 0.10 mmol) were 
dissolved in DCM at 0°C then EDC (143 mg, 0.75 mmol) was added and the reaction was allowed to 
warm to RT, followed by stirring for 14 hours. The raw product was subjected to column 
chromatography (gradient 0%-5% MeOH in DCM). Fmoc protected 36b (276 mg, 0.383 mmol, 77%) 
was obtained as a slight yellow oil. 
 
TLC [MeOH/DCM 5:95]: Rf = 0.2. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 16.7 min, purity (220 nm) = 98% 
 
1H NMR (400 MHz, CDCl3): δ 7.78 – 7.67 (m, 2H), 7.65 – 7.53 (m, 1H), 7.53 – 7.45 (m, 1H), 7.42 – 7.26 
(m, 3H), 7.25 – 7.18 (m, 1H), 6.94 – 6.53 (m, 7H), 5.73 (dt, J = 8.0, 5.8 Hz, 1H), 4.49 (dt, J = 8.9, 3.7 Hz, 
1H), 4.41 (dd, J = 10.1, 6.8 Hz, 2H), 4.34 – 4.13 (m, 1H), 4.14 – 4.07 (m, 2H), 3.85 – 3.82 (m, 6H), 3.77 
– 3.66 (m, 4H), 3.31 (td, J = 9.1, 3.2 Hz, 1H), 3.26 – 3.14 (m, 1H), 3.07 (dt, J = 10.4, 6.8 Hz, 1H), 2.80 
(dt, J = 6.9, 5.7 Hz, 4H), 2.64 – 2.52 (m, 4H), 2.35 – 2.18 (m, 1H), 2.15 – 1.96 (m, 2H), 1.95 – 1.76 (m, 
2H). 
 
13C NMR (125 MHz,CDCl3) δ 171.90, 159.63, 157.44, 150.39, 148.33, 144.14, 143.58, 139.48, 135.20, 
129.28, 127.63, 126.29, 125.14, 121.85, 120.96, 119.20, 115.53, 114.12, 113.68, 113.06, 77.03, 67.50, 
67.38, 66.80, 63.34, 56.83, 54.73, 52.94, 48.12, 47.31, 36.38, 34.08, 28.00, 24.98. 
 
Mass (ESI+): calculated [C43H48N2O8 +H]
+ 721.35, found 721.25 [M + H]+. 
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(S)-(R)-3-(3,4-Dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propyl-
pyrrolidine-2-carboxylate (9c/36b) 
 
 
 
Fmoc protected 9c/36b (234 mg, 0.32 mmol) was dissolved in 1.8 mL dry DCM, then 200 µL 
4-methyl-piperidine was added and stirred for 14 h. The product was purified using flash 
chromatography (gradient 0%-10% MeOH in DCM) to obtain 36b (140 mg, 0.28 mmol, 86%) as a 
yellow oil. 
 
TLC [MeOH/DCM 6:94]: Rf = 0.10. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 11.6 min, purity (220 nm) = 92%. 
 
1H NMR (300 MHz, CDCl3) δ 7.25 – 7.18 (m, 1H), 6.94 – 6.83 (m, 2H), 6.83 – 6.72 (m, 2H), 6.70 – 6.61 
(m, 2H), 5.72 (dd, J = 7.9, 5.9 Hz, 1H), 4.64 (dd, J = 7.8, 5.3 Hz, 1H), 4.14 – 4.07 (m, 2H), 3.85 – 3.82 (m, 
6H), 3.77 – 3.66 (m, 4H), 3.31 (td, J = 9.1, 3.2 Hz, 1H), 3.26 – 3.14 (m, 1H), 3.07 (dt, J = 10.4, 6.8 Hz, 
1H), 2.80 (dt, J = 6.9, 5.7 Hz, 4H), 2.64 – 2.52 (m, 4H), 2.35 – 2.18 (m, 1H), 2.15 – 1.96 (m, 2H), 1.95 – 
1.76 (m, 2H). 
 
13C NMR (75 MHz, CDCl3) δ 172.34, 158.73, 148.77, 147.17, 146.44, 141.28, 134.43, 133.35, 129.43, 
119.09, 118.46, 113.45, 113.13, 111.75, 111.19, 73.61, 66.82, 65.70, 59.64, 57.63, 55.92, 54.05, 
40.65, 31.64, 29.89, 24.75. 
 
Mass (ESI+): calculated [C28H38N2O6 +H]
+ 499.28, found 499.22 [M + H]+. 
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Pentafluorophenyl 2-(3,4,5-trimethoxyphenyl)acetate (20) 
 
 
 
2-(3,4,5-Trimethoxyphenyl)acetic acid (8.2 g, 36.2 mmol) was dissolved in 140 ml dry DCM, then EDC 
(10.4 g, 54.3 mmol) was added and stirred for 15 min at RT. 2,3,4,5,6-pentafluorophenol (10.0 g, 
54.3 mmol) was dissolved in 60 ml dry DCM and added to the solution. The mixture was stirred for 
6 h at RT and then concentrated and subjected to flash chromatography (EtOAc/cyclohexane, 2:8). 20 
(13.4 g, 34.1 mmol, 94%) was obtained as a white solid. 
 
TLC [EtOAc/cyclohexane, 2:8]: Rf = 0.31. 
 
HPLC [0-100% Solvent B, 30 min]: Rt = 25.8 min, purity (220 nm) = 95%. 
 
1H-NMR (300 MHz, CDCl3): δ = 6.56 (s, 2H), 3,90 (s, 2H), 3.87 (s, 6H), 3.85 (s, 3H). 
 
13C-NMR (150 MHz, CDCl3): δ = 167.39, 153.48, 137.59, 127.47, 106.19, 60.855, 56.12, 40.37. 
 
HRMS (ESI+): calculated [C17H13F5O5 + H
+] 393.0756, found 393.0711 [M] + H+. 
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(S)-4-isopropyl-3-[2-(3,4,5-trimethoxyphenyl)acetyl]oxazolidin-2-one (21)  
 
 
 
 
n-Butyllithium (2.5 M in Cyclohexane, 1.4 mL, 3.6 mmol) was added to (S)-4-Isopropyl-oxazolidin-2-
one (0.46 g, 3.6 mmol) dissolved in 17 mL dry THF at -78°C, then was stirred for 1 h -78°C. After that 
20 (1.4 g, 3.6 mmol) dissolved in 17 mL dry THF was added to the above solution and stirred for 2h at 
-78°C and 14 h at 0°C. The reaction mixture was quenched by adding sat. NH4Cl solution. The 
aqueous solution was extracted with DCM. The org. phases were dried over MgSO4. The crude 
product was concentrated and purified by column chromatography (EtOAc/cyclohexane, 1:2). 21 was 
afforded as a yellow oil (0.67 mg, 1.98 mmol, 53%). 
 
TLC [EtOAc/cyclohexane, 2:8]: Rf = 0.31. 
 
HPLC [0-100% Solvent B, 30 min]: Rt = 22.4 min, purity (220 nm) = 98%. 
 
1H-NMR (300 MHz, CDCl3): δ = 6.56 (s, 2H), 4.43-4.41 (m, 2H), 4.38-4.17 (m, 3H), 3.85 (d, 9H), 2.38-
2.27 (m, 1H), 0.96 (d, J = 6 Hz, 3H), 0.85 (d, J = 6 Hz, 3H). 
 
13C-NMR (150 MHz, CDCl3): δ = 167.39, 153.48, 137.59, 127.47, 106.19, 60.855, 56.12, 40.37. 
 
Mass (ESI+): calculated [C17H23NO6 + H
+] 338.16, found 338.20 [M] + H+. 
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(S)-4-Isopropyl-3-((S)-2-(3,4,5-trimethoxyphenyl)pent-4-enoyl)oxazolidin-2-
one (22)  
 
 
 
21 (2.0 g, 5.9 mmol) was dissolved in 5 mL anhydrous THF, cooled to -78°C and then NaHMDS 
(7.1 mL, 7.1 mmol, 1M in THF) was added to the solution. After stirring for 30min at -78°C, the 
reaction was stirred for another 30min at 0°C, then allylbromide (0.63 mL, 7.1 mmol) was added and 
stirred for 2h at -78°C, and another 10 h at 0°C. The reaction was quenched by the addition of 
saturated NH4Cl solution. The biphasic aqueous solution was extracted with DCM. The organic phases 
were combined and dried over MgSO4. The crude mixture was concentrated and purified by column 
chromatography (EtOAc/cyclohexane, 2:8). 22 was obtained as yellow oil (1.0 g, 2.7 mmol, 45%, d.r. 
>95:5). 
 
TLC [EtOAc/cyclohexane 2:8]: Rf = 0.31. 
 
HPLC [0-100% Solvent B, 30 min]: Rt = 25.0 min, purity (220 nm) = 98%. 
 
1H NMR (600 MHz, CDCl3) δ 6.60 (s, 2H), 5.80 – 5.70 (m, 1H), 5.20 – 5.15 (dd, J = 9.5, 5.8 Hz, 1H), 5.14 
– 5.07 (dq, J = 17.1, 1.6 Hz, 1H), 5.04 – 4.98 (dq, J = 10.2, 1.1 Hz, 1H), 4.40 – 4.34 (m, 1H), 4.18 – 4.13 
(m, 2H), 3.85 – 3.82 (s, 6H), 3.83 – 3.79 (s, 3H), 2.93 – 2.84 (m, 1H), 2.52 – 2.44 (m, 1H), 2.43 – 2.35 
(m, 1H), 0.92 – 0.84 (m, 6H). 
 
13C NMR (150 MHz, CDCl3) δ 173.36, 153.67, 153.04, 137.10, 135.07, 133.80, 117.14, 105.43, 62.99, 
60.82, 58.93, 56.12, 47.79, 38.67, 28.37, 17.88, 14.58. 
 
HRMS (EI+): calculated [C20H27NO6 + H]
+ 378.19, found 378.13 [M+ H]+. 
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(S)-2-(3,4,5-Trimethoxyphenyl)pent-4-enoic acid (23) 
 
 
 
22 (0.70 g, 1.86 mmol) was dissolved in 10 mL THF/H2O (1:1) and cooled to 0°C for 5min. Then LiOH 
(89 mg, 3.71 mmol) was added followed by addition of H2O2 (0.60 mL, 7.42 mmol). The reaction 
mixture was stirred at 0°C for 4 h. The reaction was quenched by the addition of 1.5 M Na2SO3. The 
aqueous solution was diluted with brine and extracted with DCM. Then, the aqueous phase was 
acidified to pH<2 and further extracted with DCM. The organic layers were combined and dried over 
MgSO4. The raw product was concentrated and purified using flash chromatography (gradient 0%-
30% EtOAc in n-hexane, 0.1% AcOH). 23 (324 mg, 1.22 mmol, 66%) was obtained as a yellow oil.  
 
TLC [EtOAc/n-hexane 1:2]: Rf = 0.22. 
 
HPLC [0-100% Solvent B, 30 min]: Rt = 17.9 min, purity (220 nm) = 98%. 
 
1H NMR (300 MHz, CDCl3) δ 6.56 (d, J = 1.1 Hz, 2H), 5.84 – 5.67 (m, 1H), 5.19 – 5.00 (m, 2H), 3.87 – 
3.84 (m, J = 0.7 Hz, 9H), 3.58 (dd, J = 8.6, 6.9 Hz, 1H), 2.88 – 2.75 (m, 1H), 2.53 (dtt, J = 14.5, 6.8, 1.4 
Hz, 1H). 
 
13C NMR (75 MHz, CDCl3) δ 178.95, 153.31, 137.47, 134.79, 133.38, 117.31, 105.08, 60.81, 56.14, 
51.50, 37.18, 20.72. 
 
Mass: (ESI+), calculated 287.12 [C14H18O5 + H]
+, found 287.13 [M + H]+. 
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2-(3-((R)-3-(3,4-Dimethoxyphenyl)-1-(((S)-1-((S)-2-(3,4,5-trimethoxyphenyl) 
pent-4-enoyl)piperidine-2-carbonyl)oxy)propyl)phenoxy)acetic acid (24) 
 
 
 
General synthesis procedure B for free acid ligands with 37a (0.10 g, 0.20 mmol) and 23 (57 mg, 
0.21 mmol) was used. The crude product was purified using flash chromatography (gradient 0%-10% 
MeOH in DCM) to obtain 24 (38 mg, 54 µmol, 55%) as a colorless oil. The diastereomeric rate was 
determined by HPLC. 
 
TLC [EtOAc/cyclohexane, 1:1, 1% AcOH]: Rf = 0.28. 
 
HPLC [60-80% Solvent B, 20 min]: Rt = 8.1 min, purity (220 nm) = 95%, dr 95:5. 
 
1H NMR (599 MHz, d6-DMSO) δ 7.20 (dd, J = 7.8, 0.8 Hz, 1H), 6.85 – 6.71 (m, 4H), 6.67 (d, J = 2.0 Hz, 
1H), 6.59 (s, 2H), 6.56 (dd, J = 8.2, 2.0 Hz, 1H), 5.76 – 5.64 (m, 1H), 5.48 (dd, J = 8.7, 4.6 Hz, 1H), 5.22 
(dd, J = 5.9, 2.5 Hz, 1H), 5.03 – 4.92 (m, 2H), 4.65 (s, 2H), 3.71 (t, J = 2.3 Hz, 3H), 3.69 (s, 3H), 3.68 (s, 
4H), 3.64 (s, 3H), 3.61 (s, 1H), 3.51 (s, 3H), 2.75 – 2.64 (m, 2H), 2.44 – 2.37 (m, 2H), 2.34 – 2.25 (m, 
2H), 2.15 – 2.06 (m, 2H), 1.84 (ddd, J = 34.5, 8.0, 5.4 Hz, 2H), 1.63 – 1.52 (m, 2H), 1.05 – 0.95 (m, 2H). 
 
13C NMR (151 MHz, CDCl3) δ 176.94, 175.44, 175.30, 162.96, 157.84, 153.83, 152.17, 147.35, 141.80, 
141.17, 140.09, 138.19, 134.63, 125.13, 123.41, 121.43, 117.28, 110.32, 80.06, 69.53, 64.83, 61.09, 
60.78, 60.65, 60.51, 56.95, 52.14, 42.66, 35.80, 31.40, 29.98, 25.70. 
 
Mass: (ESI+), calculated 728.30 [C39H47NO11+Na]
+, found 728.40 [M+H]+. 
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(S)-(R)-3-(3,4-Dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propyl-1-
((S)-2-(3,4,5-trimethoxyphenyl)pent-4-enoyl)pyrrolidine-2-carboxylate (27) 
 
 
 
General synthesis procedure A for morpholine ligands with 9c (31 mg, 62 µmol) and 23 (17 mg, 
62 µmol) was used. Then the crude product was purified using flash chromatography (gradient 0%-
10% MeOH in DCM) to obtain 27 (31 mg, 44 µmol, 67%) as a light yellow oil. The diastereomeric rate 
was determined by HPLC. 
 
TLC [MeOH/DCM, 3:97, 1% TEA]: Rf = 0.24. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.8 min, purity (220 nm) = 95%, dr 95:5. 
 
1H NMR (400 MHz, d6-DMSO) δ 7.17 (t, J = 7.9 Hz, 1H), 6.86 (t, J = 1.9 Hz, 1H), 6.82 – 6.77 (m, 2H), 
6.73 – 6.68 (m, 2H), 6.64 – 6.57 (m, 1H), 6.49 (s, 2H), 5.77 – 5.62 (m, 1H), 5.48 (dd, J = 8.3, 5.0 Hz, 1H), 
5.05 – 4.87 (m, 3H), 4.45 (dd, J = 8.7, 3.4 Hz, 1H), 4.17 – 4.02 (m, 3H), 3.77 (dd, J = 8.5, 6.0 Hz, 1H), 
3.74 – 3.62 (m, 6H), 3.59 – 3.46 (m, 9H), 3.28 – 3.18 (m, 4H), 2.68 – 2.57 (m, 4H), 2.52 – 2.37 (m, 5H), 
2.31 – 2.11 (m, 5H), 1.83 – 1.73 (m, 2H). 
 
13C NMR (100 MHz, d6-DMSO) δ 171.88, 170.71, 158.80, 153.15, 149.10, 147.33, 142.50, 137.04, 
136.45, 135.00, 133.82, 129.55, 120.44, 118.37, 116.77, 114.28, 112.73, 112.34, 112.06, 105.68, 
75.33, 66.60, 65.65, 60.08, 59.00, 57.39, 55.95, 54.07, 49.32, 46.83, 38.96, 38.10, 30.91, 29.17, 24.83. 
 
Mass: (ESI+), calculated 747.39 [C42H54N2O10+H]
+, found 747.51 [M+H]+. 
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(R)-(R)-3-(3,4-Dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propyl-4-
((S)-2-(3,4,5-trimethoxyphenyl)pent-4-enoyl)thiomorpholine-3-carboxylate 
(28) 
 
 
 
General synthesis procedure A for morpholine ligands with 9b (32 mg, 60 µmol) and 23 (20 mg, 
75 µmol) was used. The crude product was purified using flash chromatography (gradient 0%-80% 
EtOAc in cylcohexane) to obtain 28 (31 mg, 4 µmol, 67%) as a light yellow oil. The diastereomeric rate 
was determined by HPLC. 
 
TLC [EtOAc/cyclohexane, 3:7, 4% AcOH]: Rf = 0.42. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.88 min, purity (220 nm) = 92%, dr ≥ 99:1. 
 
1H NMR (400 MHz, d6-DMSO) δ 7.29 – 7.23 (m, 1H), 7.16 (t, J = 7.8 Hz, 1H), 6.95 – 6.57 (m, 5H), 6.52 
(s, 2H), 5.71 – 5.65 (m, 1H), 5.62 – 5.54 (m, 1H), 5.03 – 4.87 (m, 2H), 4.10 – 4.04 (m, 3H), 3.73 (d, J = 
2.2 Hz, 3H), 3.69 (s, 3H), 3.69 – 3.67 (m, 6H), 3.62 (d, J = 2.3 Hz, 3H), 3.60 (s, 3H), 3.57 (s, 2H), 3.55 (s, 
2H), 3.48 (d, J = 1.9 Hz, 1H), 3.32 (s, 1H), 3.14 – 3.08 (m, 1H), 2.91 (dd, J = 13.9, 4.0 Hz, 1H), 2.75 – 
2.62 (m, 5H), 2.53 – 2.44 (m, 6H), 2.38 – 2.29 (m, 1H). 
 
13C NMR (101 MHz, d6-DMSO) δ 172.40, 168.83, 158.77, 153.39, 153.14, 149.03, 149.01, 147.44, 
142.29, 142.22, 136.93, 136.73, 135.78, 135.03, 133.78, 129.93, 120.46, 116.81, 114.19, 112.68, 
112.28, 105.51, 75.80, 66.52, 65.46, 60.19, 56.36, 56.00, 55.90, 55.79, 55.75, 55.35, 54.01, 52.52, 
52.20, 51.58, 47.42, 44.49, 33.69, 31.73, 31.00, 26.99, 24.85, 22.54. 
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Mass: (ESI+), calculated 779.36 [C42H54N2O10S+H]
+, found 779.37 [M+H]+. 
 
(S)-Methyl 2-(2-nitrophenylsulfonamido)pent-4-enoate (30) 
 
 
 
30 was synthesized according to Varray et al129. L-Allyl-glycine (1.0 g, 8.69 mmol) was dissolved in 
10 mL MeOH, cooled to 0°C, and then 3 mL TMS-Cl was added. The mixture was allowed to warm to 
RT and stirred for 24 h. The solvent was removed in vacuo and the resulting white oil was dissolved in 
hot EtOAc and precipitated with hexane. L-Allyl-glycine methylester (1.1 g, 8.51 mmol, 98%) was 
obtained as white crystals without further purification and reacted with o-nitrobenzenesulfonyl 
chloride (2.08 g, 9.37 mmol). For this it was dissolved in 15 mL anhydrous DCM, then TEA (1.40 mL, 
17.03 mmol) was added and stirred for 5h. The reaction mixture was diluted with DCM and washed 
with brine. The aqueous phases were reextracted with DCM. The organic phases were combined, 
dried over MgSO4, and the solvent was removed in vacuo. The product was purified using flash 
chromatography (gradient 0%-30% EtOAc in cyclo-hexene). 30 (1.22 g, 3.88 mmol, 46%) was 
obtained as a slightly yellow solid.  
 
TLC [EtOAc/cyclohexane, 1:1.5]: Rf = 0.40. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 17.3 min, purity (220 nm) = 98%. 
 
HRMS (EI+): calculated [C12H14N2O6S+ H]
+ 315.0651, found 315.0637 [M+ H]+. 
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(S)-Methyl 2-(N-allyl-2-nitrophenylsulfonamido)pent-4-enoate (31) 
 
 
 
31 was synthesized according to Varray et al129. 30 (1.0 g, 3.18 mmol) was dissolved in 25 mL DMF. 
Then allylbromide (0.44 mL, 5.10 mmol) and potassium carbonate (2.40 g, 17.18 mmol) were added 
and stirred at RT for 10 h. The raw product mixture was diluted with H2O and then extracted with 
DCM. The organic solvent was removed in vacuo and the organic phase was dried over MgSO4. 31 
(0.94 g, 2.64 mmol, 83%) was obtained without further purification as an orange oil.  
 
TLC [EtOAc/cyclohexane, 3:7]: Rf = 0.24. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 19.1 min, purity (220 nm) = 95%. 
 
HRMS (EI+): calculated [C15H18N2O6S+ H]
+ 355.0963, found 355.0936 [M+ H]+. 
 
(S)-Methyl 1,2,3,6-tetrahydropyridine-2-carboxylate (32) 
 
 
 
32 was synthesized according to Varray et al129. 31 (0.90 g, 2.54 mmol) was dissolved in 200 mL dry 
DCM, then Grubbs II catalyst (0.22 g, 0.25 mmol) was added. The reaction was stirred for 2.5 h, then 
50 mL 15% H2O2 was added and stirred for 15 min. The aqueous phase was extracted with DCM and 
the organic phases were combined and dried over MgSO4. The raw product was subjected to flash 
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chromatography (gradient 0%-40% EtOAc in cyclohexane) to give protected 32 (0.74 g, 2.27 mmol, 
89%) as a dark brown oil.  
Protected 32 (0.64 g, 1.96 mmol) was dissolved in 1 mL dry CH3CN, then Cs2CO3 (1.0 g, 3.10 mmol) 
and Thiophenol (0.23 mL, 2.25 mmol) was added and stirred for 1.5 h. The suspension turned from 
light yellow into a strong yellow slurry. The reaction mixture was subsequently diluted with DCM and 
extracted with H2O. The aqueous Phase was reextracted with DCM. The organic phases were 
combined and dried over MgSO4. The crude product was concentrated and purified using flash 
chromatography (gradient 0%-10% MeOH in DCM) to give 32 (0.22 g, 1.59 mmol, 81%) as a dark 
brown oil.  
 
TLC [MeOH/DCM, 5:95]: Rf = 0.25, stained with KMnO4 stain 
 
HPLC: not UV active. 
 
HRMS (EI+): calculated [C7H11NO2+ H]
+ 142.0868, found 142.0864 [M+ H]+. 
 
(S)-Methyl-1-((S)-2-(3,4,5-trimethoxyphenyl)pent-4-enoyl)-1,2,3,6-
tetrahydropyridine-2-carboxylate (34) 
 
 
 
23 (0.14 g, 0.53 mmol), HATU (0.22 g, 0.58 mmol) and DIPEA (0.36 mL, 2.13 mmol) were dissolved in 
2 mL dry DCM and stirred for 15 min. Then 32 (75 mg, 0.53 mmol) in 1 mL dry DCM was added and 
stirred for 14 h at RT. The crude product was diluted with DCM and washed with brine. The organic 
layer was dried over MgSO4, concentrated and the methyl ester was cleaved by dissolving in 1 mL 1:1 
THF/H2O and addition of LiOH (10 mg, 0.42 mmol). The mixture was stirred for 14 h then was diluted 
with brine and extracted with DCM. The aqueous layer was acidified to pH=2 and again extracted 
with DCM. The organic phases were combined and dried over MgSO4. 34 (84 mg, 0.22 mmol, 79%) 
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was obtained without further purification as a pale yellow oil. The diastereomeric rate was 
determined by HPLC. 
 
TLC [EtOAc/cyclohexane, 2:1]: Rf = 0.60. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.6 min, purity (220 nm) = 95%, dr 95:5. 
 
1H NMR (300 MHz, CDCl3) δ 6.45 (s, 2H), 5.81 (ddd, J = 13.8, 6.9, 3.9 Hz, 1H), 5.76 – 5.66 (m, 1H), 5.62 
(dd, J = 6.7, 1.6 Hz, 1H), 5.56 (dd, J = 10.2, 2.9 Hz, 1H), 5.09 – 4.97 (m, 2H), 4.12 – 4.03 (m, 1H), 3.83 
(s, 6H), 3.81 (s, 3H), 3.79 – 3.72 (m, 2H), 3.63 – 3.51 (m, 1H), 2.85 (d, J = 6.4 Hz, 1H), 2.70 (dd, J = 17.4, 
5.9 Hz, 1H), 2.43 (m, 2H). 
 
13C NMR (75 MHz, CDCl3) δ 176.22, 172.77, 153.28, 136.85, 136.32, 133.90, 123.33, 122.98, 116.51, 
105.05, 60.86, 56.11, 50.17, 49.37, 43.19, 39.33, 26.36. 
 
Mass: (ESI+), calculated 376.18 [C20H25NO6+H]
+, found 376.28 [M+H]+. 
 
2-(3-((R)-3-(3,4-Dimethoxyphenyl)-1-(((S)-1-((S)-2-(3,4,5-trimethoxyphenyl) 
pent-4-enoyl)-1,2,3,6-tetrahydropyridine-2-carbonyl)oxy)propyl)phenoxy) 
acetic acid (35) 
 
 
 
34 (20 mg, 53 µmol), DMAP (1.0 mg, 5.3 µmol) and DCC (7.0 mg, 59 µmol) were dissolved in 1 mL 
DCM at 0°C and stirred for 15 min. Then 37b (23 mg, 59 µmol) in 500 µL DCM was added, and the 
mixture was allowed to warm to RT and stirred for 14 h. The crude product was concentrated and 
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purified using flash chromatography (gradient 0%-8% MeOH in DCM). 35 (17 mg, 22.4 µmol, 42 %) 
was obtained as a colorless oil. The diastereomeric rate was determined by HPLC. 
 
TLC [MeOH/DCM, 6:94]: Rf = 0.42. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 16.6 min, purity (220 nm) = 98%, dr 95:5. 
 
1H NMR (400 MHz, d6-DMSO) δ 7.23 (ddd, J = 10.0, 7.7, 3.1 Hz, 1H), 7.14 – 7.08 (m, 1H), 6.88 – 6.77 
(m, 2H), 6.72 – 6.56 (m, 3H), 6.55 (s, 1H), 6.44 (d, J = 7.7 Hz, 1H),  5.71 – 5.63 (m, 1H), 5.57 (d, J = 2.8 
Hz, 1H), 5.49 – 5.45 (m, 1H), 5.38 (dd, J = 8.5, 5.1 Hz, 1H), 5.29 (dt, J = 5.7, 2.6 Hz, 1H), 4.98 (dd, J = 
17.2, 2.1 Hz, 1H), 4.91 (dd, J = 10.2, 2.2 Hz, 1H), 4.08 – 4.03 (m, 3H), 3.72 – 3.69 (m, 3H), 3.67 -3.63 
(m, 6H), 3.60 (s, 3H), 3.57 (s, 3H), 3.55 (s, 2H), 3.54 (s, 2H), 3.50 – 3.47 (m, 2H), 2.69 (dd, J = 12.8, 6.1 
Hz, 2H), 2.67 – 2.61 (m, 3H), 2.43 (t, J = 5.0 Hz, 3H), 2.30 (dd, J = 8.8, 7.0 Hz, 2H), 2.24 (t, J = 7.4 Hz, 
2H), 1.95 (d, J = 6.5 Hz, 2H). 
 
13C NMR (101 MHz, d6-DMSO) δ 173.73, 172.42, 158.74, 153.18, 149.05, 147.40, 142.24, 136.62, 
134.74, 133.73, 133.41, 130.14, 124.03, 122.95, 120.36, 118.25, 116.77, 114.02, 112.69, 112.22, 
105.67, 75.54, 66.62, 65.79, 60.30, 57.54, 56.39, 56.30, 56.02, 55.92, 55.75, 54.07, 51.56, 49.97, 
49.38, 48.03, 42.98, 33.65, 31.71, 27.03, 26.55, 24.84. 
 
Mass: (ESI+), calculated 759.39 [C43H54N2O10+H]
+, found 759.42 [M+H]+. 
 
(S)-1-((9H-Fluoren-9-yl)methyl)ester-2-(1,7-di(pyridin-3-yl)heptan-4-yl) 
piperidine-2-dicar-boxylate  
 
 
 
A solution of alcohol 5c (0.30 g, 1.1 mmol) and carboxylic acid 6a (0.39 g, 1.1 mmol) in 10 mL DCM 
was treated with EDC (0.23 g, 1.2 mmol). The reaction mixture was stirred for 14 h at RT. The solvent 
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was removed in vacuo and the crude mixture was purified by flash chromatography (gradient 0%-
100% EtOAc in cyclohexane) to afford Fmoc protected 37c as a yellow oil (0.49 g, 0.8 mmol, 73%). 
 
TLC [EtOAc 99% + 1% TEA]: Rf = 0.2. 
 
LCMS: [0-100% Solvent B, 10 min]: Rt = 7.1 min, purity (220 nm) = 96%. 
 
1H NMR (300 MHz, CDCl3) δ 8.47 – 8.34 (m, 4H), 7.77 (d, J = 7.1 Hz, 2H), 7.63 – 7.56 (m, 2H), 7.53 – 
7.45 (m, 2H), 7.45 – 7.27 (m, 4H), 7.24 – 7.06 (m, 2H), 4.93 (dd, J = 29.0, 23.9 Hz, 2H), 4.50 – 4.23 (m, 
3H), 4.23 – 4.01 (m, 1H), 2.67 – 2.47 (m, 4H), 2.23 (d, J = 13.3 Hz, 1H), 1.82 – 1.38 (m, 10H), 1.35 – 
1.16 (m, 4H). 
 
13C NMR (75 MHz, CDCl3) δ 171.54, 156.48, 149.32, 147.14, 143.57, 141.28, 137.13, 135.83, 127.71, 
127.04, 125.09, 123.28, 120.07, 74.16, 67.71, 60.38, 54.22, 47.09, 41.86, 33.45, 32.37, 29.69, 26.28, 
24.46, 21.27, 20.55, 14.25. 
 
Mass: (ESI+), calculated 604.32 [C38H41N3O4 + H]
+, found 604.30 [M + H]+. 
 
(S)-1,7-Di(pyridin-3-yl)heptan-4-yl piperidine-2-carboxylate (37c) 
 
 
 
Fmoc-protected 37c (0.44 g, 0.73 mmol) was dissolved in 1.8 mL dry DCM, then 0.2 mL 
4-Methylpiperidin was added and stirred for 14 h at RT. The crude mixture was concentrated and 
purified by flash chromatography (gradient 0%-15% MeOH in DCM). 37c (0.22 g, 0.58 mmol, 80%) 
was obtained as a slight yellow oil.  
 
TLC [MeOH/DCM 10:90]: Rf = 0.42. 
 
HPLC [0-50% Solvent B, 20 min]: Rt = 9.0 min, purity (220 nm) = 90%. 
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1H NMR (300 MHz, CDCl3) δ 8.46 – 8.38 (m, 4H), 7.42-7.38 (m, 2H), 7.18-7.14 (m, J = 7.5 Hz, 2H), 4.83 
(tt, J = 6.3, 4.9 Hz, 1H), 3.16 – 3.03 (m, 2H), 2.73 (dt, J = 12.2, 5.2 Hz, 1H), 2.62 – 2.56 (m, 4H), 2.12 
(ddt, J = 12.0, 7.5, 5.9 Hz, 1H), 2.00 (s, 1H), 1.78 – 1.69 (m, 1H), 1.69 – 1.63 (m, 4H), 1.62 – 1.56 (m, 
3H), 1.55 – 1.51 (m, 1H), 1.51 – 1.46 (m, 4H). 
 
13C NMR (75 MHz, CDCl3) δ 169.23, 149.61, 147.27, 137.42, 137.13, 136.99, 136.08, 135.90, 123.48, 
75.55, 56.98, 45.31, 43.48, 36.56, 32.26, 27.26, 26.20, 22.20. 
 
Mass: (ESI+), calculated 382.25 [C23H31N3O2 + H]
+, found 382.20 [M + H]+. 
 
(S)-1-((9H-Fluoren-9-yl)methyl)ester-2-((R)-1-(3-(2-(tert-butoxy)-2-oxoethoxy) 
phenyl)-3-(3,4-dimethoxyphenyl)propyl) piperidine-2-carboxylate 
 
 
 
6a (0.25 g, 0.71 mmol), DIPEA (0.37 g, 2.85 mmol) and HATU (410 mg, 1.07 mmol) were dissolved in 
1.5 mL DMF and stirred for 30 min. Then (R)-tert-butyl-2-(3-(1-amino-3-(3,4-dimethoxyphenyl) 
propyl)phenoxy)acetate 5e (0.29 g, 0.71 mmol) dissolved in 2 mL DCM was added to the reaction 
mixture and stirred at RT for 14 h. The solvent was removed in vacuo and the crude product was 
purified by flash chromatography (EtOAc/cyclohexane 3:7) to afford Fmoc protected 37e (0.48 g, 
0,65 mmol, 92%) as a slightly yellow solid.  
 
TLC [EtOAc/cyclohexane 3:7]: Rf = 0.25. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 20.5 min, purity (220 nm) = 98% 
 
1H NMR (400 MHz, DMSO) δ 7.83-7.80 (m, 2H), 7.63-7.58 (m, 2H), 7.46 – 7.39 (m, 4H), 7.32 – 7.20 (m, 
2H), 7.04-7.02 (m, 2H), 6.88-6.84 (m, 3H), 6.80 – 6.74 (m, 2H), 5.20-5.17 (m, 1H), 5.00 – 4.93 (m, 4H), 
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4.83 (t, J = 6.2 Hz, 1H), 4.17-4.11 (m, 1H), 3.83 (s, 3H), 3.75 (s, 3H), 3.53-3.47 (m, 1H), 2.82 (t, J = 4.3 
Hz, 1H), 2.69 (t, J = 7.9 Hz, 2H), 2.34-2.20 (m, 2H), 2.08-1.91 (m, 2H), 1.79-1.66 (m, 3H), 1.34 (s, 9H). 
 
13C NMR (101 MHz, DMSO) δ 170.45, 168.32, 162.49, 158.23, 155.70, 148.71, 147.54, 145.61, 144.45, 
141.16, 134.01, 129.35, 128.18, 127.22, 125.45, 120.40, 119.48, 113.43, 112.65, 112.08, 81.47, 64.94, 
59.93, 55.91, 54.51, 51.97, 46.97, 41.90, 38.41, 36.27, 32.22, 31.25, 28.31, 26.80, 24.78, 21.20. 
 
Mass: (ESI+), calculated 531.25 [C44H50N2O8+H]
+, found 531.21 [M+H]+. 
 
 
tert-Butyl-2-(3-((R)-3-(3,4-dimethoxyphenyl)-1-((S)-piperidine-2-
carboxamido)propyl) phenoxy) acetate (37e) 
 
 
 
Fmoc protected 37e (0.43 mg, 0.59 mmol) was dissolved in 4.5 mL dry DCM, then was added 0.5 mL 
4-methylpiperidine and stirred for 14 h. The raw product was concentrated and subjected to flash 
chromatography (gradient 0-100% EtOAc in cyclohexane, then EtOAc/MeOH 99:1, 1% TEA). 37e (160 
mg, 0.312, 53%) was obtained as a white solid.  
 
TLC [EtOAc/MeOH 99:1, 1% TEA]: Rf = 0.20. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 14.8 min, purity (220 nm) = 95% 
 
1H NMR (300 MHz, CDCl3) δ 7.26 – 7.20 (m, 1H), 7.18 (d, J = 9.4 Hz, 1H), 6.94 – 6.88 (m, 1H), 6.86 (dd, 
J = 2.6, 1.5 Hz, 1H), 6.78 – 6.72 (m, 2H), 6.69 – 6.64 (m, 2H), 4.96 (q, J = 7.7 Hz, 1H), 4.49 (s, 2H), 3.85 
(s, 3H), 3.83 (s, 3H), 3.23 – 3.15 (m, 1H), 3.02 – 2.91 (m, 1H), 2.68 – 2.58 (m, 1H), 2.59 – 2.50 (m, 2H), 
2.21 – 2.00 (m, 4H), 1.98 – 1.87 (m, 1H), 1.80 – 1.70 (m, 1H), 1.59 – 1.49 (m, 1H), 1.47 (s, 9H). 
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13C NMR (75 MHz, CDCl3) δ 172.71, 167.65, 158.24, 148.73, 146.82, 144.02, 133.90, 129.60, 120.08, 
119.82, 113.37, 112.87, 111.74, 111.20, 82.20, 65.69, 60.12, 55.90, 52.51, 45.68, 37.93, 32.24, 29.75, 
28.02, 25.69, 23.88. 
 
Mass: (ESI+), calculated 530.30 [C29H40N2O6+H]
+, found 530.28 [M+H]+. 
 
N-((1S,2S)-1-Hydroxy-1-phenylpropan-2-yl)-N-methyl-2-(3,4,5-trimethoxy 
phenyl)acetamide (40) 
 
 
 
Trimethoxyphenyl acetic acid 11 (5.0 g, 22.1 mmol), triethylamine (3.5 mL, 46.0 mmol), EDC-HCl 
(3.9 g, 20.26 mmol) and HOAt (2.76 g, 20.26 mmol) were dissolved in DCM at 0°C. Then 
(S,S)-pseudoephedrine (3.0 g, 18.4 mmol) was added and the reaction was stirred at RT for 14 h. The 
crude product was concentrated and purified using flash chromatography (gradient 0%-100% EtOAc 
in cyclohexane). 40 (6.37 g, 17.06 mmol, 92%) was obtained as a white solid.  
 
TLC [EtOAc, 1% TEA]: Rf = 0.33. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 14.4 min, purity (220 nm) ≥ 99%. 
 
1H NMR (300 MHz, CDCl3) δ 7.38 – 7.20 (m, 5H), 6.47 (s, 2H), 4.66 – 4.40 (m, 1H), 4.25 – 3.94 (m, 1H), 
3.84 (s, 6H), 3.82 (s, 3H), 3.65 (s, 2H), 2.85 (s, 3H), 1.11 – 1.02 (m, 3H). 
 
13C NMR (75 MHz, CDCl3) δ 173.11, 153.10, 142.00, 136.81, 130.26, 128.65, 128.40, 127.78, 126.77, 
126.49, 105.74, 75.43, 60.81, 58.73, 56.13, 42.02, 32.76, 14.40. 
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Mass: (ESI+), calculated 374.20 [C21H27NO5+H]
+, found 374.20 [M+H]+. 
 
(S)-3-Cyclopropyl-N-((1S,2S)-1-hydroxy-1-phenylpropan-2-yl)-N-methyl-2-
(3,4,5-trimethoxyphenyl)propanamide (41a) 
 
 
 
40 (1.0 g, 2.7 mmol) and Lithiumchloride (0.68 mg, 16.07 mmol) were put each into a Schlenck flask 
and kept under high vacuum for 14 h. Additionally LiCl was heated to 150°C using an oil bath. Then 
40 was dissolved in 18 mL anhydrous THF and added to the dry LiCl. The mixture was cooled to -78°C. 
LDA (2.95 mL, 5.89 mmol, 2.0 M in THF/heptane/ethylbenzene) was addded dropwise and then 
stirred for 1h. The reaction mixture was warmed to 0°C, and stirred for 15 min, finally warmed briefly 
to RT, then cooled again to 0°C and treated with cyclopropylmethylbromide (1.3 mL, 13.4 mmol). The 
reaction mixture was stirred for 2h at 0°C then slowly warmed to RT and stirred for another 14 h. The 
raw product was diluted with brine, acidified with 1 M HCl to pH~2 and extracted with DCM. The 
organic phases were combined and dried over MgSO4. The crude product was concentrated and 
purified by flash chromatography (gradient 0%-50% EtOAc in cyclohexane). 41a (0.65 g, 1.51 mmol, 
56%) was obtained as yellow crystals.  
 
TLC [MeOH/DCM, 5:95]: Rf = 0.40. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 14.4 min, purity (220 nm) = 98%, dr 95:5. 
   
1H NMR (300 MHz, CDCl3) δ 7.41 (s, 1H), 7.38 – 7.31 (m, 2H), 7.28 (d, J = 1.0 Hz, 2H), 6.52 (s, 2H), 4.58 
(d, J = 6.3 Hz, 1H), 4.14 (d, J = 7.1 Hz, 1H), 3.87 – 3.80 (m, 9H), 3.65 (t, J = 7.2 Hz, 1H), 2.79 (s, 3H), 
2.12 – 1.93 (m, 1H), 1.58 – 1.46 (m, 1H), 1.14 (d, J = 6.8 Hz, 3H), 0.67 (s, 1H), 0.43 (dd, J = 8.5, 4.6 Hz, 
2H), 0.23 – -0.00 (m, 2H). 
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13C NMR (75 MHz, CDCl3) δ 175.54, 153.41, 142.33, 136.85, 135.47, 128.31, 127.60, 126.37, 104.71, 
75.45, 60.83, 56.18, 50.68, 40.34, 27.33, 14.17, 9.42, 4.66, 4.63. 
 
Mass: (ESI+), calculated 428.24 [C25H33NO5+H]
+, found 428.52 [M+H]+. 
 
(S)-3-cyclopropyl-2-(3,4,5-trimethoxyphenyl)propanoic acid (39a) 
 
 
 
41a (0.28 mg, 0,66 mmol) was dissolved in 4 mL dioxane at RT. 4 mL of a 4 M solution of H2SO4 in 
water were added dropwise. The mixture was refluxed for 4h (150°C). The reaction was quenched by 
addition of 50% (w/v) NaOH followed by extraction with DCM. The aqueous phase was acidified with 
1 M HCl to pH<2 and extracted again. The organic layers of the acidic extraction were combined and 
dried over MgSO4. The raw product was concentrated and purified using preparative TLC 
(MeOH/DCM, 9:91, 1% AcOH). 39a (68 mg, 0.24 mmol, 37%) was obtained as a yellow oil. 
 
TLC [EtOAc/cyclohexane, 1:1, 1% AcOH]: Rf = 0.35. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.1 min, purity (220 nm) = 95%. 
 
1H NMR (300 MHz, CDCl3) δ 6.57 (s, 2H), 3.87 (s, 6H), 3.84 (s, 3H), 3.62 (dd, J = 8.2, 7.0 Hz, 1H), 1.91 
(dt, J = 13.9, 7.8 Hz, 1H), 1.75 (dt, J = 13.7, 6.8 Hz, 1H), 0.75 – 0.61 (m, 1H), 0.49 – 0.41 (m, 2H), 0.16 – 
0.04 (m, 2H). 
 
13C NMR (75 MHz, CDCl3) δ 179.79, 153.24, 137.35, 134.17, 105.09, 60.44, 56.14, 52.16, 38.39, 9.20, 
4.46. 
 
Mass: (ESI+), calculated 281.14 [C15H20O5+H]
+, found 281.37 [M+H]+. 
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(S)-3-phenyl-2-(3,4,5-trimethoxyphenyl)propanoic acid (39b) 
 
 
 
40 (0.5 g, 1.34 mmol) and dry Lithiumchloride (0.34 g, 8.03 mmol, dried as described for 41a) were 
dissolved in 5 mL anhydrous THF and cooled to -78°C. LDA (1.4 mL, 2.95 mmol) was added and stirred 
for 1 h. The reaction mixture was warmed to 0°C, and stirred for 15 min, finally warmed briefly to RT, 
then cooled again to 0°C and treated with Benzylbromide (0.8 mL, 6.69 mmol). The reaction mixture 
was stirred at 0°C for 14 h. The crude product was concentrated and purified by flash 
chromatography (gradient, 0%-40% EtOAc in cyclohexane). 41b (0.33 mg, 0.77 mmol, 58%) was 
obtained as a yellow oil which was directly further reacted. 
 
TLC [EtOAc/cyclohexane, 2:1]: Rf = 0.33. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 23.5 min, purity (220 nm) = 95%, dr = 95:5. 
 
Mass (ESI+), calculated 464.24 [C28H33NO5+H]
+, found 464.27 [M+H]+. 
 
41b (0.28 mg, 0.60 mmol) was dissolved in 4 mL dioxane and then 3.5 mL of a 4 M aq solution of 
H2SO4 was added. The mixture was refluxed for 4h. (150°C). The reaction was quenched by addition 
of 50% (w/v) NaOH then was extracted with DCM. Now was acidified with 1 M HCl to pH<2 and again 
extracted. These organic layers were combined and dried over MgSO4. The raw product was purified 
using preparative TLC (EtOAc/cyclohexane, 3:7, 4% AcOH). 39b (113 mg, 0.36 mmol, 60%) was 
obtained as a yellow oil. 
 
TLC [EtOAc/cyclohexane, 3:7, 4% AcOH]: Rf = 0.42. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 19.9 min, purity (220 nm) ≥ 99%. 
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1H NMR (300 MHz, CDCl3) δ 7.29 – 7.20 (m, 3H), 7.14 (dd, J = 7.9, 1.7 Hz, 2H), 6.53 (s, 2H), 3.85 (s, 
6H), 3.84 (s, 3H), 3.40 (dd, J = 13.8, 8.5 Hz, 2H), 3.04 (dd, J = 13.7, 6.8 Hz, 1H). 
 
13C NMR (75 MHz, cdcl3) δ 178.92, 153.27, 138.58, 137.50, 133.49, 130.37, 128.90, 128.41, 126.54, 
105.19, 60.84, 56.16, 53.59, 39.38, 20.76, 1.03. 
 
Mass: (ESI+), calculated 317.14 [C18H20O5+H]
+, found 317.13 [M+H]+. 
 
(S)-(R)-3-(3,4-dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propyl-1-
((S)-3-cyclopropyl-2-(3,4,5-trimethoxyphenyl)propanoyl)pyrrolidine-2-
carboxylate (42) 
 
 
 
General synthesis procedure A for morpholine ligands with 36b (40 mg, 80 µmol) and 39a (22 mg, 
80 µmol) was used. Then was purified using preparative HPLC (gradient 55%-70% Solvent B in Solvent 
A, 20min) to obtain 42 (17 mg, 7.7 µmol, 28%) as a colorless oil. The diastereomeric rate was 
determined by HPLC. 
 
TLC [MeOH/DCM, 8:92]: Rf = 0.44. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 16.3 min, purity (220 nm) = 95%, dr 95:5 
 
1H NMR (400 MHz, d6-DMSO) δ 7.52 (d, J = 7.7 Hz, 1H), 7.33 – 7.20 (m, 1H), 6.97 – 6.85 (m, 2H), 6.84 
– 6.78 (m, 2H), 6.64 – 6.56 (m, 2H), 6.50 (s, 1H), 5.54 (ddd, J = 37.2, 8.3, 4.8 Hz, 2H), 4.46 (dd, J = 8.6, 
3.4 Hz, 1H), 4.41 – 4.29 (m, 3H), 3.84 – 3.74 (m, 3H), 3.73 – 3.69 (m, 5H), 3.69 – 3.67 (m, 5H), 3.61 – 
3.58 (m, 3H), 3.56 – 3.49 (m, 6H), 2.59 (s, 4H), 2.47 (p, J = 1.8 Hz, 1 H), 2.38 – 2.28 (m, 1H), 2.23 – 2.05 
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(m, 2H), 1.93 – 1.76 (m, 2H), 1.75 – 1.65 (m, 1H), 1.37 – 1.26 (m, 1H), 1.22 (dt, J = 12.1, 6.8 Hz, 2H), 
0.60 (s, 1H), 0.36 – 0.22 (m, 2H), 0.02 (qd, J = 10.2, 4.6 Hz, 2H). 
 
13C NMR (101 MHz, d6-DMSO) δ 171.83, 171.50, 158.19, 153.15, 152.99, 149.04, 147.39, 142.69, 
136.39, 135.86, 133.76, 133.68, 123.98, 120.49, 114.37, 112.75, 112.42, 105.67, 75.17, 63.75, 62.51, 
60.23, 56.30, 55.99, 55.78, 52.16, 49.87, 46.13, 30.78, 29.12, 24.88, 21.14, 14.40, 9.61, 8.81, 4.85. 
 
Mass: (ESI+), calculated 761.40 [C43H56N2O10+H]
+, found 761.41 [M+H]+. 
 
 
2-(3-((R)-1-(((S)-1-((S)-3-cyclopropyl-2-(3,4,5-trimethoxyphenyl)propanoyl) 
piperidine-2-carbonyl)oxy)-3-(3,4-dimethoxyphenyl)propyl)phenoxy)acetic 
acid (43) 
 
 
 
General synthesis procedure B for free acid ligands with 37a (100 mg, 0.20 mmol) and 39a (55 mg, 
0.20 mmol) 57.0 mg, 0.21 mmol) was used. The crude product was concentrated and purified using 
flash chromatography (gradient 0%-10% MeOH in DCM) to obtain 43 (38 mg, 54 µmol, 55%) as a 
colorless oil. The diastereomeric rate was determined by HPLC. 
 
TLC [MeOH/DCM, 6:94]: Rf = 0.27. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 19.3 min, purity (220 nm) = 95%, dr = 95:5. 
 
1H NMR (400 MHz, d6-DMSO) δ 7.22 (s, 1H), 7.12 (dd, J = 15.6, 7.9 Hz, 1H), 6.85 – 6.69 (m, 3H), 6.63 – 
6.55 (m, 2H), 6.51 (s, 1H), 5.50 (dd, J = 8.2, 5.2 Hz, 1H), 5.25 (s, 1H), 4.64 (s, 2H), 3.71 (d, J = 2.0 Hz, 
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2H), 3.68 (s, 3H), 3.67 (s, 3H), 3.60 (d, J = 2.5 Hz, 1H), 3.56 (s, 6H), 3.53 (s, 3H), 2.68 – 2.60 (m, 1H), 
2.52 (t, J = 5.3 Hz, 2H), 2.45 – 2,40 (s, 2H), 2,38 – 2,33 (m, 2H), 2.14 (d, J = 12.0 Hz, 1H), 1.94 – 1.84 
(m, 2H), 1.64 – 1,57 (m, 4H), 0,63 – 0,56 (m, 1H), 0.36 – 0.28 (m, 2H), 0.07 – -0.03 (m, 2H). 
 
13C NMR (101 MHz, d6-DMSO) δ 172.66, 170.73, 170.52, 158.01, 153.09, 149.14, 147.59, 142.39, 
136.43, 135.93, 133.44, 129.79, 120.34, 113.88, 112.82, 112.64, 112.34, 109.94, 105.52, 75.34, 64.87, 
60.20, 57.45, 56.30, 55.95, 55.88, 52.05, 47.92, 43.37, 30.92, 26.67, 21.10, 14.38, 9.71, 4.73. 
 
Mass: (ESI+), calculated 720.34 [C40H49NO11+H]
+, found 720.32 [M+H]+. 
 
(S)-(R)-3-(3,4-dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propyl-1-
((S)-3-cyclopropyl-2-(3,4,5-trimethoxyphenyl)propanoyl)piperidine-2-
carboxylate (44) 
 
 
 
General synthesis procedure A for morpholine ligands with 39a (8 mg, 29 µmol) and 37b (14 mg, 
27 µmol) was used. Then was purified using flash chromatography (gradient 0%-10% MeOH in DCM) 
to obtain 44 (6 mg, 7.74 µmol, 29%) as a colorless oil. The diastereomeric rate was determined by 
HPLC. 
 
TLC [MeOH/DCM, 8:92]: Rf = 0.52. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 15.1 min, purity (220 nm) = 95%, dr 95:5 
 
1H NMR (600 MHz, CDCl3) δ 7.26-7.24 (m, 1H), 7.02 – 6.97 (m, 1H), 6.90 – 6.71 (m, 5H), 6.60 (s, 2H), 
5.45-5.43 (m, 1H), 4.88-4.86 (m, 1H), 4.08-4.05 (m, 2H), 3.84 – 3.74 (m, 6H), 3.72 – 3.70 (m, 8H), 3.70 
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– 3.59 (m, 2H), 3.55-3.53 (m, J = 4.7 Hz, 4H), 3.49 – 3.45 (m, 1H), 2.76 – 2.64 (m, 4H), 2.53 – 2.41 (m, 
5H), 2.16 – 2.06 (m, 3H), 1.99-1.97 (m, J = 7.2 Hz, 1H), 1.92 – 1.82 (m, 3H), 1.74 – 1.60 (m, 3H), 0.88 – 
0.75 (m, 1H), 0.31 – 0.20 (m, 2H), 0.05 – -0.06 (m, 2H). 
 
13C NMR (125 MHz, CDCl3) δ 175.62, 170.15, 159.63, 156.01, 150.39, 148.33, 143.58, 137.88, 135.20, 
132.08, 129.28, 121.85, 119.20, 115.53, 114.12, 113.68, 113.06, 107.04, 77.03, 67.38, 66.80, 60.70, 
58.74, 56.83, 54.73, 52.94, 48.18, 43.29, 36.38, 34.08, 33.96, 25.91, 25.47, 22.24, 9.61, 7.11. 
 
Mass: (ESI+), calculated 775.42 [C44H58N2O10+H]
+, found 775.48 [M+H]+. 
 
2-(3-((R)-3-(3,4-dimethoxyphenyl)-1-(((S)-1-((S)-3-phenyl-2-(3,4,5-trimethoxy 
phenyl) propanoyl)piperidine-2-carbonyl)oxy)propyl)phenoxy)acetic acid (45) 
 
 
 
General synthesis procedure B for free acid ligands with 41b (68 mg, 0.21 mmol) and 37a (100 mg, 
0.20 mmol) was used. Then was purified using reversed phase flash (Gradient 40%-70% MeOH in H2O 
+ 1%AcOH) to obtain 45 (49 mg, 0.13 mmol, 49%) as a slight yellow oil. The diastereomeric rate was 
determined by HPLC. 
 
TLC [MeOH/DCM, 8:92]: Rf = 0.20. 
 
HPLC [isochratic 60% B, 20 min]: Rt = 10.4 min, purity (220 nm) = 98%, dr 95:5. 
 
1H NMR (599 MHz, d6-DMSO) δ 7.27 – 7.03 (m, 6H), 6.86 – 6.65 (m, 5H), 6.59 (s, 2H), 5.50 (dd, J = 8.2, 
5.1 Hz, 1H), 5.19 (dd, J = 6.0, 2.5 Hz, 1H), 4.61 (s, 2H), 4.35 (dd, J = 8.9, 6.0 Hz, 1H), 3.99 (d, J = 13.2 
Hz, 1H), 3.70 (s, 3H), 3.69 (s, 3H), 3.66 (s, 1H), 3.62 (s, 6H), 3.53 (d, J = 0.7 Hz, 3H), 3.31 – 3.26 (m, 2H), 
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2.85 (dd, J = 13.5, 5.9 Hz, 1H), 2.70 (td, J = 13.4, 2.9 Hz, 1H), 2.43 (ddd, J = 14.0, 9.0, 5.7 Hz, 1H), 2.33 
(dt, J = 14.0, 8.1 Hz, 1H), 2.08 (d, J = 13.4 Hz, 1H), 1.88 (qd, J = 8.5, 8.0, 5.4 Hz, 2H), 1.54 – 1.44 (m, 
2H), 1.44 – 1.35 (m, 1H), 1.12 – 1.03 (m, 1H), 1.01 – 0.93 (m, 1H). 
 
13C NMR (151 MHz, d6-DMSO) δ 172.30, 170.60, 158.34, 153.05, 149.12, 147.61, 142.67, 140.25, 
136.47, 135.16, 133.44, 130.00, 129.79, 129.59, 129.38, 129.37, 128.49, 128.26, 126.26, 120.50, 
118.49, 113.89, 112.61, 112.53, 112.42, 105.76, 75.42, 65.12, 60.25, 56.09, 55.98, 55.86, 55.72, 
52.13, 49.02, 43.34, 41.21, 38.10, 31.04, 26.52, 20.78. 
 
Mass: (ESI-), calculated 756.34 [C43H49NO11+H]
-, found 756.33 [M+H]+. 
 
(S)-3-((S)-2-((S)-cyclohex-2-en-1-yl)-2-(3,4,5-trimethoxyphenyl)acetyl)-4-
isopropyl-oxazolidin-2-one (46a) 
 
 
 
21 (3.0 g, 8.89 mmol) was dissolved in 1 mL anhydrous THF and cooled to -78 °C. Then NaHMDS 
(14.23 mL, 14.23 mmol, 1 M in THF) was added dropwise and stirred for 1h. The reaction mixture was 
briefly warmed to 0°C and cooled again to -78°C. Cyclohexene bromide (1.0 mL, 8.9 mmol) was 
added dropwise and stirred for 1h at -78°C finally it was slowly warmed to 0°C and stirred for another 
14 h. The reaction mixture was quenched with sat. NH4Cl solution and extracted with DCM. The 
organic phase was dried over MgSO4 and the solvent was removed in vacuo. The raw product was 
purified using column chromatography (EtOAc/cyclohexane 1:3) to obtain a mixture of 46a/b (2.03 g, 
4.9 mmol, 55%) as yellow orange solid. A dr at Cß of 85:15 was determined via 
13C NMR (Annex 
Fig. D). The distribution shown above is based on the co-crystal structure with 51.  
 
TLC [EtOAc/n-hexane 1:2]: Rf = 0.5. 
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HPLC 46a/b [55-65% Solvent B, 20 min]: Rt = 20.3 min, purity (220 nm) ≥ 99%. 
HPLC 46a/b [55-65% Solvent B, 20 min]: Rt = 16.6 min, purity (220 nm) ≥ 99%. 
 
1H NMR (300 MHz, d6-DMSO) major diastereomer δ 6.54 – 6.53 (s, 2H), 5.74 – 5.66 (m, 1H), 5.61 – 
5.54 (dd, J = 10.3, 2.3 Hz, 1H), 4.73 – 4.67 (d, J = 11.2 Hz, 1H), 4.49 – 4.42 (m, 1H), 4.34 – 4.27 (m, 1H), 
4.20 – 4.15 (dd, J = 9.0, 3.1 Hz, 1H), 3.70 – 3.69 (s, 6H), 3.62 – 3.60 (s, J = 1.9 Hz, 3H), 1.68 – 1.55 (m, 
3H), 1.47 – 1.35 (m, 2H), 1.34 – 1.20 (dd, J = 14.4, 7.5 Hz, 2H), 1.11 – 0.98 (m, 1H), 0.73 – 0.69 (d, J = 
7.0 Hz, 3H), 0.35 – 0.32 (d, J = 6.8, 3H). 
 
13C NMR (75 MHz, d6-DMSO) major diastereomer δ 172.85, 172.83, 153.81, 153.09, 137.22, 133.09, 
129.97, 128.88, 106.30, 63.53, 60.45, 57.97, 56.30, 54.06, 37.30, 28.12, 26.52, 25.25, 20.99, 17.56, 
14.44. 
 
Mass: (ESI+), calculated 418.22 [C23H31NO6+H]
+, found 418.25 [M+H]+. 
 
(S)-2-((R)-Cyclohex-2-en-1-yl)-2-(3,4,5-trimethoxyphenyl)acetic acid (47) 
 
 
 
46 (0.65 mg, 1.56 mmol) was dissolved in 13 mL THF/H2O 8:5 at RT. Then lithium hydroxide (75 mg, 
3.12 mmol) and hydrogen peroxide (0.68 mL, 28.1 mmol) were added and stirred until complete 
dissolved. The reaction mixture was cooled to 0°C and stirred for 4h and another 2h at RT. Finally the 
reaction was quenched with 5 mL 1.5 M Na2SO3 solution and was subsequently diluted with brine and 
extracted with DCM. The aqueous phase was acidified to pH<2 and extracted again with DCM. All 
organic phases were checked with TLC and LCMS, product containing phases were combined, dried 
over MgSO4 and concentrated. 47 (470 mg, 1.53 mmol, 96%) was obtained without further 
purification as a yellow oil with a dr 85:15 (determined via 13C NMR).  
 
TLC [EtOAc/n-hexane 1:1.5, 1% AcOH]: Rf = 0.40. 
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HPLC [55-65% Solvent B, 20 min]: Rt = 19.0 min, purity (220 nm) = 98%. 
 
1H NMR (300 MHz, d6-DMSO) major diastereomer δ 6.61 (s, 2H), 5.72 (dd, J = 10.0, 2.3 Hz, 1H), 5.61 
(d, J = 10.3 Hz, 1H), 3.72 (s, 6H), 3.62 (s, 3H), 3.50 (dtd, J = 8.6, 6.1, 1.1 Hz, 1H), 3.13 (dd, J = 11.1, 4.6 
Hz, 1H), 1.91 (s, 2H), 1.41 – 1.20 (m, 3H), 1.10 – 0.91 (m, 1H). 
 
13C NMR (75 MHz, d6-DMSO) major diastereomer δ 174.80, 159.27, 153.00, 136.89, 134.47, 129.95, 
128.78, 105.95, 60.30, 57.67, 56.28, 38.26, 26.37, 25.16, 20.75,  
 
Mass: (ESI+), calculated 307.15 [C17H22O5 +H]
+, found 307.18 [M+H]+. 
 
(S)-3-((S)-2-Cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)-4-isopropyl 
oxazolidin-2-one (48) 
 
 
 
46 (0.20 mg, 0.48 mmol) was dissolved in 10 mL of MeOH and placed in an autoclave (Roth, Lab 
autoclave model II). Palladium on activated charcoal (10% Pd basis, 20 mg, 18.8 µmol) was added and 
the autoclave was flushed with argon and hydrogen gas. Finally it was filled with 30 bar hydrogen gas 
and the reaction mixture stirred for 2 d. The reaction progress was monitored by LCMS. If educt was 
still present another amount of Palladium on activated charcoal (10% Pd basis, 10 mg, 9.40 µmol) 
was added and above described procedure repeated. The palladium containing crude product was 
filtered through celite and concentrated. 48 (188 mg, 0.45 mmol, 94%, dr 99:1) was obtained as 
slight yellow oil and used without further purification. No residual 46 could be observed in the NMR 
spectra. The diastereomeric rate was determined by HPLC. 
 
TLC [EtOAc/n-hexane 1:2]: Rf = 0.5. 
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HPLC [60-70% Solvent B, 20 min]: Rt = 17.9 min, purity (220 nm) = 98%, dr ≥ 99:1. 
 
1H NMR (300 MHz, d6-DMSO) δ 6.56 (s, 2H), 4.79 (d, J = 10.6 Hz, 1H), 4.38 (dt, J = 7.3, 3.5 Hz, 1H), 
4.27 – 4.21 (m, 2H), 3.71 (s, 6H), 3.61 (s, 3H), 2.25 (td, J = 7.0, 3.4 Hz, 1H), 2.04 (d, J = 10.9 Hz, 1H), 
1.65 (d, J = 11.0 Hz, 2H), 1.56 (d, J = 8.0 Hz, 2H), 1.25 – 0.99 (m, 6H), 0.84 (d, J = 1.6 Hz, 3H), 0.80 (d, J 
= 6.9 Hz, 3H). 
 
13C NMR (75 MHz, d6-DMSO) δ 173.58, 154.13, 153.06, 137.13, 133.36, 108.74, 106.47, 63.15, 60.37, 
58.76, 56.19, 53.74, 31.49, 30.26, 28.33, 26.28, 25.80, 25.66, 17.88, 14.63. 
 
Mass: (ESI+), calculated 420.24 [C23H33NO6 +H]
+, found 420.25 [M+H]+. 
 
(S)-2-Cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetic acid (49) 
 
 
 
48 (0.50 g, 1.19 mmol) was dissolved in 6 mL THF/H2O 8:5 and cooled to 0°C, then lithium hydroxide 
(57.1 mg, 2.38 mmol) and hydrogen peroxide (0.52 mL, 21.45 mmol) were added and stirred for 24 h. 
Subsequently the reaction mixture was quenched by adding 5 mL of a 1.5 M Na2SO3 solution. Finally 
the reaction was quenched with 5 mL 1.5 M Na2SO3 solution and was subsequently diluted with brine 
and extracted with DCM. The aqueous phase was acidified to pH<2 and extracted again with DCM. All 
organic phases were checked with TLC and LCMS, product containing phases were combined, dried 
over MgSO4 and concentrated. 49 (220 mg, 0.71 mmol, 60%) was obtained as a pale yellow oil 
without further purification. 
 
TLC [EtOAc/n-hexane 1:1.5, 1% AcOH]: Rf = 0.33. 
 
HPLC [60-70% Solvent B, 20 min]: Rt = 14.4 min, purity (220 nm) = 95% 
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1H NMR (300 MHz, CDCl3) δ 6.54 (s, 2H), 3.84 (s, 6H), 3.82 (s, 3H), 3.12 (d, J = 10.7 Hz, 1H), 2.01 – 1.83 
(m, 3H), 1.81 – 1.59 (m, 3H), 1.42 – 1.21 (m, 2H), 1.20 – 0.99 (m, 3H). 
 
13C NMR (75 MHz, CDCl3) δ 179.31, 153.13, 137.33, 132.79, 105.60, 60.80, 58.89, 56.12, 40.86, 31.91, 
30.25, 26.23, 25.91. 
 
Mass: (ESI+), calculated 309.17 [C17H24O5+H]
+, found 309.20 [M+H]+. 
 
2-(3-((R)-1-(((S)-1-((S)-2-((S)-Cyclohex-2-en-1-yl)-2-(3,4,5-trimethoxyphenyl) 
acetyl)piperidine-2-carbonyl)oxy)-3-(3,4-dimethoxyphenyl)propyl)phenoxy) 
acetic acid (50) 
 
 
 
General synthesis procedure B for free acid ligands with 37a (50 mg, 0.20 mmol) and 47 (29.8 mg, 
0.20 mmol) was used. Then was purified using flash chromatography (gradient 0%-4% MeOH in DCM) 
to obtain 50 (25 mg, 33.5 µmol, 67%, dr 85:15) as a slight yellow oil. The dr was determined by NMR. 
 
TLC [MeOH/DCM, 6:94]: Rf = 0.12. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 20.0 min, purity (220 nm) = 98%. 
 
1H NMR (600 MHz, d6-DMSO) major diastereomer δ 7.08 (td, J = 8.1, 1.7 Hz, 1H), 6.80 (dd, J = 8.3, 1.1 
Hz, 1H), 6.75 (ddd, J = 8.3, 2.6, 0.9 Hz, 1H), 6.69 – 6.66 (m, 2H), 6.64 (d, J = 11.4 Hz, 2H), 6.60 – 6.58 
(m, 1H), 6.38 – 6.34 (m, 1H), 5.69 – 5.65 (m, 1H), 5.59 (dq, J = 9.8, 3.6 Hz, 1H), 5.52 (dd, J = 10.0, 2.4 
Hz, 1H), 5.47 – 5.40 (m, 1H), 5.30 – 5.25 (m, 1H), 4.62 (d, J = 1.3 Hz, 1H), 4.13 (d, J = 13.4 Hz, 1H), 3.71 
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(d, J = 0.8 Hz, 1H), 3.69 (s, 3H), 3.68 (s, 3H), 3.62 – 3.61 (m, 3H), 3.59 (s, 3H), 3.57 (s, 3H), 3.53 (d, J = 
0.7 Hz, 3H), 2.82 – 2.71 (m, 2H), 2.67 – 2.53 (m, 1H), 2.42 – 2.32 (m, 1H), 2.25 (ddt, J = 24.0, 13.8, 8.2 
Hz, 2H), 2.11 (d, J = 12.9 Hz, 1H), 1.90 (s, 2H), 1.84 – 1.73 (m, 2H), 1.62 – 1.51 (m, 2H), 1.24 – 1.12 (m, 
1H), 1.06 (dtd, J = 22.1, 12.1, 3.1 Hz, 1H) 
 
13C NMR (151 MHz, d6-DMSO) major diastereomer δ 171.70, 170.42, 158.01, 152.87, 149.01, 147.50, 
142.19, 136.44, 133.42, 129.78, 128.05, 120.17, 118.44, 113.74, 112.91, 112.46, 112.01, 106.25, 
105.80, 75.23, 64.94, 60.03, 56.06, 56.05, 55.92, 55.76, 52.41, 51.92, 43.29, 38.91, 38.02, 30.80, 
26.69, 25.42, 21.21. 
 
Mass: (ESI+), calculated 746.35 [C42H51NO11+H]
+, found 746.38 [M+H]+. 
 
(S)-(R)-3-(3,4-Dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propyl-1-
((S)-2-((S)-cyclohex-2-en-1-yl)-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-2-
carboxylate (51) 
 
 
 
General synthesis procedure A for morpholine ligands with 47 (10 mg, 33 µmol) and 37b (17 mg, 
33 µmol) was used. The product was purified using flash chromatography (gradient 0%-6% MeOH in 
DCM). 51 (16 mg, 20 µmol, 75%, dr 85:15) was obtained as a colorless oil. The dr was determined by 
NMR. 
 
TLC [MeOH/DCM, 6:94]: Rf = 0.22. 
 
HPLC [50-60% Solvent B, 20 min]: Rt = 10.5 min, purity (220 nm) = 98%. 
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1H NMR (400 MHz, d6-DMSO) major diastereomer δ 7.08 (t, J = 7.9 Hz, 1H), 6.93 – 6.87 (m, 1H), 6.83 
– 6.76 (m, 2H), 6.72 (q, J = 2.5, 2.0 Hz, 1H), 6.68 (d, J = 2.0 Hz, 1H), 6.62 (d, J = 11.1 Hz, 2H), 6.36 (t, J = 
7.1 Hz, 1H), 5.69 – 5.63 (m, 1H), 5.55 – 5.49 (m, 1H), 5.47 – 5.38 (m, 1H), 5.26 (s, 1H), 4.06 (dd, J = 
14.6, 6.1 Hz, 2H), 3.72 – 3.70 (m, 2H), 3.69 (s, 3H), 3.67 (s, 3H), 3.61 (t, J = 1.5 Hz, 1H), 3.58 (s, 1H), 
3.55 (s, 2H), 3.53 (s, 2H), 3.29 – 3.27 (m, 10H), 2.82 – 2.70 (m, 2H), 2.65 – 2.56 (m, 1H), 2.32 – 2.22 
(m, 2H), 2.11 (d, J = 13.2 Hz, 2H), 1.90 (s, 2H), 1.80 (dt, J = 14.9, 6.8 Hz, 3H), 1.59 (d, J = 13.8 Hz, 3H), 
1.49 – 1.36 (m, 1H), 1.21 (d, J = 3.6 Hz, 3H), 0.88 – 0.77 (m, 2H). 
 
13C NMR (101 MHz, d6-DMSO) major diastereomer δ 172.07, 170.39, 158.51, 153.10, 148.83, 147.53, 
142.35, 136.56, 133.51, 130.70, 129.85, 128.16, 120.38, 118.26, 114.15, 112.85, 112.65, 112.33, 
106.17, 75.31, 66.60, 65.63, 60.20, 60.11, 57.40, 56.45, 56.04, 55.93, 55.77, 54.00, 52.60, 52.01, 
51.96, 43.13, 37.92, 30.92, 28.64, 28.01, 26.71, 25.32, 22.42, 21.21, 20.82. 
 
Mass: (ESI+), calculated 801.43 [C46H60N2O10+H]
+, found 801.42 [M+H]+. 
 
(S)-1,7-Di(pyridin-3-yl)heptan-4-yl-1-((S)-2-((S)-cyclohex-2-en-1-yl)-2-(3,4,5-
trimethoxy phenyl) acetyl)piperidine-2-carboxylate (52) 
 
 
 
47 (42 mg, 0.14 mmol) was dissolved in 500 µL DMF, then HATU (91 mg, 0.25 mmol) and DIPEA (86 
µL, 0.50 mmol) were added and stirred for 30 min. Then 37c (48 mg, 0.14 mmol) in 500µL DMF was 
added and stirred for 14 h. Subsequently, 3 mL H2O/MeOH 1:1 with 0.1% TFA was added and 
subjected to reversed phase flash chromatography (gradient 0%-45% MeOH in H2O + 0.1% TFA). 52 
(53 mg, 79 µmol, 63%, 85:15) was obtained as a yellow oil. The dr was determined by NMR. 
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TLC [MeOH/DCM, 15:85]: Rf = 0.25. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 13.2 min, purity (220 nm) = 95%. 
 
1H NMR (300 MHz, CDCl3) major diastereomer δ 8.69 (d, J = 15.8 Hz, 4H), 8.23 (dd, J = 24.2, 7.7 Hz, 
2H), 7.81 (s, 2H), 6.51 (d, J = 12.9 Hz, 2H), 5.83 – 5.68 (m, 1H), 5.65 – 5.48 (m, 1H), 5.30 (s, 1H), 4.84 
(s, 1H), 3.85 – 3.82 (m, 1H), 3.81 (s, 3H), 3.78 (s, 6H), 3.63 – 3.43 (m, 1H), 2.95 – 2.84 (m, 2H), 2.80 – 
2.67 (m, 4H), 2.21 (d, J = 12.9 Hz, 2H), 1.99 (s, 3H), 1.76 – 1.34 (m, 14H), 1.12 (d, J = 11.3 Hz, 1H). 
 
13C NMR (75 MHz, CDCl3) major diastereomer δ 172.71, 172.51, 171.03, 170.84, 152.77, 145.17, 
144.97, 141.86, 141.49, 139.45, 136.89, 133.18, 130.02, 128.94, 126.52, 105.84, 72.97, 60.90, 56.13, 
53.91, 52.42. 
 
Mass: (ESI+), calculated 670.39 [C40H51N3O6+H]
+, found 670.39 [M+H]+. 
 
(S)-2-(3,4-Dimethoxyphenoxy)ethyl-1-((S)-2-((R)-cyclohex-2-en-1-yl)-2-(3,4,5-
trimethoxy phenyl)acetyl)piperidine-2-carboxylate (53) 
 
 
 
47 (45 mg, 0.15 mmol) was dissolved in 700 µL dry DMF then N-ethyl-N-isopropylpropan-2-amine 
(102 µL, 0.60 mmol) and HATU (83 mg, 0.22 mmol) was added and stirred for 15 min. Then 37d 
(45 mg, 0.15 mmol) was dissolved in 600 µL DCM/DMF 1:1 and added to the reaction mixture. Then 
was stirred for 14 h at RT. The product was purified using flash chromatography (Gradient 0%-
50% EtOAc in cyclohexane). 53 (12 mg, 20 µmol, 13%, dr 85:15) was obtained as a slight yellow oil. 
The dr was determined by NMR. 
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TLC [EtOAc/cyclohexane, 1:1]: Rf = 0.29. 
 
HPLC [60-80% Solvent B, 20 min]: Rt = 12.0 min, purity (220 nm) = 95%. 
 
1H NMR (400 MHz, d6-DMSO) major diastereomer δ 6.81 – 6.77 (m, 1H), 6.67 (d, J = 6.9 Hz, 1H), 6.59 
(s, 2H), 6.46 (d, J = 2.7 Hz, 1H), 5.68 – 5.63 (m, 1H), 5.55 – 5.52 (m, 1H), 5.15 – 5.12 (m, 1H), 4.44 – 
4.39 (m, 1H), 4.16 – 4.10 (m, 2H), 4.02 – 3.95 (m, 2H), 3.82 – 3.76 (m, 1H), 3.69 (s, 3H), 3.67 (s, 6H), 
3.66 (s, 3H), 3.62 – 3.60 (m, 3H), 3.59 – 3.52 (m, 1H), 2.73 – 2.66 (m, 2H), 2.09 – 2.01 (m, 1H), 1.98 – 
1.86 (m, 3H), 1.84 – 1.73 (m, 2H), 1.70 – 1.52 (m, 3H), 1.32 (d, J = 7.5 Hz, 2H). 
 
 
13C NMR (101 MHz, d6-DMSO) major diastereomer δ 172.25, 171.15, 153.21, 152.92, 150.00, 143.62, 
136.44, 134.87, 133.53, 131.40, 128.24, 113.13, 106.42, 104.61, 101.36, 66.53, 63.39, 60.70, 56.48, 
56.37, 56.19, 55.83, 52.76, 52.36, 43.22, 38.91, 26.91, 26.74, 26.58, 25.39, 21.13, 20.93. 
 
Mass: (ESI+), calculated 598.30 [C33H43NO9+H]
+, found 598.28 [M+H]+. 
 
(S)-(R)-3-(3,4-dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propyl-1-
((S)-2-((R)-cyclohex-2-en-1-yl)-2-(3,4,5-trimethoxyphenyl)acetyl)pyrrolidine-2-
carboxylate (54) 
 
 
 
General synthesis procedure A for morpholine ligands with 47 (30 mg, 98 µmol) and 37b (40 mg, 
80 µmol). The product was purified using flash chromatography. 54 (44 mg, 20 µmol, 70%, dr 85:15) 
was obtained as colorless oil. The dr was determined by NMR. 
C. Experimental Section_______________________________________________________________ 
126 
 
TLC [MeOH/DCM, 8:92]: Rf = 0.29. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 16.6 min, purity (220 nm) = 98%. 
 
1H NMR (400 MHz, d6-DMSO) major diastereomer δ 7.24 – 7.14 (m, 1H), 6.94 (d, J = 29.5 Hz, 1H), 
6.88 – 6.78 (m, 2H), 6.70 (dd, J = 6.1, 2.0 Hz, 1H), 6.68 – 6.63 (m, 1H), 6.63 – 6.59 (m, 1H), 6.57 (d, J = 
5.9 Hz, 2H), 5.72 – 5.64 (m, 1H), 5.58 (ddd, J = 14.8, 10.1, 2.2 Hz, 1H), 5.41 (ddd, J = 12.6, 8.2, 5.0 Hz, 
1H), 5.09 (dd, J = 10.2, 2.5 Hz, 1H), 4.47 (ddd, J = 14.3, 8.6, 3.1 Hz, 1H), 4.22 – 4.13 (m, 1H), 3.73 – 
3.71 (m, 1H), 3.70 (s, 2H), 3.68 (s, 3H), 3.64 – 3.61 (m, 3H), 3.55 (s, 3H), 3.54 (d, J = 1.5 Hz, 4H), 3.32 
(s, 9H), 3.23-3.19 (m, 1H), 2.89 – 2.74 (m, 2H), 2.75 – 2.61 (m, 2H), 2.46 – 2.24 (m, 2H), 2.25 – 2.13 
(m, 2H), 1.97 – 1.86 (m, 2H), 1.80 – 1.67 (m, 3H), 1.67 – 1.54 (m, 1H), 1.53 – 1.29 (m, 3H), 1.27 – 1.14 
(m, 1H). 
 
13C NMR (101 MHz, d6-DMSO) major diastereomer δ 171.90, 171.05, 159.55, 153.08, 149.26, 147.35, 
142.64, 136.73, 133.54, 130.79, 129.87, 129.38, 128.68, 120.50, 114.23, 112.82, 112.32, 106.54, 
106.04, 75.16, 67.84, 66.99, 60.86, 59.81, 58.96, 57.75, 56.19, 54.80, 53.88, 47.26, 32.66, 30.54, 
29.34, 28.63, 25.48, 24.79, 21.81, 21.31. 
 
Mass: (ESI-), calculated 787.42 [C45H58N2O10 +H]
-, found 787.35 [M+H]+. 
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2-(3-((R)-1-((S)-1-((S)-2-((R)-Cyclohex-2-en-1-yl)-2-(3,4,5-trimethoxyphenyl) 
acetyl)piper-idine-2-carboxamido)-3-(3,4-dimethoxyphenyl)propyl)phenoxy) 
acetic acid (55) 
 
 
 
General synthesis procedure B for free acid ligands with 37e (50 mg, 0.20 mmol) and 47 (30 mg, 0.20 
mmol) was used. The product was purified using preparative TLC (MeOH/DCM 8:92) to obtain 55 
(25 mg, 33.5 µmol, 67%, dr 85:15) as a slight yellow oil. The diastereomeric rate was determined by 
NMR.  
 
TLC [MeOH/DCM, 8:92]: Rf = 0.29. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 11.7 min, purity (220 nm) = 98%. 
 
1H NMR (400 MHz, dmso) major diastereomer δ 7.10 – 7.05 (m, 1H), 6.92 – 6.86 (m, 1H), 6.81 (t, J = 
8.4 Hz, 1H), 6.72 (dq, J = 11.8, 2.0 Hz, 2H), 6.69 – 6.64 (m, 1H), 6.63 – 6.57 (m, 1H), 6.56 – 6.51 (m, 
2H), 5.70 – 5.61 (m, 1H), 5.53 (d, J = 10.2 Hz, 1H), 5.12 – 5.04 (m, 1H), 4.79 – 4.66 (m, 2H), 4.66 – 4.53 
(m, 3H), 3.73 – 3.69 (m, 2H), 3.69 – 3.66 (m, 6H), 3.62 – 3.60 (m, 1H), 3.55 – 3.51 (m, 9H), 2.93 – 2.81 
(m, 2H), 2.79 – 2.67 (m, 2H), 2.40 – 2.27 (m, 2H), 2.16 – 2.02 (m, 2H), 1.96 – 1.84 (m, 2H), 1.84 – 1.73 
(m, 3H), 1.56 (d, J = 8.2 Hz, 2H), 1.31 (d, J = 9.6 Hz, 1H). 
 
13C NMR (101 MHz, dmso) δ 172.44, 170.72, 170.56, 158.10, 152.97, 149.05, 147.45, 145.74, 136.42, 
134.04, 133.70, 131.15, 129.51, 128.15, 120.46, 113.07, 112.76, 112.70, 112.19, 106.01, 64.77, 63.52, 
60.15, 56.41, 55.97, 55.92, 55.78, 52.86, 52.23, 51.90, 43.24, 38.97, 38.62, 32.03, 27.78, 27.48, 26.54, 
25.31, 21.12, 20.41. 
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Mass: (ESI-), calculated 745.37 [C42H52N2O10 +H]
+, found 745.40 [M-H]+. 
 
2-(3-((R)-1-(((S)-1-((S)-2-Cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl) 
piperidine-2-carbonyl)oxy)-3-(3,4-dimethoxyphenyl)propyl)phenoxy)acetic 
acid (56) 
 
 
 
 
General synthesis procedure B for free acid ligands with 37a (96 mg, 0.20 mmol) and 49 (58 mg, 
0.20 mmol) was used. The crude product was purified using preparative TLC (EtOAc/cyclohexane 
1:1.5 +1% AcOH) to obtain 56 (17 mg, 33.5 µmol, 23%) as a colorless oil.  
 
TLC [EtOAc/cyclohexane 1:1]: Rf = 0.20. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 20.6 min, purity (220 nm) ≥ 99%. 
 
1H NMR (599 MHz, d6-DMSO) δ 7.03 (t, J = 7.9 Hz, 1H), 6.90 – 6.84 (m, 1H), 6.83 – 6.73 (m, 2H), 6.70 
– 6.65 (m, 2H), 6.62 (s, 1H), 6.57 (dd, J = 8.1, 2.0 Hz, 1H), 6.28 (d, J = 7.6 Hz, 1H), 5.40 (dd, J = 7.6, 6.0 
Hz, 1H), 5.27 (dd, J = 5.8, 2.4 Hz, 1H), 4.36 (s, 2H), 4.19 (d, J = 13.4 Hz, 1H), 3.69 (s, 3H), 3.67 (s, 3H), 
3.60 (s, 1H), 3.58 (s, 6H), 3.51 (s, 3H), 3.48 – 3.43 (m, 1H), 2.67 – 2.60 (m, 1H), 2.37 – 2.29 (m, 2H), 
2.22 (dt, J = 13.9, 8.1 Hz, 1H), 2.14 – 2.06 (m, 2H), 1.99 – 1.91 (m, 2H), 1.78 – 1.69 (m, 2H), 1.63 (d, J = 
12.4 Hz, 1H), 1.54 – 1.41 (m, 2H), 1.35 – 1.28 (m, 1H), 1.19 (d, J = 17.2 Hz, 2H), 1.15 – 1.02 (m, 2H), 
0.96 – 0.85 (m, 2H), 0.80 (ddt, J = 20.6, 12.1, 7.3 Hz, 2H). 
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13C NMR (151 MHz, d6-DMSO) δ 172.48, 172.08, 170.61, 158.61, 152.66, 149.15, 147.47, 142.13, 
136.20, 134.32, 133.43, 120.48, 118.07, 113.80, 113.07, 112.53, 112.13, 106.25, 75.16, 66.46, 60.33, 
56.62, 55.90, 55.74, 53.12, 52.03, 43.53, 41.10, 37.94, 32.41, 31.32, 30.58, 29.98, 26.87, 26.32, 25.93, 
25.38, 20.93. 
 
Mass: (ESI-), calculated 748.37 [C42H53NO11+H]
+, found 768.41[M+H]+. 
 
(S)-(R)-3-(3,4-dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propyl-1-
((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-2-carboxylate 
(57) 
 
 
 
General synthesis procedure A for morpholine ligands with 49 (30 mg, 97 µmol) and 37b (50 mg, 
97 µmol). The product was purified using flash chromatography (gradient 0%-15% MeOH in DCM). 57 
(11 mg, 13.6 µmol, 14%) was obtained as a colorless oil. 
 
TLC [MeOH/DCM 6:94]: Rf = 0.44. 
HPLC [0-100% Solvent B, 20 min]: Rt = 17.7 min, purity (220 nm) = 98%. 
 
1H NMR (400 MHz, d6-DMSO) δ 7.08 (t, J = 7.9 Hz, 1H), 6.93 – 6.87 (m, 1H), 6.83 – 6.76 (m, 2H), 6.72 
(q, J = 2.5, 2.0 Hz, 1H), 6.68 (d, J = 2.0 Hz, 1H), 6.62 (d, J = 11.1 Hz, 2H), 6.36 (t, J = 7.1 Hz, 1H), 5.47 – 
5.38 (m, 1H), 5.26 (s, 1H), 4.06 (dd, J = 14.6, 6.1 Hz, 2H), 3.72 – 3.70 (m, 2H), 3.69 (s, 3H), 3.67 (s, 3H), 
3.61 (t, J = 1.5 Hz, 1H), 3.58 (s, 1H), 3.55 (s, 3H), 3.53 (s, 3H), 3.29 - 3.27 (m, 10H), 2.82 – 2.70 (m, 2H), 
2.65 – 2.56 (m, 1H), 2.32 – 2.22 (m, 2H), 2.11 (d, J = 13.2 Hz, 2H), 1.90 (s, 2H), 1.80 (dt, J = 14.9, 6.8 
Hz, 4H), 1.59 (d, J = 13.8 Hz, 4H), 1.49 – 1.36 (m, 1H), 1.21 (d, J = 3.6 Hz, 3H), 0.88 – 0.77 (m, 2H). 
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13C NMR (151 MHz, d6-DMSO) δ 172.55, 170.94, 162.94, 153.03, 149.33, 147.72, 137.03, 133.56, 
129.26, 120.19, 112.20, 75.37, 60.37, 56.68, 55.84, 55.30, 53.99, 51.62, 46.53, 43.54, 36.39, 32.08, 
30.77, 27.00, 25.93, 25.39, 21.16, 17.17, 9.63. 
 
Mass: (ESI-), calculated 803.34 [C46H62N2O10+H]
+, found 803.38[M+H]+. 
 
2-Oxo-2-(3, 4, 5-trimethoxyphenyl) acetic acid 58 
 
 
 
1-(3,4,5-Trimethoxyphenyl)ethanone (2.93g, 13.9mmol) and selenium dioxide (2.32 g, 20.9 mmol) in 
60 mL pyridine were heated to 100°C for 14 h. The mixture was filterted through celite, concentrated 
in vacuo and purified with flash chromatography (EtOAc/cyclohexane 15:1, 1% AcOH). 58 (2.2 g, 
9.1 mmol, 65%) was obtained as a yellow solid.  
 
TLC [EtOAc/cyclohexane, 15:1, + 1% AcOH]: Rf = 0.14. 
 
HPLC [0-100% B, 20 min]: Rt = 10.8 min, purity (220 nm) 90%. 
 
1HNMR (600 MHz, CDCl3) δ= 3.91(s, 6H), 3.95(s, 3H),7.50 (s, 2H). 
13C NMR (150 MHz, CDCl3) δ= 56.31, 61.03, 108.04, 127.55, 144.19, 153.06, 165.74, 186.94. 
 
HRMS(EI+), calculated 240.0634[C11H12O6+H
+] +.found 240.0624[M+H+] 
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(R)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)pent-4-enoic acid (59) 
 
 
 
58 (100 mg, 0.42 mmol) was dissolved in 3.5 ml dry THF and cooled to -78°C then 
Allylmagnesiumbromid (1 M in THF, 0.42 mL, 0.42 mmol) was added dropwise, stirred for 4 h then 
was allowed to warm to RT and the reaction mixture was quenched, using NH4Cl (sat). The aqueous 
phase was extracted with DCM and the product was purified by silica chromatography 
(EtOAc/cyclohexane, 1:1 +1% AcOH). 59 (88mg, 0.36 mmol, 87%) was obtained as white crystals. 
 
TLC [EtOAc/cyclohexane, 1:1 + 5% AcOH]: Rf = 0.38. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 17.7 min, purity (220 nm) = 98%. 
 
1H NMR (300 MHz, CDCl3) δ 6.89 (s, 2H), 5.79 (dt, J = 17.2, 8.3 Hz, 1H), 5.32 – 5.21 (m, 2H), 3.89 (s, 
6H), 3.86 (s, 3H), 3.03 (dd, J = 13.9, 7.3 Hz, 1H), 2.80 (dd, J = 14.0, 7.0 Hz, 1H). 
 
Mass: (ESI-), calculated 281.10 [C14H18O6+H]
-, found 281.13 [M+H]+. 
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(S)-1,7-Di(pyridin-3-yl)heptan-4-yl-1-(2-oxo-2-(3,4,5-
trimethoxyphenyl)acetyl)piperidine-2-carboxylate (63) 
 
 
 
58 (94 mg, 0.40 mmol) was dissolved in 500 µL DMF, then HATU (191 mg, 0.52 mmol) and DIPEA 
(0.18 mL, 1.05 mmol) were added and stirred for 30min. Subsequently, 37c (0.10 g, 0.26 mmol) in 
500 µL DMF was added and stirred for 14 h at RT. The solvent was reduced in vacuo. The crude 
product was dissolved in 4 mL MeOH/H2O 1:1 solution and purified with reversed phase flash 
chromatography (Column: Interchim puriFlash IR-50C18-20G, gradient 0%-20% MeOH in H2O + 1% 
TEA). 63 was obtained as a slight brown oil (104 mg, 0.17 mmol, 66%)  
 
TLC [MeOH/DCM 20:80]: Rf = 0.15. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 11.6 min, purity (220 nm) = 95%. 
 
1H NMR (300 MHz, d6-DMSO) δ 8.67 (dd, J = 11.4, 5.7 Hz, 4H), 8.26 – 8.18 (m, 2H), 7.77 (td, J = 8.3, 
5.4 Hz, 2H), 7.22 (s, 2H), 5.17 (d, J = 5.7 Hz, 1H), 4.97 (s, 1H), 3.82 (s, 6H), 3.77 (s, 3H), 3.31 (d, J = 13.1 
Hz, 1H), 3.13 – 3.05 (m, 1H), 2.78 – 2.70 (m, 4H), 2.16 (d, J = 13.8 Hz, 1H), 1.83 – 1.69 (m, 1H), 1.70 – 
1.56 (m, 6H), 1.53 – 1.45 (m, 1H), 1.45 – 1.31 (m, 2H), 1.28 – 1.19 (m, 2H), 1.19 – 1.11 (m, 1H). 
 
13C NMR (75 MHz, d6-DMSO) δ 190.83, 190.80, 170.86, 170.67, 170.12, 167.75, 167.53, 158.66, 
158.59, 153.87, 153.48, 144.31, 144.16, 142.19, 141.00, 127.91, 126.57, 118.59, 107.23, 75.25, 60.99, 
56.71, 51.82, 44.25, 33.28, 31.93, 26.27, 26.10, 24.53, 20.99. 
 
Mass: (ESI-), calculated 604.30 [C34H41N3O7+H]
+, found 604.31[M+H]+. 
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(S)-1,7-Di(pyridin-3-yl)heptan-4-yl-1-((R)-2-cyclohexyl-2-hydroxy-2-(3,4,5-
trimethoxy phenyl)acetyl)piperidine-2-carboxylate (64a) 
 
 
 
63/Biricodar (69 mg, 0.11 mmol) was dissolved in 700 µL anhydrous THF and cooled to -78°C. Then 
cyclohexylmagnesium bromide (1 M in THF, 343 µL, 0.34 mmol) was added and stirred for 2h. The 
reaction mixture was quenched with NH4Cl (sat) solution and extracted with DCM. The organic 
phases were combined and dried over MgSO4. The diastereomers were separated using preparative 
HPLC (Gradient 45%-60% solvent B in Solvent A) yielding 64a (14 mg, 20 µmol, 20%). The 
diastereomeric rate was determined by HPLC. 
 
TLC [MeOH/DCM 5:95]: Rf = 0.45. 
 
HPLC 64a [25-40% Solvent B, 20 min]: Rt = 15.7 min, purity (220 nm) = 95%, dr ≥ 99:1  
HPLC 64b [25-40% Solvent B, 20 min]: Rt = 16.7 min, purity (220 nm) = 95%, dr ≥ 99:1 
 
1H NMR (599 MHz, d6-DMSO) δ 8.31 (t, J = 7.9 Hz, 2H), 8.22 – 8.09 (m, 2H), 7.74 (s, 2H), 7.71 – 7.64 
(m, 2H), 6.49 (d, J = 18.9 Hz, 2H), 4.92 – 4.85 (m, 1H), 4.04 (dd, J = 11.4, 3.6 Hz, 1H), 3.66 (s, 6H), 3.64 
(s, 3H) 2.77 – 2.63 (m, 6H), 2.19 – 2.15 (m, 2H), 1.99 (dd, J = 14.2, 3.3 Hz, 2H), 1.79 – 1.43 (m, 14H), 
1.37 – 1.11 (m, 4H), 1.11 – 0.95 (m, 4H). 
 
13C NMR (101 MHz, d6-DMSO) δ 177.12, 170.90, 156.48, 151.65, 146.83, 141.45, 135.84, 135.72, 
123.83, 104.86, 84.10, 79.16, 60.70, 58.79, 56.83, 43.78, 40.62, 35.64, 31.32, 29.27, 27.81, 26.75, 
26.02, 25.91, 25.47, 22.24. 
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Mass: (ESI+), calculated 688.40 [C40H53N3O7+H]
+, found 688.39 [M-H]+. 
 
2-(3-((R)-3-(3,4-Dimethoxyphenyl)-1-(((S)-1-(2-oxo-2-phenylacetyl)piperidine-
2-carbonyl) oxy)propyl)phenoxy)acetic acid (68) 
 
 
 
General synthesis procedure B for free acid ligands with 37a (50 mg, 97 µmol) and Phenylglyoxylic 
acid (16 mg, 0.11 mmol was used. The crude mixture was concentrated and purified using flash 
chromatography (Gradient 0%-60% EtOAc in cyclohexane +0.1 % AcOH) to obtain 68 (33 mg, 72 
µmol, 89%) as a brownish oil. 
 
TLC [EtOAc/cyclohexane 45:50 + 5% AcOH]: Rf = 0.18. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 16.1 min, purity (220 nm) = 98% 
 
1H NMR (600 MHz, CDCl3) δ 7.81 (dd, J = 7.5, 1.5 Hz, 2H), 7.61 – 7.53 (m, 1H), 7.53 – 7.45 (m, 2H), 
7.25 (d, J = 14.9 Hz, 1H), 7.04 – 6.97 (m, 2H), 6.90 – 6.83 (m, 2H), 6.82 – 6.74 (m, 2H), 5.68 (t, J = 7.0 
Hz, 1H), 4.64 (s, 2H), 4.48 (t, J = 8.3 Hz, 1H), 3.83 (s, 3H), 3.75 (s, 3H), 3.66 (dt, J = 12.2, 6.0 Hz, 1H), 
3.54 (dt, J = 12.3, 6.0 Hz, 1H), 2.65 (t, J = 7.9 Hz, 2H), 2.28 (td, J = 7.9, 6.9 Hz, 1H), 2.08 – 1.96 (m, 2H), 
1.81 (ddt, J = 12.3, 8.4, 5.6 Hz, 1H), 1.74 – 1.54 (m, 4H). 
 
13C NMR (125 MHz, CDCl3) δ 190.18, 171.80, 170.15, 163.11, 159.07, 150.39, 148.33, 144.02, 135.46, 
135.20, 133.32, 130.12, 129.38, 129.32, 121.85, 119.24, 115.58, 114.12, 113.68, 113.54, 77.03, 66.03, 
59.12, 56.83, 42.84, 36.38, 34.08, 25.91, 25.47, 22.24. 
 
Mass: (ESI+), calculated 612.22 [C33H35NO9+Na]
+, found 612.24 [M-Na]+. 
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2-(3-((R)-3-(3,4-dimethoxyphenyl)-1-(((S)-1-(2,2-diphenylacetyl)piperidine-2-
carbonyl) oxy)propyl)phenoxy)acetic acid (69) 
 
 
 
 
General synthesis procedure B for free acid ligands with 37a (50 mg, 0,097 mmol) and Diphenyl 
acetic acid (22 mg, 0.11 mmol) was used. Then was purified using flash chromatography (Gradient 
0%-50% EtOAc in cyclohexane +0.1 % AcOH) to obtain 69 (42 mg, 72 µmol, 89%) as a brownish oil.  
 
TLC [EtOAc/cyclohexane 45:50 + 5% AcOH]: Rf = 0.34. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 19.8 min, purity (220 nm) = 95% 
 
1H NMR (600 MHz, CDCl3) δ 7.39 – 7.35 (m, 6H), 7.27 – 7.23 (m, 1H), 7.23 – 7.19 (m, 4H), 7.02 – 6.98 
(m, 1H), 6.95 – 6.92 (m, 1H), 6.89 – 6.84 (m, 2H), 6.81 – 6.74 (m, 2H), 5.92 (t, J = 7.0 Hz, 1H), 4.82 (s, 
1H), 4.69 – 4.60 (m, 3H), 3.83 (s, 3H), 3.75 (s, 3H), 3.74 – 3.66 (m, 1H), 3.45 (dt, J = 12.2, 6.1 Hz, 1H), 
2.64 – 2.54 (m, 2H), 2.47 – 2.38 (m, 1H), 2.27 – 2.19 (m, 1H), 2.06 – 1.97 (m, 1H), 1.76 – 1.56 (m, 5H). 
 
13C NMR (125 MHz, CDCl3) δ 172.91, 171.80, 170.15, 159.07, 150.39, 148.33, 144.02, 137.82, 135.20, 
130.60, 129.38, 128.97, 127.61, 121.85, 119.24, 115.58, 114.12, 113.68, 113.54, 77.03, 66.03, 58.74, 
56.83, 56.11, 43.29, 36.38, 34.08, 25.91, 25.47, 22.24. 
 
Mass: (ESI+), calculated 674.27 [C39H41NO8+Na]
+, found 674.30 [M-Na]+. 
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(S)-(R)-3-(3,4-Dimethoxyphenyl)-1-(3-(2-morpholinoethoxy)phenyl)propyl-1-
(2,2-dicyclo hexylacetyl)pyrrolidine-2-carboxylate (70) 
 
 
 
General synthesis procedure A for morpholine ligands with 65 (18 mg, 80 µmol) and 37b (39 mg, 
80 µmol) was used. The crude product was concentrated and purified using flash chromatography 
(gradient 0%-15% MeOH in DCM). 70 (14 mg, 30 µmol, 38%) was obtained as a slight yellow oil. 
 
TLC [MeOH/DCM 5:95]: Rf = 0.39. 
 
HPLC [0-100% Solvent B, 20 min]: Rt = 14.7 min, purity (220 nm) ≥ 99%. 
 
1H NMR (600 MHz, CDCl3) δ 7.30-7.25 (m, 1H), 7.03 – 6.94 (m, 3H), 6.90 – 6.74 (m, 3H), 5.61 (t, J = 6.8 
Hz, 1H), 4.63 (t, J = 4.0 Hz, 1H), 4.06 (t, J = 3.8 Hz, 2H), 3.83 (s, 3H), 3.75 (s, 3H), 3.57 (t, J = 4.8 Hz, 4H), 
3.52 – 3.37 (m, 4H), 2.73 – 2.63 (m, 2H), 2.50 (t, J = 4.7 Hz, 4H), 2.44 (dt, J = 6.7, 5.6 Hz, 1H), 2.34 (dt, J 
= 6.8, 5.7 Hz, 1H), 2.21 – 2.17 (m, 1H), 2.10-1.98 (m, 3H), 1.95 – 1.86 (m, 6H), 1.71-1.59 (m, 4H), 1.64-
1.62 (m, 3H), 1.32-1.25 (m, 4H), 1.12-1.11 (m, 2H), 0.97-0.81 (m, 4H). 
 
13C NMR (125 MHz, CDCl3) δ 176.24, 171.90, 159.63, 150.39, 148.33, 143.58, 135.20, 129.28, 121.85, 
119.20, 115.53, 114.12, 113.68, 113.06, 77.03, 67.38, 66.80, 61.22, 56.83, 54.73, 52.94, 52.72, 46.25, 
41.21, 38.97, 36.38, 34.08, 32.08, 30.69, 28.00, 26.27, 26.02, 25.90, 25.55, 24.98. 
 
Mass: (ESI+), calculated 705.45 [C42H60N2O7+H]
+, found 705.35 [M-H]+. 
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TBS-Rap (71) 
 
 
 
Rapamycin (50 mg, 55 µmol) was dissolved in 1 mL DCM and cooled to 0°C. Then TBDMS-OTf (65 mg, 
0.25 mmol) and 2,6-Lutidine (38 µL, 0.33 mmol) was added. Then it was stirred further at 0°C for 2h. 
The reaction was quenched, using NH4Cl (sat) solution. The aqueous phase was extracted with DCM. 
The organic phase was dried over MgSO4. The product was purified using column chromatography 
(EtOAc/cyclohexane 2:8). 71 (95 mg, 83 µmol, 38%).  
 
TLC [EtOAc/cyclohexane 2:8]: Rf = 0.29. 
 
HPLC reversed phase [isochratic 100% Solvent B without TFA, 20 min]: Rt = 27.8 min, purity (220 nm) 
= 98%. 
HPLC normal phase* [isochratic EtOAc/n-hexane 1:1, 30 min]: Rt = 3.9 min, purity (280 nm) = 98%. 
*(Phenomenex Luna Silica (2) column, Waters 515 HPLC pump, LCD Analytical spectromonitor 5000 
detector, 277 nm) 
 
1H NMR (599 MHz, CDCl3) δ 6.41 (dd, J = 14.8, 11.1 Hz, 1H), 6.34 – 6.26 (m, 1H), 6.15 (dd, J = 15.1, 
10.3 Hz, 1H), 6.04 (d, J = 10.9 Hz, 1H), 5.33 – 5.22 (m, 2H), 5.05 (d, J = 4.2 Hz, 1H), 4.17 (dd, J = 13.0, 
6.4 Hz, 1H), 3.83 (d, J = 5.7 Hz, 1H), 3.80 (s, 1H), 3.71 (dd, J = 9.2, 6.0 Hz, 1H), 3.64 (s, 1H), 3.41 (s, 3H), 
3.38 – 3.35 (m, 2H), 3.35 – 3.32 (m, 1H), 3.27 (s, 3H), 3.13 (d, J = 6.6 Hz, 3H), 2.92 – 2.84 (m, 1H), 2.70 
– 2.64 (m, 1H), 2.60 (dd, J = 16.0, 8.1 Hz, 1H), 2.39 (dd, J = 15.9, 3.5 Hz, 1H), 2.33 – 2.24 (m, 2H), 2.03 
– 1.94 (m, 2H), 1.86 – 1.80 (m, 2H), 1.80 – 1.75 (m, 2H), 1.64 (s, 3H), 1.62 – 1.55 (m, 3H), 1.54 – 1.45 
(m, 3H), 1.44 – 1.35 (m, 3H), 1.35 – 1.30 (m, 3H), 1.27 – 1.23 (m, 2H), 1.22 – 1.14 (m, 2H), 1.12 – 1.09 
(m, 2H), 1.06 (dd, J = 6.7, 2.3 Hz, 2H), 1.02 (d, J = 6.6 Hz, 3H), 1.00 – 0.96 (m, 3H), 0.93 – 0.89 (m, 4H), 
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0.90-0.87 (m, 18H), 0.82 (d, J = 11.0 Hz, 8H), 0.70 (q, J = 12.1 Hz, 2H), 0.07 (s, ,3H), 0.05 (s, 3H), -0.01 
(s, 3H), -0.07 (s, 3H). 
 
13C NMR (151 MHz, CDCl3) δ 210.83, 208.14, 193.46, 169.38, 166.11, 139.10, 137.78, 135.90, 132.82, 
130.58, 129.24, 127.05, 126.68, 98.58, 84.70, 84.29, 84.12, 78.81, 75.43, 66.89, 58.25, 57.93, 55.85, 
51.20, 46.84, 44.05, 42.20, 41.66, 40.09, 38.77, 38.52, 35.99, 35.00, 34.09, 33.86, 32.88, 31.71, 31.07, 
27.20, 26.85, 25.85, 25.75, 25.64, 25.16, 21.40, 20.50, 18.12, 16.08, 15.53, 15.11, 14.18, 13.81, 12.68, 
10.13, -4.52, -4.77, -5.00. 
 
Mass: (ESI+), calculated 1164.72 [C63H107NO13Si2+Na]
+, found 1164.73 [M-Na]+. 
 
TBS-Rap-OH (72) 
 
 
 
To a stirred solution of 71 (132 mg, 0.12 mmol) in 3.5 mL Methanol at -5°C (ice/Aceton bath) was 
added in several portions NaCNBH3 (145 mg, 2.31 mmol). After addition was complete reaction was 
allowed to warm to RT and then heated to 50°C and stirred for 1h. The reaction was quenched, using 
NaHCO3 (sat) solution and extracted with DCM. The organic phases were dried over MgSO4. The 
product was purified using flash chromatography (gradient 0%-50% i-Propanol in cyclohexane). 73 
(27 mg, 24 µmol, 20%) was obtained as a slight yellow oil.  
 
TLC [EtOAc/cyclohexane 1:1]: Rf = 0.42. 
 
HPLC [10-30% Solvent B, 20 min]: Rt = 14.7 min, purity (280 nm) 96%. 
HPLC normal phase* [10-30% EtOAc in n-hexane, 30 min]: Rt = 18.3 min, purity (220 nm) = 98%. 
*(Phenomenex Luna Silica (2) column, Beckmann 126s solvent module, detector 168, 220/280 nm) 
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1H NMR (600 MHz, CDCl3) δ 6.36 (dd, J = 14.6, 11.0 Hz, 1H), 6.21 (dd, J = 14.7, 10.6 Hz, 1H), 6.16 – 
6.08 (m, 2H), 5.53 (dd, J = 14.9, 8.7 Hz, 1H), 5.27 – 5.20 (m, 2H), 5.18 (dt, J = 8.2, 4.3 Hz, 1H), 4.23 
(tdd, J = 10.8, 5.4, 3.3 Hz, 2H), 4.16 (dd, J = 7.2, 2.4 Hz, 1H), 4.13 – 4.06 (m, 1H), 3.85 (dd, J = 7.2, 3.5 
Hz, 1H), 3.81 (t, J = 7.1 Hz, 1H), 3.38 (s, 3H), 3.36 (dd, J = 10.6, 5.9 Hz, 1H), 3.34 – 3.29 (m, 1H), 3.25 (s, 
3H), 3.14 (s, 3H), 2.89 – 2.81 (m, 1H), 2.75 (dtd, J = 13.6, 6.5, 3.5 Hz, 1H), 2.65 – 2.56 (m, 2H), 2.47 – 
2.37 (m, 1H), 2.31 (s, 1H), 2.23 (d, J = 15.0 Hz, 1H), 2.03 – 1.94 (m, 2H), 1.86 – 1.80 (m, 2H), 1.80 – 
1.75 (m, 2H), 1.64 (s, 3H), 1.62 – 1.55 (m, 3H), 1.54 – 1.45 (m, 3H), 1.44 – 1.35 (m, 3H), 1.35 – 1.30 
(m, 3H), 1.27 – 1.23 (m, 2H), 1.22 – 1.14 (m, 2H), 1.12 – 1.09 (m, 2H), 1.06 (dd, J = 6.7, 2.3 Hz, 2H), 
1.02 (d, J = 6.6 Hz, 3H), 1.00 – 0.96 (m, 3H), 0.93 – 0.89 (m, 4H), 0.88 (d, J = 2.5 Hz, 12H), 0.82 (d, J = 
11.0 Hz, 8H), 0.70 (q, J = 12.1 Hz, 2H), 0.07 (s, ,3H), 0.05 (s, 3H), -0.01 (s, 3H), -0.07 (s, 3H). 
 
13C NMR (150 MHz, CDCl3) δ 213.07, 207.99, 174.14, 171.78, 169.84, 139.27, 137.70, 135.61, 133.14, 
130.26, 129.22, 127.79, 126.64, 84.16, 82.81, 78.85, 75.63, 74.88, 60.02, 58.05, 55.83, 52.74, 46.67, 
43.10, 41.28, 40.64, 40.01, 39.03, 38.57, 36.02, 34.85, 33.83, 33.21, 33.08, 31.83, 31.52, 30.94, 29.73,  
29.14, 28.43, 26.33, 24.79, 22.60, 21.62, 20.55, 18.11, 17.97, 17.36, 15.34, 15.27, 14.16, 11.81, 10.96, 
-4.43, -4.53, -4.74, -5.12. 
 
Mass: (ESI+), calculated 1166.73 [C63H108NO13Si2+Na]
+, found 1166.73 [M-Na]+. 
 
Allyl-Rap (75) 
 
 
 
Rapamycin (20 mg, 22 µmol) was placed in a flask and dried over night at high vacuum Then it was 
dissolved in 200 µL anhydrous THF and cooled to -78°C. indium(III) trifluoromethanesulfonate 
(18 mg, 33 µmol) and a tetraallylstannane (98 µL, 98 µmol, 1 M in THF) were added dropwise. The 
reaction mixture was stirred for 1h at -78°C and 14 h at -20°C. The raw product was diluted with 4 mL 
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MeOH, filtered and the variously substituted products were purified with preparative HPLC (gradient 
50%-70% CH3CN in H2O without TFA). Fractions containing compounds with masses + allyl 
 
HPLC (75-978) [65%-75% solvent B in 20min]: Rt = 13.1 min, purity (220 nm) = 97% 
UV spectra (λmax): 210nm, 265 nm, 278 nm, 288 nm (characteristic for triene moiety of rapamycin 
based on Sehgal et al143, λmax: 267 nm, 277 nm, 288 nm) 
Mass: (ESI+), calculated 978.59 [C54H85NO13+Na]
+, found 978.57 [M-Na]+. 
 
HPLC (75-1021) [65%-75% solvent B in 20min]: Rt = 18.0 min, purity (220 nm) = 90% 
UV spectra (λmax): 220 nm, 268 nm, 278 nm, 289 nm 
Mass: (ESI+), calculated 1020.64 [C57H91NO13+Na]
+, found 1020.60 [M-Na]+. 
 
HPLC (75-1062) [70%-100% solvent B in 20min]: Rt = 13.3 min, purity (220 nm) = 85% 
UV spectra (λmax): 220 nm, 265 nm, 278 nm, 289 nm 
Mass: (ESI+), calculated 1062.69 [C60H97NO13+Na]
+, found 1062.72 [M-Na]+. 
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MFP590-Rap (F3) 
 
 
 
C40-Glycyl-rapamycin 87 was synthesized as described.144 87 (1 mg, 1.0 µmol) was dissolved in 10 µL 
DMF, then DIEPA (2 µL, 2.1 µmol) was added. MFP590 (0.5 mg, 0.6 µmol) was dissolved in 20 µL DMF 
and was added to the above solution and stirred for 48h. The crude product was diluted with 2 mL 
CH3CN/H2O 80:20 filtered and purified with semi preparative HPLC (gradient 60%-100% CH3CN in 
H2O). F3 was obtained as 183 µM solution in DMSO. The concentration was determined by 
absorption spectroscopy using ε597 = 1.2x10
5 M-1cm-1 of MFP590.  
 
HPLC [60%-80% solvent B in 20 min]: Rt = 18.2 min. 
 
UV spectra (λmax): 267 nm, 278 nm, 289 nm, 597 nm (characteristic for triene moiety of rapamycin 
based on Sehgal et al143, λmax: 267 nm, 277 nm, 288 nm) 
 
UV/Vis spectra (80 % MeOH, 20 % Tris-HCl, 5 mM, pH 8.8) 10 µM: ε597 = 1.2x10
5 M-1cm-1 
 
Mass: (ESI+), calculated 1543.85 [C90H119F3N4O18]
+, found 1543.80 [M]+. 
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Fluorescent iFit ligand (F4) 
 
 
 
50 (5 mg, 6.7 µmol) was dissolved in 50 µL DCM then HATU (5 mg, 13 µmol) and DIPEA (5 µL, 
29 µmol) was added and stirred for 15min. Subsequently 4'-(Aminomethyl)-fluorescein (2 mg, 
6.7 µmol) was added and stirred at RT for 2.5 h. The crude product was diluted with 1 mL MeOH and 
purified with preparative HPLC (gradient 50%-90% MeOH in H2O without TFA, 30 min, Rt = 20 -
22 min, 220 nm). F4 was obtained as a yellow fluorescent solid (1.7 mg, 1.6 µmol, 23%). 
 
HPLC [60%-90% solvent B, 20 min]: Rt = 13.0 min, purity (220 nm) = 98% 
 
UV/Vis spectra (80 % MeOH, 20 % Tris-HCl, 5 mM, pH 8.8) 5.4 µM: ε278 = 15850 M
-1cm-1, ε280 = 15650 
M-1   cm-1, ε498 = 46900 M
-1cm-1. 
 
Mass: (ESI+), calculated 1089.44 [C63H64N2O15+H]
+, found 1089.40 [M+H]+. 
 
tert-Butyl 4-vinylbenzylcarbamate (89) 
 
 
 
To 4-vinylaminobenzene (1 g, 7.5 mmol, TCI Europe) and TEA (0.73 mL, 9.0 mmol) dissolved in 20 mL 
dry MeOH was added Boc-anhydride (2.5 g, 11.3 mmol). After stirring for 14 h, the resulting reaction 
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mixture was concentrated in vacuo and flash chromatographed (silica gel, EtOAc/i-Hex) to obtain 74 
as a white solid (1.75g, quant. yield).  
 
TLC [EtOAc/i-Hex 1:9]: Rf = 0.38. 
 
HPLC [0%-100% solvent B, 20 min]: Rt = 25.0 min, purity (220 nm) = 98% 
 
1H NMR (300 Mhz, CDCl3): δ = 7.38 (d, J = 9 Hz, 2 H), 7.26 (d, J = 9 Hz, 2 H), 6.72 (dd, J = 10.86 Hz, 
17.61 Hz 1H), 5.75 (dd, J = 0.93 Hz, 17.60 Hz, 1 H), 5.25 (dd, J = 0.92 Hz, 10.88 Hz, 1 H), 4.31 (d, J = 
5.00 Hz, 2 H), 1.48 (s, 9 H). 
 
13C NMR (75 MHz, CDCl3): δ = 155.87, 138.55, 136.72, 136.43, 127.65, 126.42, 113.77, 44.45, 28.41.  
 
HRMS: calculated 234.1494 [C14H19NO2+H]
+, found: 234.1481 [M+H]+. 
 
Cyclosporin with linker (90) 
 
 
 
CsA (100 mg, 84 µmol) and Grubbs catalyst 2nd Generation (3.5 mg, 4.2 µmol, Aldrich) were 
dissolved in 1 mL dry DCM. Then 89 (196 mg, 0.84 mmol) was added and refluxed for 20 h. The 
resulting mixture was filtered through celite, concentrated in vacuo and flash chromatographed 
(silica gel, EtOAc/i-hexane) to obtain 90 as a brown oil (60 mg, 43 µmol, 52 % yield). 
 
TLC [EtOAc, 100% ]: Rf = 0.36. 
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HPLC [65%-85% solvent B, 20 min]: Rt = 18.1 min, purity (220 nm) = 95% 
 
1H NMR (600 Mhz, CDCl3): δ = 8.00 (d, J = 9.76 Hz, 1H), 7.64 (d, J = 7.68 Hz, 1H), 7.50 (d, J = 8.24 Hz, 
1H), 7.29 (d, 8.18 Hz, 2H), 7.20 (d, J = 8.04 Hz, 2H), 7.10 (d, J = 8.00 Hz, 1H), 6.30 (d, J = 15.82 Hz, 1H), 
6.15 (m, 1H), 5.68 (dd, J = 4.38 Hz, 10.98 Hz, 1H), 5.56, (d, J = 5.65 Hz, 1H), 5.32, (dd, 3.94 Hz, 11.55 
Hz, 1H), 5.12 (d, J = 10.82 Hz, 1H), 5.04 (dd, J = 7.09 Hz 14.11 Hz, 2H), 4.93 (d, J = 6.02 Hz, 1H), 4.91 (d, 
J = 6.14 Hz, 1H), 4.82 (m, 1H), 4.74 (d, J = 13.93 Hz, 1H), 4.66 (m, 1H), 4.54 (t, J = 7.41 Hz, 7.41 Hz, 1H), 
4,27 (s, J = 7.68 Hz, 2H), 3.78 (m, 1H), 3.53 (s, 3H), 3.40 (s, 3H), 3.26 (s, 3H), 3.11 (s, 3H), 3.09 (s, 3H), 
2.70 (s, 3H), 2.68 (s, 3H), 2.44 (m, 2H), 2.12 (m, 2H), 1.98 (m, 2H), 1.78 (m, 2H), 1.72 (m, 2H), 1.61 (m, 
2H), 1.45 (s, 9H), 1.34 (d, J = 7.27 Hz, 6H), 1.24 (d, J = 6.89 Hz, 6H), 1.21 (d, J = 6.11 Hz , 6H), 1.08 (d, J 
= 6.55 Hz, 6H), 1.03 (d, J = 6.78 Hz, 6H), 0.96-0.83 (m, 21H), 0.80 (d, J = 6.60 Hz, 3H), 0.71 (d, J = 6.36 
Hz, 3H). 
 
13C NMR (150 MHz, CDCl3): δ = 173.96, 173.78, 173.70, 173.43 171.58, 171.34, 171.10, 170.54, 
170.31, 170.16, 170.08, 155.82, 137.09, 130.86, 129.69, 128.87, 127.65, 126.24, 75.22, 64.41, 58.94, 
57.84, 57.58, 55.52, 55.48, 55.45, 50.35, 48.75, 48.49, 48.18, 45.11, 40.39, 39.56, 38.92, 37.53, 36.85, 
36.60, 36.60, 34.21, 31.51, 31.34, 31.17, 29.79, 29.78, 29.51, 29.22, 28.40, 25.34, 24.87, 24.60, 24.30, 
23.82, 23.69, 23.64, 23.46, 23.39, 21.82, 21.09, 20.40, 19.93, 18.69, 18.38, 18.20, 16.83, 16.03, 9.91. 
 
HRMS: calculated 1393.8377 [C73H124N12O14+H]
+, found 1393.8974 [M+H]+. 
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Cyclosporin with deprotected linker (91) 
 
 
 
90 (40 mg, 29 µmol) was dissolved in 1.8 mL dry DCM and cooled to 0°C in an ice bath. Then 200 µL 
TFA was added drop wise. The reaction was stirred for 2h. DCM/TFA was evaporated via air blow. 
The mixture was flash chromatographed (MeOH/DCM, 5:95, 1%TEA) to obtain 91 as white solid 
(30 mg, 23 µmol, 81% yield). 
 
TLC [MeOH/DCM,5:95 + 1% TEA]:  Rf = 0.28. 
 
HPLC [30%-70% solvent B, 20 min]: Rt = 18.6 min, purity (220 nm) = 90 % 
 
1H NMR (600 Mhz, CDCl3): δ = 7.98 (d, J = 9.75 Hz, 1H), 7.64 (d, J = 7.60 Hz, 1H), 7.52 (m, 1H), 7.49 (d, 
J = 8.32 Hz, 1H), 7.29 (d, 8.29 Hz, 2H), 7.20 (d, J = 8.04 Hz, 2H), 7.09 (d, J = 7.95 Hz, 1H), 6.29 (d, J = 
18.00 Hz, 1H), 6.14 (m, 1H), 5.67 (dd, J = 4.30 Hz, 11.06 Hz, 1H), 5.53, (d, J = 5.75 Hz, 1H), 5.30 (dd, 
3.96 Hz, 11.41 Hz, 1H), 5.11 (d, J = 15.00 Hz, 1H), 5.03 (m, 2H), 4.92 (dd, J = 3.96 Hz, 11.41 Hz, 1H), 
4.81 (m, 1H), 4.71 (d, J = 13.99 Hz, 1H), 4.64 (dd, J = 8.44 Hz, 9.66 Hz, 1H), 4.52 (m, 1H), 3.89 (s, 1H) 
3.78 (m, 1H), 3.51 (s, 3H), 3.38 (s, 3H), 3.23 (s, 3H), 3.08 (s, 3H), 3.07 (s, 3H), 2.69 (s, 3H), 2.66 (s, 3H), 
2.42 (ddd, J = 6.66 Hz, 13.45 Hz, 16.19 Hz, 2H), 2.11 (m, 2H), 1.98 (m, 2H), 1.76 (m, 2H), 1.70 (m, 2H), 
1.59 (m, 2H), 1.33 (d, J = 7.07 Hz, 6H), 1.22 (d, J = 6.91 Hz, 6H), 1.22 (d, J = 6.09 Hz, 6H), 1.09 (s, 3H), 
1.08 (s, 3H) 1.06 (d, J = 6.69 Hz, 6H), 1.01 (d, J = 6.64 Hz, 6H), 0.97-0.83 (m, 18H), 0.79 (d, J = 6.00 Hz, 
3H), 0.71 (d, J = 6.00 Hz, 3H). 
 
13C NMR (150 MHz, CDCl3): δ = 173.88, 173.73, 173.68, 173.43, 171.53, 173.31, 171.08, 170.48, 
170.32, 170.17, 170.09, 137.43, 130.80, 129.79, 128.21, 127.75. 127.35, 75.73, 67.94, 58.88, 57.85, 
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57.62, 57.55, 55.47, 55.42, 55.40, 50.33, 48.75, 48.48, 48.17, 45.10, 40.38, 39.50, 38.92, 37.50, 36.72, 
36.47, 35.95, 34.14, 31.56, 31.31, 31.20, 29.79, 29.77, 29.51, 29.19, 28.60, 25.58, 25.33, 24.86, 24.60, 
24.29, 23.80, 23.68, 23.63, 23.45, 23.37, 23.32, 21.07, 20.38, 19.88, 18.67, 19.37, 18.17, 16.83, 16.02, 
9.83. 
 
HRMS: calcultated 1293.8914 [C68H116N12O12+H]
+, found 1293.8667 [M+H]+. 
 
CsA-Fl 
 
 
 
92 (5 mg, 4 µmol) and TEA (1 µL, 12 µmol, Roth) was dissolved in 600 µL DCM/THF then 5(6)- 
carboxyfluorescein N-hydroxy-succinimide (2 mg, 4 µmol) was added and stirred at RT for 2h. 1 mL 
80:20 MeOH/H2O was added and filtrated. The crude mixture was purified by preparative HPLC 
(gradient: 65%-85% MeOH in H2O, + 0.1% TFA). CsA-Fl (0.54 mg, 0.9 µmol, 23%) was obtained as a 
yellow solid.  
 
HPLC: [gradient 65%-85% solvent B in solvent A]: Rt = 9 min, purity (220 nm) = 96 %  
 
UV/Vis spectra (80 % MeOH, 20 % Tris-HCl, 5 mM, pH 8.8) 10 µM: ε254 = 22100 M
-1cm-1, ε280 = 
12100 M-1cm-1, ε468 = 7500 M
-1cm-1. 
 
 
HRMS: calculated 1651.9391 [C89H126N12O18+H]
+,  found 1651.8666 [M+H]+. 
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4.4 Biochemical Methods 
 
All biochemical assays were performed under the guidance of Dr. Christian Kozany and Bastian 
Hoogeland.  
 
Inhibition of the cis–trans peptidyl–prolyl isomerase activity  
 
The PPIase activity was determined as described108 using Suc-AAPF-pNA (Sigma–Aldrich) as peptide 
substrate. The peptide substrate (4 mM) was dissolved in a solution of LiCl (470 mM) in dry 
trifluoroethanol and stored under argon. All solutions and buffers used were precooled to 4°C.  
A 40x concentrated protein solution (25 µL, 400 nM Cyp18 or 4 µM Cyp40), 5 µL DMSO or 5 µL of a 
200x stock of CsA or CsA-Fl in DMSO were added to 845 µL assay buffer (50 mM HEPES pH 8, 100 mM 
NaCl). The samples were incubated in protein low binding cups (Eppendorf) for 30 minutes at room 
temperature and were then transferred to cuvettes. After addition of chymotrypsin (100 µL, 60 
mg/mL; Carl Roth GmbH) the reaction was started by addition of the peptide substrate (25 µL, 4 
mM). The increase in absorption was recorded at 390 nm and 4°C. The amount of released p-
nitroanilide (pNA) is directly proportional to the trans isomer of the peptide substrate, starting from 
a cis–trans mixture. The measured absorption units were correlated to release pNA by the molar 
extinction coefficient of 13,300 M-1 cm-1at 390 nm. The curves were analyzed by using Sigma Plot11 
and fitted with a three parameter fit (single) for an exponential rise to a maximum. Since 
subsaturating final substrate concentration (100 µM) were ([S] << KM) the measured IC50 could be 
directly converted to Ki . 
 
Fluorescence polarization assay for the binding of CsA-Fl to cyclophillins 
 
For fluorescence polarization assays a 10 µM stock solution of proteins was serially diluted 1:1 in 
assay buffer (20 mM HEPES pH 8, 0.01% Triton-X100). 30 µL of each protein dilution was mixed with 
30 µL of CsA-Fl (20 nM in assay buffer) and transferred to a black 384-well assay plate (No.: 3575; 
Corning Life Sciences B.V.). After incubation at room temperature for 30 min the fluorescence 
anisotropy was measured with a plate reader (GENios Pro, Tecan) by using an excitation filter of 
485/20 nm and emission filters of 535/25 nm. The binding assays were performed in duplicates. The 
binding curves were analysed by using SigmaPlot 11. Data were fitted to the equation according to 
Kozany et al. to derive KD values.
108 
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Fluorescence polarization competition assay for binding of unlabelled 
cyclophilin ligands 
 
A 2 mM stock solution of CsA dissolved in DMSO was serially diluted 1:1 in DMSO. Every sample of 
this serial dilution was diluted by a factor of 50 in assay buffer (20 mM HEPES pH 8, 0.01% Triton-
X100) supplemented with 20 nM ligand  CsA-Fl. To 30 µL of each of these competitive ligand 
mixtures, 30 µL of protein (20 nM Cyp18, 200 nM Cyp40) dissolved in assay buffer were added. The 
samples were transferred to black 384-well assay plates (No.: 3575; Corning Life Sciences) and 
treated as described above. The competition curves were analyzed by using Sigma Plot 11. For the 
analysis of Ki values, data were fitted according to Kozany et al108. 
 
Fluorescence polarization assay for the binding of fluorescent iFit ligand F4 to 
FKBP51 
 
For fluorescence polarization assays a 97 µM stock solution of protein was serially diluted 1:1 in 
assay buffer (20 mM HEPES pH 8, 0.01% Triton-X100). 20 µL of each protein dilution was mixed with 
20 µL of F4 (20 nM in assay buffer) and transferred to a black 384-well assay plate (No.: 3575; 
Corning Life Sciences B.V.). After incubation at room temperature for 30 min the fluorescence 
anisotropy was measured with a plate reader (GENios Pro, Tecan) by using an excitation filter of 
485/20 nm and emission filters of 535/25 nm. The binding assays were performed in duplicates. The 
binding curves were analysed by using SigmaPlot 11. Data were fitted to the equation according to 
Kozany et al. to derive KD values.
108  
 
Fluorescence polarization competition assay for binding of unlabelled FKBP 
ligands 
 
A stock solution of test compound was dissolved in DMSO and serially diluted 1:1 in DMSO. Every 
sample of this serial dilution was diluted by a factor of 33,33 in assay buffer (20 mM HEPES pH 8, 
0.01% Triton-X100) supplemented with 3 nM ligand F4. To 20 µL of each of these competitive ligand 
mixtures, 20 µL of protein (4.5 nM FKBP51FK1) dissolved in assay buffer were added. The samples 
were transferred to black 384-well assay plates (No.: 3575; Corning Life Sciences) and measured as 
described above. The competition curves were analyzed by using Sigma Plot 11. For the analysis of Ki 
values, data were fitted according to Kozany et al.108 
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D. Abbrevations 
 
 
ACTH  Adrenocorticotropic Hormone 
AR  Androgen Receptor 
Brine  Saturated NaCl solution 
BuLi  n-butyllithium 
CID  Chemical Inducer of Dimerization 
CK2  Casein Kinase 2 
CN  Calcineurin 
CRH  Corticotropin Releasing Hormone 
CsA  Cyclosporine A 
Cyp  Cyclophilin 
DCM  Dichloromethane 
DCC  N,N′-Dicyclohexylcarbodiimide 
DIPEA  N,N-Diisopropylethylamine  
EDC   1-Ethyl-3-(3-dimethylaminopropyl)carbodiimid 
EE  Ethyl acetate 
ER  Estrogen Receptor 
F  Phenylalanine 
FKBP  FK506 binding protein 
FP  Fluorescence Polarisation 
GR  Glucocorticoid receptor 
HOAt 1-Hydroxy-7-azabenzotriazole 
HATU O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate 
HPA Hypothalamus pituitary adrenal 
HPLC High Pressure Liquid Chromatography 
Hsp90 Heat shock protein 90 
LDC Lead Discovery Center 
LiHMDS Lithium hexamethyldisilazid 
LiOH  Lithium hydroxide 
LMU  Ludwig Maximilian University 
MeOH  Methanol 
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MD  Major depression 
MPI  Max Planck Institute 
MR  Mineralcorticoid Receptor 
mTOR  mammalian target of rapamycin 
NaHMDS Natrium hexamethyl disilazid 
NF-AT  Nuclear factor of activated T-cells 
n-Hex  n-Hexane 
NMR  Nuclear magnetic resonance 
PPIase  Peptidyl-prolyl-cis/trans-Isomerase  
PR  Progesterone Receptor 
PTSD  Post-traumatic stress disorder 
Rap  Rapamycin 
RT  Room Temperature 
SAR  Structure Activity Relationship 
SHR  Steroid Hormone Receptor 
TFA  Trifluoroacetic acid 
TEA  Triethylamine 
TLC  Thin layer chromatography 
THF  Tetrahydrofuran 
V  Valine 
WT  Wildtype 
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E. Annex 
 
 
 
 
Annex: (A) Crude product of 46. (B) Purified minor product 46c/d.  
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Annex: (C) Purified major product 46a/b. (B) 
13
C spectra of 46a/b as a mixture of diastereomers 
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Annex: (E) Partial resolution of 47a/b, no tailing for the reduced 49. (F) Tailing of 46a/b, no tailing for the reduced 48. 
E 
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Annex: (G) 
13
C NMR of 49. No diastereomers can be observed.  
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